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Abdominal aortic aneurysm (AAA) is a permanent and irreversible localised                    
dilation of the aortic wall which if left untreated can rupture leading to severe 
haemorrhage and death affecting over 5% of males over 50 years of age. 
The pathology of AAA is poorly understood, however research has shown 
that increased activity of matrix metalloproteinases (MMPs) leads to the 
destruction of major structural elements such as elastin and collagen within 
the aortic wall leading to weakening and resulting in aneurysm formation.  
Arterial wall hypoxia, which has been investigated in other pathological 
conditions  may also play  role in the pathogenesis of AAA. Research has 
also shown that hypoxia exists in vivo in the aneurysms of patients. This 
study has investigated the possible role of aortic wall hypoxia as a 
contributing factor for the increased expression of MMPs and also the affects 
if any on the endogenous inhibitors of MMPs known as TIMPs (tissue 
inhibitors of metalloproteinases). The major hypoxia transcription factor HIF-
1α, along with Ets-1 and VEGF are also being investigated as mediating 
factors. 
 
Results demonstrated significant increases in expression of MMP-2 levels 
when human aortic smooth muscle cells were exposed to severe hypoxia 
over 48 hours. Increased levels of  Tissue Inhibitor of Metalloproteinases 
(TIMPs) 1 and 2 were also noted in the HASMC supernatant of hypoxic 
VHASMC samples. Ets-1 and VEGF demonstrated raised levels in hypoxic 
HASMC whole cell lysate samples.  
 
Interestingly when HASMCS were treated with Bisphenol A (BpA) to inhibit 
the transcription factor HIF-1α during exposure to severe hypoxia, results 
showed an effect on the expression of MMP-2 levels in BpA treated hypoxic 
samples. Conclusions from this study could support a role for hypoxia and 











1.Introduction: Vascular Biology 
 
 
1.1   Structural Components of the Normal Aorta 
 
The aorta is characteristically highly elastic allowing it to accommodate large 
fluctuations in arterial blood pressure created by the heartbeat. Histologically 
the vessel wall is composed of concentric layers, the tunica intima, tunica 
media and tunica adventitia. The innermost layer, the tunica intima consists 
of a monolayer of simple squamous endothelial cells that border the lumen, 
underlain by the basal lamina and a subendothelial layer of connective 
tissue composed of collagenous tissue and elastin. Separated from the 
intima by a fenestrated layer of elastin known as the internal elastic lamina, 
the tunica media is the thick middle layer containing circumferentially 
arranged smooth muscle cells, collagenous fibres and elastic lamellae 
arranged as concentric fenestrated sheets. The outer collagenous tunica 
adventitia prevents the artery from stretching beyond its physiological limits 









Figure 1    Schematic Diagram of an Elastic Artery  
The tunica intima, tunica media and outer tunica adventitia are illustrated along with 
their cellular and extracellular components. (Adapted from Rhodin, 1963). 
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Although most of the aortic media is avascular and receives nourishment 
from the luminal blood supply, in the thoracic aorta, the tunica adventitia 
contains vasa vasorum (small blood vessels) that penetrate from the 
adventitia into the outer layers of the aortic media to supply oxygen and 
nutrients to cells in the vessel wall too far from the lumen to be nourished by 
diffusion (Heistad et al., 1978).  In contrast the abdominal aorta is largely 
devoid of medial vasa vasorum and relies on luminal blood flow to a  greater 
extent for oxygenation and nutrition of the tissues (Zarins et al., 2001).                            
The arterial extracellular matrix (ECM) consists of the structural proteins 
collagen and elastin (which confer resistance to aneurysmal dilatation under 
haemodynamic stress), and specialised proteins such as fibrillin, fibronectin, 
laminin, proteoglycans and plasma components) which are secreted at a 
local level by cells within the ECM, in particular smooth muscle cells, 
endothelial cells and fibroblasts (Stary et al., 1992). 
 
 
1.1.1   Elastin    
                                                                                                    
Elastin is the major component of elastic fibres, giving the extensibility and 
elastic recoil to blood vessels essential for their physiological function. 
(Hofmann et al., 2005).  Formation of elastin by smooth muscle cells occurs 
early during the development of the aorta, with little or no synthesis in adults 
due to destabilisation of elastin mRNA which appears to be an important 
factor in the regulation of this protein (Hew et al., 1999) and as a 
consequence there is a decrease in the elastin content relative to collagen 
with increasing age ( Hosoda et al., 1984). The human elastin gene (ELN) is 
a single copy gene localised to the long arm of chromosome 7 within the 
q11.1-21.1 region and consists of 34 exons occupying ~47kb of genomic 
DNA (Fazio et al., 1991). An intron: exon ratio of 20:1 indicates that relatively 
small exons are interspersed within large introns, furthermore the exon-
intron boundaries always split codons in the same manner (Bashir et al., 
1989) allowing extensive alternative splicing of the transcripts without 
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disrupting the reading frame resulting in multiple isoforms of tropoelastin 
(Rosenbloom et al., 1993). Elastin consists of two morphologically distinct 
components, the initial product of the ELN gene is soluble tropoelastin, a 72 
kDa polypeptide rich in glycine, proline and hydrophobic amino acids, which 
is secreted by cells into the extracellular space (Rosenbloom et al., 1993). 
The second component, 10-15 nm microfibrils are thought to provide a 
scaffold that facilitates elastin molecular alignment and subsequent 
formation of intermolecular cross-links known as desmosines (Mecham and 
Davis, 1994). Cross-linking of tropoelastin requires the oxidation of lysyl 
residues catalyzed by the copper-dependent enzyme lysyl oxidase and 
subsequently forms highly insoluble elastin (Sato et al., 2007). 
Recently Halm et al., (2016) developed techniques for visualizing 
tropoelastin (TE) production and its fibre assembly in a long-term human 
elastic fibre cell culture model expressing fluorescence-labelled TE. This 
will allow the tracking of TE produced under various conditions and serve 
as a tool for investigating fibre degradation processes in a disease-in-a-
dish-model which may prove useful in AAA research where elastin is 
degraded during aneurysm formation. 
Elastin is a vital protein for maintaining stabilityof the aortic wall which led 
researchers to evaluate a novel small-molecular-weight elastin-specific MR 
probe for the in vivo assessment of aortic wall integrity in AAAs. They were 
able to visualize and quantify changes in elastin content at different stages 
of aneurysmal disease which could enable more accurate risk stratification 
and guide treatment options (Makowski et al., 2014). 
 
The degradation of elastin is an important factor in the formation of AAA and, 
in an attempt to address this, Tian et al., (2014) investigated whether 
adipose derived stem cells (ADSCs) could promote the secretion of elastin 
by SMCs in a rat model of AAA. Results demonstrated that ADSCs promote 
the expression of elastin in SMCs and contribute to the reconstruction of 















Figure 2    Formation of Elastin    
After translation the tropoelastin molecule is bound by an elastin binding protein 
(EBP) in the rough endoplasmic reticulum. The EBP acting as a chaperone 
prevents premature aggregation of the tropoelastin until the EBP/tropoelastin 
complex is secreted onto the cell surface where the chaperone interacts with the 
galactosugars of the microfibrils and releases the tropoelastin molecule. The EBP is 
recycled and the tropoelastin is aligned and modified by lysyl oxidase to be 
incorporated into the growing elastin network. (Adapted from Hinek, 1997). 
 
 
1.1.2   Fibrillins 
 
Fibrillins-1, 2 and 3 are large (~350kDa) cysteine-rich glycoproteins that are 
a known component of microfibrils (Saki et al., 1991) Fibrillin  aligns in a 
head to tail fashion as parallel bundles of six to eight molecules to form most 
of the microfibrillar structure (Gibson et al., 1996).Fibrillin-1 mutations result 
in Marfan syndrome, a connective tissue disorder affecting many structures, 
including the skeleton, lungs, eyes, heart and blood vessels, including aortic 
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dilatations, while fibrillin-2 mutations result in congenital arachnodactyly (Lee 
et al., 1991). Additionally a novel fibrillin-1 gene missense mutation 
associated with neonatal Marfan Syndrome (nMFS), a rare and severe form 
of Marfan Syndrome leading to death during early childhood, was reported 
recently (Peng et al., 2016). Several other proteins also associate with 
microfibrils including the microfibril-associated proteins (MAGPs), fibulins 
and Elastin Microfibril Interface-Located Protein-1  (EMILIN-1)  (Kielty et al., 
2002). 
 
1.1.2.1   Microfibril-associated Proteins (MAGPs) 
 
Microfibril-associated  glycoprotein-1 (MAGP-1) is a small (~31kDa) 
glycoprotein that has been shown to bind to both tropoelastin and fibrillin 
(Jenson et al., 2001) .It is thought that MAGP-1 may stabilise the head to tail 
interactions of fibrillin-1 within the beaded region of microfibrils by disulfide 
linkages (Henderson et al., 1996) and mediate the binding and alignment of 
tropoelastin onto the microfibril template (Gibson et al., 1991). MAGP-2 has 
also been shown to bind fibrillin but has a more restricted pattern of tissue 
localization than MAGP-1 suggesting it may have developmental stage-
specific expression (Gibson et al., 1998). 
Fibulins are a six-member family of glycoproteins associated with elastic 
fibres and believed to function as molecular ‗bridges‘ that participate in the 
assembly, organization and stabilization of extracellular matrix structures 
(Argraves et al., 2003). Fibulins-1, 2 and 5 all bind to tropoelastin (Sasaki et 
al., 1999), while fibulin-3 is expressed only in capillaries Hanada et al., 
(2007) demonstrated that reduced expression of fibulin-4 leads to aneurysm 
formation in mice. Fibulin-5 (FBLN5) mediates cell-ECM interactions and 
elastic fibre assembly and is critical for ECM remodelling. Orriels et al., 
(2016) found FBLN5 expression was significantly decreased in human 
aneurysmatic aortas compared with healthy aortas and identified a 
SOX9/HDAC dependent mechanism involved in the down-regulation of 
FBLN5 by inflammation. They concluded that HDAC inhibitors or 
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pharmacological approaches aimed to preserve FBLN5 could be useful to 
prevent the disorganisation of ECM induced by inflammation in AAA. 
EMILIN-1 is a cysteine-rich extracellular matrix glycoprotein abundantly 
expressed in elastin-rich tissues such as blood vessels and skin and is 
localised to the interface between amorphous elastin and surrounding 
microfibrils. Bressan and colleagues (1993) found that antibodies against 
EMILIN-1 inhibited elastin deposition by smooth muscle cells in vitro 
suggesting that the protein may play a role in elastogenesis. EMILIN-1 was 
also found to bind elastin and fibulin-5 and the association of fibulin-5 with 
elastin is altered in the absence of EMILIN-1 (Zanetti et al., 2004). EMILIN-1 
is is encoded by the EMILIN1 gene and recently Capuano et al., (2016) 
identified a heterozygous missense alteration in exon 1 of this gene. Their 
findings may represent a new disease gene associated with an autosomal-
dominant connective tissue disorder which interestingly can also present in 
ascending and descending aortic aneurysms in affected patients. 
 
 
1.1.3   Collagen 
 
Collagen is the second major structural protein of the aortic wall, accounting 
for approximately 20% of the total protein in the normal aorta and is 
responsible for maintaining the structural integrity of the aortic wall.   
Twenty-five types of collagen  chain have now been identified resulting in at 
least  sixteen types of collagen which are synthesized as longer precursor 
proteins called procollagen (Alberts et al.,1994). The regulation of 
procollagen synthesis appears to occur predominantly at the level of gene 
transcription (Vuorio and De Crombrugghe, 1990). All commonly share a 
triple helical structure composed of three polypeptide  chains consisting of 
Gly-X-Y repeats, where X is any amino acid, and Y is frequently proline or 
hydroxyproline.  These three left-handed helices wind around each other to 
form a right-handed superhelix (Sato et al., 2002). During collagen 
biosythesis, stability of the helical structure is significantly increased post-
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translationally by conversion of proline residues by the enzyme prolyl-4 
hydroxylase to 4-hydroxyproline in the Y position in the nascent procollagen 
chain. When lysine is present in the Y position of the Gly-X-Y triplet, it can be 
converted to hydroxylysine residues by lysyl hydroxylase which can then 










Figure 3   Formation of Collagen 
 
The primary structure shows the repetitive triplet sequence Gly-X-Y characteristic of 
collagen and the left-handed helix of the secondary structure. The tertiary structure 
of this type-I collagen molecule is composed of three intertwined peptide chains, (2 
1 and 12), each triple-stranded helix is 300 nm in length and 1.5 nm in diameter, 
and approximately 300 kilodaltons in molecular weight. The collagen molecules are 
assembled in a ‗head-to-tail‘ alignment in a staggered  side by side arrangement to 
form fibrils, adjacent molecules are displaced from one another by 67nm producing 
the striated effect seen in electron micrographs. The fibrils then aggregate into 






In the normal adult artery the majority of collagen exists in the form of  two 
interstitial collagens, type I and type III,  although other collagen types 
including IV, V and VI are also  present  to a lesser extent (Stary et al., 
1992). Smooth muscle cells (SMCs) within the media are the major cell type 
responsible for collagen synthesis in the vessel wall and it is thought SMC 
hyperplasia alters the ratio of types I and III collagen in favour of type I in the 
aging aorta (Morton and Barnes, 1982).  
The collagen fibres lie between the elastic lamellae and the surrounding 
SMC within the aortic media, in the adventia they form a loose mesh-like 
network where they are thought to be able to align more effectively during 
higher degrees of tensile loading to accommodate the physical forces 



















TYPE α CHAINS GENES LOCALIZATION 
I              [1(I)2[(I)] COL1A1           
COL1A2 
Skin, tendon, bone, 
artery walls (most 
abundant collagen) 
II                 [1(II)]3 COL2A1 Cartilage, vitreous 
humor 
III                 [1(III)]3 COL3A1 Skin, artery walls, 
organs 






All basal lamina, highly 
vascularised tissues e.g. 
placental villi 
V     [1(V)][2(V)]3(V)] COL5A1 
COL5A2 
COL5A3 
Bone, skin, tendons, 
ligaments, cornea 
VI  [1(VI)][2(VI)] [3(VI)] COL6A1 
COL6A2 
COL6A3 
Most connective tissue 
VII             [1(VII)]3 COL7A1 Epithelia 
VIII             [1(VIII)]3 COL8A1 
COL8A2 
 
IX  [1(IX)][2(IX)][3(IX)] COL9A1 
COL9A2 
COL9A3 
Tissues associated with 
Type II 
X               [1(X)]3 COL10A1  Hypertrophic cartilage 
XI  [1(XI)][2(XI)][3(XI)] COL11A1 
COL11A2 
 Cartilage 










Adventitial collagen structure provides the aorta with tensile strength and its 
degradation is a key characteristic of AAA. Urabe et al.,  (2016) investigated  
whether the structural characteristics of aortic advential collagen changed 
with aging, location or aneurysm formation. Results showed that, although 
the basic structure was maintained in abdominal aortas regardless of age or 
location, the molecular structure at the subfibril level changed and was 
enhanced in AAA; they concluded that alterations within the molecular 
structure of collagen such as in cross linkages may be associated with 
aneurysm formation. Change in collagen structure has also been studied by 
other researchers such as Dai et al., (2015) who demonstrated that Smad3 
deficiency promotes vessel wall remodelling, and collagen fibre 
reorganization in an inflammatory AAA mouse model after their earlier study 
found Smad3-mediated TGF-β signalling (which is an important mechanism 
in the pathogenesis of aneurysms) plays a protective role in the 
pathogenesis of AAA (Dai et al., 2013). Furthermore, other research has 
established that the degradation of decorin, a key regulator of collagen 
organization by the pro-apoptotic protease Granzyme B (GZMB) results in 
reduced collagen organization and tensile strength, possibly resulting in 
aortic rupture (Granville et al., 2013). Gregoli and colleagues, (2015) using a 
AAA mouse model discovered  collagen degradation through  increased 
MMP activity could be altered through inhibition of microRNA (miR)-181b (a 
validated repressor of TIMP-3 protein expression) by promoting collagen 
preservation and accumulation via TIMP-3 modulation stabilizing AAA 
formation.  
Of concern, Daneman et al., (2015) carried out a study which reported a 
novel and important association between fluoroquinolones,  a family of  
frequently prescribed antibiotics, and aortic aneurysms.  They concluded 
fluoroquinolone-associated collagen degradation may affect the aortic wall 






1.1.4   Fibronectin and Laminin 
 
The glycoproteins fibronectin and laminin are also present in the 
extracellular matrix (ECM) of the normal intima of the aorta and other blood 
vessels.  Cotrufo et al., (2005) found that in AAA  the basal lamina of the 
aortic wall exhibited important changes to some of its major components, 
including the laminin alpha2 chain and fibronectin which lost their regular 
arrangement in pathological specimens along with decreased expression in 
comparison to  normal aortic wall specimens. 
 
1.1.4.1 Fibronectin  
                                            
Fibronectin exists in both soluble and fibrillar forms and in humans there are 
up to twenty different isoforms arising from alternative splicing of mRNA from 
a single fibronectin gene (Potts and Campbell, 1994). Fibronectin is a 
dimeric glycoprotein composed of two 250 kDa subunits joined by disulphide 
bonds at the carboxyl terminal end. The rod-like structure contains three 
different types of homologous repeating modules (type 1, II and III) which 
are folded into at least six tightly folded domains each with a high affinity for 
a different substrate such as heparin sulphate, collagen, fibrin and cell-
surface receptors (Peterson et al., 1983). The most abundant module is the 
fibronectin type III repeat which contains synergy sequences and a specific 
tripeptide sequence (Arg-Gly-Asp) or RGD receptor recognition sequence 
known to be involved in cell adhesion (Main et al., 1992).  
Fibronectin is involved in many cellular processes, including tissue repair, 
embryogenesis, blood clotting, cell migration and serves as a general cell 
adhesion molecule by anchoring cells to collagen or proteoglycan 
substrates. In addition,  it can organize cellular interaction with the ECM by 
binding to different components of the extracellular matrix and to membrane-
bound fibronectin receptors on cell surfaces (Potts and Campbell, 1996). 
Studies have shown that fibronectin production by many cell types has been 
enhanced by a variety of cytokines in particular interleukin 1 (IL1) and 
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Transforming Growth Factor-β (TGF-beta). Recent reports have also shown 
fibronectin affects proliferation, morphology, migration and differentiation of 
the smooth muscle cells during the development of atherosclerosis 











Figure 4   Structure of a Fibronectin Dimer 
B: Fibronectin is a V–shaped dimer made up of two polypeptide chains which are 
similar but not identical due to alternative splicing and are joined by two disulfide 
bonds near the C-termini. Fibronectin has several binding domains which can bind 
heparin, collagen, cells (via integrins) or itself. C: The three-dimensional structure of 
two type III fibronectin repeats which are the main repeating module in fibronectin 
and depicts the Arg-Gly-Asp (RGD) and the ―synergy‖ sequences as part of the 
major cell-binding site. (Adapted from Leahy, 1997). 
 
1.1.4.2   Laminin 
Laminin is a major basement membrane glycoprotein composed of three 
polypeptide chains, alpha (), beta (β) and gamma () that are disulfide-
bonded into an asymmetric crosslike structure (Rhodes and Simons, 2007). 
Several different laminin isoforms have been identified, assembled from the 
five different  chains, three β chains and three  chains, each with a 
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characteristic tissue distribution. The ends of the ‗cross‘ can bind cell 
receptors and the crosspieces allow laminin to bind other laminin molecules, 
additionally there are binding sites available for matrix components nidogen 
and perlecan which are necessary for the correct functioning of basal lamina 
(Timpl and Brown,1994). The major activity of laminin is the mediation of cell 
attachment (via integrin receptors) but it also has other roles in cellular 
proliferation, differentiation and migration.  More recently its ability to 
promote the contractile phenotype of smooth muscle cells has been reported 
(Chuang et  al., 2014). 
    










Figure 5    The General Structure of Laminin 
Laminin is a heterotrimer of the three subunits, β and  joined by interchain 
disulfide bonds to create a cross-like structure.  The three short arms of the ‗cross‘ 
are formed by the N-terminal regions of the chains and the -helical coiled-coiled 
long arm is formed by the C-terminal region where a large globular domain known 
as the G domain is located. Cysteine-rich EGF (epidermal growth factor)-like 
repeats separate the globular domains of the short arms. The sites of some binding 
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1.1.5   Proteoglycans 
 
Proteoglycans are a group of macromolecules consisting of a core protein 
with one or more glycosaminoglycan (GAG) chain(s) covalently attached 
through O-glycosidic linkages to serine residues. Proteoglycans are 
synthesized by the endothelial and SMCs of the arterial wall and are vital for 
functions such as cell proliferation, migration and adhesion, viscoelasticity, 
permeability, ion exchange, lipid metabolism and filtration in these vessels. 
They are also thought to be important in the stabilization of the spatial 
arrangement of collagen fibres (Starey et al., 1992, Bosman and 
Stamenkovic, 2003, Kresse and Schonher, 2001). 
 They are generally categorized by size and the nature of their GAG chains 
and those identified in the arterial wall include hyaluronic acid, dermatan 
sulfate (biglycan) associated with collagen fibrils, heparin sulfate  (syndecan, 
perlecan) present in arterial basement membranes and associated with 
elastin fibres and chondroitin 4- and 6-sulfate ( versican) found in the 
interstitial matrix of the arterial ECM (Volker et al., 1987). Proteoglycans are 
minor components of the normal arterial wall, but their accumulation in 
intimal lesions of blood vessels is a typical event in the early phases of 
atherosclerotic occlusive disease and AAA development (Wight, 1980,1989). 
This suggested to Melrose et al., (1998) that proteoglycans may influence 
aortic physicochemical properties and subsequently a study was undertaken 
to compare proteoglycans synthesized by smooth muscle cells from AAA 
tissue or atherosclerotic occlusive disease sufferers to normal controls to 
determine whether variations in these proteoglycans can be correlated with 
disease processes in the vessel wall.  Results showed that the levels of 
perlecan, versican, and biglycan synthesized by AAA smooth muscle cells in 
monolayer culture were significantly higher than synthesized by the other 
smooth muscle cells,  but were unable to explain to what extent this cellular 
behaviour contributes to AAA development in vivo. In contrast Tamarina et 
al., (1998) found a marked decrease in biglycan mRNA levels in aneurysmal 
aorta,  which could  reflect important regulatory changes specific for AAA 
and have a broad impact on the physiology and matrix architecture of the 
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aorta. This also correlates with other researchers who have shown that GAG 
content was decreased and their molecular differentiation was changed in 
the AAA wall (Sobolewski et al., 1995, Theocharis et al., 1999, Theocharis et 
al., 2002). More recently in 2015,  Ueda  et al  investigated the role of 
decorin, a small leucine-rich repeat proteoglycan in the pathogenesis of 
AAA. Their results suggested that  adventitial decorin in normal aorta may 
protect against the development of AAA, but macrophages expressing 




1. 2  Physiology of the Aorta 
 
1.2.1    Haemodynamic Forces in the Aorta 
The aortic wall is continuously subjected to mechanical forces created by 
blood flow and it is now recognized that these haemodynamic forces directly 
influence vascular cell biology and play a role in modulating vascular tone 
and vascular remodelling. Fluid flow across the endothelial cells (ECs) lining 
the intimal surface of the aortic vasculature results in shear stress whereas 
both endothelial, SMCs and the underlying matrix are subjected to cyclic 
strain (stretch) resulting from transmural pressure gradients and smooth 
muscle tone (Patrick and McIntire, 1995). These physical forces can affect a 
number of EC functions; in particular it is well known that they respond to 
increases in flow by modulating the release of bioactive molecules including 
the vasorelaxants nitric oxide (NO) (Busse and Fleming, 1998), prostacyclin, 
(PGI2), the vasoconstrictor endothelin-1 and tissue plasminogen activator 
(Carosi and McIntire, 1994). NO is a diatomic gas formed by the conversion 
of L-arginine to L-citrulline by NO synthases (NOS) and plays a major role in 
regulating blood flow by inhibiting smooth muscle contraction, platelet 
adhesion, aggregation (Moncada and Higgs, 1993) as well as SMC  
proliferation (Schwartz and Liaw, 1993). Activation of constitutive NOS in 
ECs by inhibitory G-proteins and subsequent release of NO results in the 
stimulation of soluble guanyly cyclase leading to a rise in guanosine 3‘, 5‘-
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cyclic monophosphate (cGMP) in SMCs and platelets (Stamler et al., 1992). 
Stimulation of these G-proteins can initiate a number of signalling cascades 
including activation of potassium channels, phospholipase C, phospholipase 
A2, protein kinase C and adenylyl cyclase (Wand et al., 1993). The effect of 
cyclic strain on SMCs has shown it induces the production of platelet-derived 
growth factor and stimulates cell proliferation, furthermore under 
inflammatory conditions SMCs can express iNOS (inducible NOS) which 
also is capable of synthesizing large quantities of NO (Busse and Mulsch, 
1990). Wagner et al., (1997) also reported that SMCs exposed to shear 
stress express another diatomic gas carbon monoxide (CO) with similar 
properties to NO causing blood vessel relaxation and inhibiting platelet 
reactivity through a cGMP-dependent mechanism. 
Analysis of haemodynamics has demonstrated that when the pulse wave 
generated by the heartbeat is transmitted from the aortic root to the inguinal 
region, the pulse pressure increases with the largest pulsatile load being 
localized to the infrarenal aorta. This localization of haemodynamic stress is 
due to the distal tapering of the aorta, the progressive stiffening of the aortic 
wall resulting from the decrease in the number of elastic lamellae (especially 
as it enters the abdomen) and the additive effects of retrograde pressure 
waves that reflect from the iliac bifurcation (Dobrin, 1989). These factors 
appear to correlate with the propensity for AAAs to form in this segment of 
the aorta.  
Dobrin and colleagues, (1984) looked at the relative contributions made by 
elastin and collagen to the biophysical properties of the aortic wall by 
treating arteries with elastase or collagenase. Treatment with elastase led to 
marked arterial dilatation and stiffening at physiologic pressures, whereas 
treatment with collagenase led to arterial rupture with little dilatation  
demonstrating that elastin degradation was a key step in the development of 
aneurysmal dilatation but that collagen degradation was ultimately required 
for aneurysm rupture. 
Recently researchers suggested that haemodynamic forces and intraluminal 
thrombus (ILT), another feature of AAA, interact and affect each other. Their 
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study looked at the relationship between aneurysm expansion, wall shear 
stress (WSS) and ILT accumulation. Comparison between AAAs with and 
without thrombus showed that aneurysm with ILT recorded lower values of 
WSS and higher values of AAA expansion than those without thrombus. 
Results suggested that low WSS may promote ILT accumulation and that, by 
increasing WSS levels, ILT accumulation may be prevented (Zambrano et 
al., 2016).  
Haemodynamic forces appear to play an influential role in the evolution of 
aneurysms and studies have usually focused on WSS, attempting to find 
correlations between patterns of haemodynamic indices and regions 
subjected to disease formation and progression. Poelma et al., (2015) 
instead demonstrated the role of transitional flow in aneurysms which can 
lead to significantly different WSS distributions in consecutive cardiac cycles. 
Therefore accurate determination of time-averaged haemodynamic indices 
may thus require simulation of a large number of cycles, which contrasts with 
the common approach to determine parameters using data from a single 
cycle. 
 
1.2.2    Endothelin-1 
 
Endothelin (ET)-1  is a 21 amino acid peptide that is produced by the 
vascular endothelium from a 39 amino acid precursor, big ET-1, through the 
actions of an endothelin converting enzyme (ECE) (Yanagisawa et al., 
1988). There are three  isoforms known as ET-1, -2 and -3 which are 
encoded by separate genes and  are implicated in a wide variety of 
physiological and pathological processes in the body. Endothelins are the 
most potent vasoconstrictors known  and  although vascular endothelial cells 
are the major source of endothelin it is also produced by a wide variety of 
other cell types including vascular SMCs (Inoue et al.,1989). 
AAA  is associated with increased ET-1 levels both systemically and locally 
within the aorta. Tresca et al., (1999) discovered plasma levels of  ET-1  
were elevated in patients with AAA  which  also correlated with aneurysm 
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diameter and suggested a role for ET-1–induced vascular remodelling in the 
pathogenesis of AAA. Chew and colleagues, (2003)  proposed  increased 
ET-1 and elastase activities in AAA patients modulated the effects of 
elastase on the vasoconstrictive actions of ET-1 during AAA formation by 
elastase inhibition of ET-1 induced aortic contraction.  
In 2013, Li et al concluded that ET-1 is implicated in  the progression of 
athersclerosis and AAA formation by  decreasing high-density lipoprotein 
and increasing oxidative stress, inflammatory cell infiltration and MMP-2 in 




 1.2.3 Cells of the Arterial Intima 
 
1.2.3.1 Smooth muscle cells 
SMCs are the major cell type of the tunica media of medium and large sized 
arteries, contributing to lipid metabolism, vascular tone, vascular remodelling 
and are responsible for the synthesis and deposition of important 
components of the extracellular matrix including collagen, elastin and 
proteoglycans. Vascular SMCS normally exhibit a contractile phenotype 
(Munro and Cotran, 1988) but under certain pathological conditions the 
SMCs may become exposed  to growth factors and cytokines that induce a 
transformation  from the contractile to synthetic state allowing the SMCs to 
proliferate and accumulate within the intimal layer (Ross et al., 1989). 
Importantly, like other vascular cells SMCs have the capacity to express 
components of the ECM, growth factors and proteases including matrix 
metalloproteinases (MMPs), enzymes that selectively digest components of 
the ECM during normal events such as angiogenesis or after stimulation with 
various cytokines associated with vascular homeostasis or in pathological 
conditions such as AAA (Lesauskaite et al., 2003). 
Zhang et al., (2015) sought to determine the role of Smad4 in SMCs in the 
pathogenesis of aortic aneurysms. Smad4 is the central mediator of the 
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canonical TGF-β signalling pathway which is known to be involved in 
aneurysm formation.  Their research showed Smad4-deficient SMCs directly 
triggered aortic wall inflammation via the excessive production of 
chemokines to recruit macrophages and further demonstrated Smad4-
dependent TGF-β signalling in SMCs protects against aortic aneurysm 
formation. 
 
1.2.3.2 Endothelial cells 
The vascular endothelial cells of the tunica intima are also involved in many 
aspects of vascular biology including synthesis of ECM components (Jaffe,  
1987) control of platelet adhesion, maintaining a balance of fibrinolytic and 
prothrombic activity, regulating vascular tone and a critical role in regulating 
the recruitment of leukocytes into inflammatory sites (Springer, 1995). The 
arterial endothelium is also permeable to all plasma proteins allowing the 
transport of lipoproteins and other macromolecules across the endothelium 
through a complex system of interendothelial cell junctions (Schwartz and 
Benditt, 1972). 
Endothelial cells respond to a number of stimulating factors, including 
smoking, hypertension  and non-uniform distribution of wall stress so their 
ability to produce NO is crucial in order to adapt. Endothelial cells contribute 
to AAA development due to increased oxidative stress which is partly 
mediated by impaired NO bioavailability due to endothelial  dysfunction and 
NADPH oxidase overexpression (Siasos et al., 2015). 
 
1.2.3.3  Fibroblasts  
The fibroblast is the principal cell type in the adventitia and increasingly it is 
thought that they play a significant role in normal vascular homeostasis, the 
vascular response to injury and vascular remodelling (Stenmark et al., 2002). 
The vascular adventitia could be considered the principle injury-sensing 
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tissue of vessel walls and in response to environmental stresses resident 
fibroblasts are activated and can rapidly modulate their functions, including 
cell proliferation, expression of ECM proteins and secretion of factors 
affecting vascular tone and growth (Stenmark et al., 2006). 
Aortic adventitial fibroblasts (AoAF) are a rich source of cytokines and ECM  
and they participate in arterial wall remodelling and have been implicated in 
the pathophysiology of AAA and atherosclerosis. Although  little is known 
about signalling pathways  that regulate fibroblasts in cardiovascular 
diseases Zhao et al., (2013) examined the role of Notch signalling in 
adventitial fibroblasts in normal human aorta, AAA and atherosclerotic  
samples and the effect of Notch signalling on cytokines and ECM production 
by fibroblasts. Significantly increased Notch activity was observed in 
fibroblasts from AAA samples and decreased Notch activity was found in 
fibroblasts from atherosclerotic aorta whilst Notch activation also inhibited 
cell proliferation and induced differentiation of the cells to myofibroblasts. 
They concluded Notch signalling is activated in aortic fibroblasts at the site 
of aortic aneurysms and results in increased production of TGF-β by these 
cells,  implicating involvement of Notch-TGF-β signalling in the formation of 
aortic aneurysms. 
 
1.3    Matrix metalloproteinases (MMPs) 
 
MMPs are a family of zinc-mediated endopeptidases present in the ECM that 
are involved in a variety of physiological processes including inflammation, 
wound healing, embryogenesis and remodelling of structural proteins such 
as elastin and collagen.) Addionally, MMPs play a central role in diseases 
such as cancer, arthritis, atheroma and tissue ulceration (Woessner., 1998). 
The important role MMPs play in the pathogenesis of AAA will be discussed  
in detail later in Chapter 2 (Vascular Pathology) Section 2.2.1. They are 
produced in an inactive form by various mesenchymal cells such as 
fibroblasts, endothelial cells and SMCs as well as cells involved in the 
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inflammatory cascade (neutrophils, macrophages) and can be activated by a 
number of proteinases including plasmin and other  MMPs. Activation occurs 
by removal of the signal sequence and the propeptide domain which 
contains a conserved cysteine which chelates the active zinc site. Under 
normal circumstances MMPs are strictly regulated at the level of 
transcription and through activation of precursor zymogens or inhibition by 
endogenous inhibitors termed tissue inhibitors of matrix metalloproteinases 
(TIMPs) (Nigase and Woessner, 1999). 
 








Figure 6   The Domain Structure of MMP-2  (Gelatinase) 
Secreted MMPs contain an amino-terminal signal sequence (Pre) that directs them 
to the endoplasmic reticulum, a propeptide (Pro) domain containing the highly 
conserved sequence PRCGVPD around the chelating cysteine known as the 
‗cysteine switch‘ that maintains them as inactive zymogens. The simple hemopexin-
domain thought to confer much of the substrate specificity to MMPs as well as 
mediating interactions with TIMPs is connected to the catalytic domain by the small 
proline-rich hinge region which allows folding of the C-terminal domain onto the 
catalytic domain.The first and the last of the four repeats in the hemopexin-like 
domain are linked by a disulphide bond (S-S). The gelatin-binding MMPs also 
contain inserts that resemble collagen-binding type II repeats of fibronectin and are 
required to bind and cleave collagen and elastin. 
 
 
The MMP family consists of at least 23 distinct proteases in humans and are 
usually defined by their homologous structure at the protein and DNA levels 
I I 











as well as their substrate specificity by which they are categorized into 6 
main groups as shown in Table 2 (Visse and Nigase, 2003).    All members 
of the MMP family share several basic features within their five-domain 
structure including a pre-domain which contains a signal peptide responsible 
for secretion,  the  pro-domain which keeps the enzyme inactive  by the 
cysteine residue interacting with the Zn2+ from the catalytic domain to 
prevent binding and cleavage of the substrate, and the haemopexin-like 
domain which is linked to the catalytic domain by a flexible hinge region (Pei 
and Kang, 2000). 
Although a general proteolytic mechanism of activation is understood for 
MMPs, the mechanism of the inceptive period of protein insertion into the 
active site of the MMP prior to activation remains unknown.  Crystallographic    
data continues to suggest an active site that is too narrow to encompass  the 
respective substrate. Nash et al., (2016) undertook a fully parameterised 
Molecular Dynamics (MD) study of the structural properties of an MMP-1-
collagen crystallographic structure  followed by an exploration of the free 
energy surface of a collagen polypeptide chain entering the active site using 
a combined meta-dynamics and umbrella sampling (MDUS) approach. They 
concluded that interactions between MMP-1 and the collagen substrate 
indicated an energetic barrier for a local uncoiling and insertion event and 
this knowledge would  help to elucidate future collagen-peptide non-bonded 
association steps with the active site prior to proteolytic mechanisms to 
provide a better understanding of the role of the enzyme in the ECM. 
Another research group examined the Importance of the linker region 
between the catalytic (CAT) and hemopexin-like (HPX) domains in matrix 
metalloproteinase-1 and results of MD revealed that interactions between 
the  collagen-model triple-helical peptide with both the CAT and HPX 
domains of MMP-1 are dynamic in nature, and the linker region of MMP-1 
influences the interactions and dynamics of both the CAT and HPX domains 






1.3.2 Classification of MMPs 
 
 
Table 2    Classification of MMPs and Subtrates 
   
Classification MMP 
Collagenases 1, 8, 13, 18 
Gelatinases 2,9 
Stromelysins 3, 10, 11 
Matrilysins 7, 26 
Membrane-type MMPs 14, 15, 16, 17,24,25 




1.3.2.1  Collagenases 
 
MMP-1, MMP-8, MMP-13, and MMP-18 are in this group and have the ability 
to cleave native fibrillar collagen types I, II, III, V and IX and can also digest 
a number of other ECM and non-ECM molecules (Knäuper et al., 1996). The 
collagenases differ in their substrate specificities and functional roles. MMP-
1 preferably degrades collagen III whilst MMP-8 prefers type I collagen and 
MMP-13 collagen II (Massova et al., 1998, Knäuper et al.,1996).  
Recently Fischer and Riedl, (2016) used MMP-13 as the target enzyme for 
the structure-based design and synthesis of inhibitors able to recognize the 
catalytic zinc ion in addition to an allosteric binding site in order to increase 
the affinity of the ligand. They  optimized an initial allosteric inhibitor by 
addition of linker fragments and weak zinc binders for recognition of the 
catalytic centre and improved the lipophilic ligand efficiency (LLE) of the 





1.3.2.2   Gelatinases 
 
Gelatinase A (MMP-2) and gelatinase B (MMP-9) are able to digest  
denatured collagens and gelatin due to three fibronectin type II repeats 
within the catalytic domain that bind to gelatin, collagen and laminin. They 
also digest a number of ECM molecules including type IV, V, XI collagens 
and  aggrecan core protein. Additionally  MMP-2 but not MMP-9 is able to 
digest Type I, II, and III collagens in a similar way to collagenases  (Aimes  
and Quigley, 1995, Patterson et al., 2001). Both gelatinases contain Zn2+ 
and Ca2+ binding sites,  but  studies on MMP-9 by Tobwala and Srivastava, 
(2013) have also revealed that calcium ions are not just a structural 
requirement but also have a role in regulating the catalytic activity of MMP-9 
by modifying the active site. 
 
 
1.3.2.3   Stromelysins 
 
MMP-3, MMP-10 and MMP-11 have a domain arrangement similar to that of 
collagenases although they do not cleave interstitial collagens. MMP-3 and 
MMP-10 are similar in structure and substrate specificity and digest a 
number of ECM molecules. In addition  MMP-3 participates in the activation 
of a number of proMMPs and is critical for the generation of fully active 
MMP-1 (Suzuki et al., 1990). MMP-11 contains a  furin recognition motif 
RX[R/K]R at the C-terminal end of the propeptide and therefore  is activated 
intracellularly (Pei and Weiss, 1995). MMP-11in comparison to MMP-3 and 
MMP-10 has very weak activity toward ECM molecules, but readily cleaves 
serpins (Murphy et al., 1993, Pei et al., 1994). 
 
1.3.2.4  Matrilysins 
 
MMP-7 and MMP-26 are characterized by the lack of a hemopexin domain 
(Uria and López-Otín, 2000) and both digest a number of ECM components. 
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MMP-7 also processes cell surface molecules such as pro–α-defensin, Fas-
ligand, pro–tumor necrosis factor (TNF)-α, syndecan 1and E-cadherin (Parks 
et al., 2004). MMP-26, also known as endometase (Park et al.,2000) cleaves 
gelatin and β-casein (de Coignac et al., 2000) type IV collagen, fibronectin, 
fibrinogen, vitronectin (Marchenko et al., 2001, Uria and López-Otín., 2000), 
alpha 1-antitrypsin (Li et al., 2004), alpha 2-macroglobulin (Ahokas et al., 
2005), alpha (1)-proteinase inhibitor (Park et al., 2000, Li et al., 2004) and  
insulin-like growth factor-binding protein 1(Park et al., 2002). Moreover 
MMP-26 also has the ability to cleave and fully activate MMP-9 (Urıa and 
López-Otı́n, 2000).  
 
 
1.3.2.5   Membrane-type MMPs (MT-MMPs) 
 
MT-MMPs include four type I transmembrane proteins (MMP-14, -15, -16, 
and -24) and two glycosylphosphatidylinositol (GPI) anchored proteins  
(MMP-17 and -25). They all have a furin recognition sequence RX[R/K]R at 
the C-terminus of the propeptide and are therefore activated intracellularly, 
and active enzymes are likely to be expressed on the cell surface (Zucker et 
al., 2003, Shiomo and Okada, 2003), Folgueras et al., 2004). Apart from 
MMP-17, all MT-MMPs are capable of activating pro-MMP–2  (Thomas, 
2002, Zucker et al., 2003, Zhao et al., 2004). MMP-14 (MT1–MMP)  also 
activates MMP–13 and has collagenolytic activity on type I, II, III collagens  
and is able to cleave gelatin, fibronectin, laminin–1, vitronectin, cartilage, 
proteoglycans and fibrillin–1. MMP-15 (MT2–MMP)  can also activate MMP–
13 and can degrade laminin, fibronectin,and tenascin. MMP-16 (MT3–MMP) 
hydrolyzes gelatin, casein, type III collagen, and fibronectin (Zucker et al., 
2003). MMP-17 (MT4–MMP) has tumor necrosis factor-alpha convertase 
activity but does not activate MMP-2, but may have a role in the regulation of 
cell surface proteins, inflammatory processes and has the ability to degrade 
fibrinogen and fibrin (English et al., 2000). MMP-24 (MT5-MMP) is believed 
to function both as a membrane-bound and soluble proteinase  and can 
degrade several ECM components, such as inhibitory chondroitin sulfate 
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proteoglycans (Wang et al., 1999, Hayashita-Kinoh et al., 2001) and 
mediates the cleavage of the cell-adhesion molecule N-cadherin in 
heterologous cells (Monea  et al., 2006). MMP-25 (MT6–MMP) cleaves 
collagen type-IV, gelatin, fibronectin and fibrin (English et al., 2001) as well 
as cleaving and inactivating α1-proteinase inhibitor (Nie and Pei, 2004). 
Invasion of most normal cells across basement membranes and collagen-
rich interstitial  tissues  involves  degradation of  the ECM by membrane 
type-1 matrix metalloproteinase (MT1-MMP/MMP14) (Willis et al., 2013). To  
achieve  this activity MT1-MMP is transported to podosomes, the specialized 
ECM-degrading membrane protrusions found in highly migratory cells 
(Murphy and Courtneidge, 2011).  
More recently, an unexpected function independent of its proteolytic activity 
has been described for the MT1-MMP/MM-14 cytoplasmic domain in 
imprinting spatial memory for podosome reformation via assembly in 
membrane islets acting as cellular memory devices (Gucciardo et al., 2016, 
El Azzouzi et al., 2016). 
 
 
1.3.2.6  Other MMPs  
 
MMP-12 (Metalloelastase) is expressed primarily  in macrophages  and 
digests elastin, type IV collagen, type I gelatin, fibronectin,laminin, 
vitronectin, proteoglycans, myelin basic protein, and α1-antitrypsin (Shiomi 
and Okada, 2003). Zheng et al., (2015) looked at the role of the innate 
immune cells in the pathobiology of aneurysms and demonstrated that 
inactivation of p110δ expressed by leukocytes and which regulates immune 
function leads to extracellular matrix degradation in vessels and promotes 
aneurysm development via dysregulation of MMP-12 expression. 
 MMP-19 digests many ECM molecules including the components of 
basement membranes (Stracke et al., 2000). It is also known as  RASI-1 
(rheumatoid arthritis synovial inflammation-1) and is recognised as an 
autoantigen in patients with rheumatoid arthritis and systemic lupus 
erythematosis (Sedlacek et al., 1998). MMP-20 (Enamelysin) is primarily 
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located within newly formed tooth enamel and digests amelogenin (Ryu et 
al., 1999). MMP-21, MMP-23 and MMP-28 have a furin recognition 
sequence before the catalytic domain and therefore they are likely to be 
activated intracellularly and secreted as active enzymes. MMP-21 is known 
to digest gelatin but its activity on the other components of the ECM is 
largely unknown. MMP-23 is a unique member of the MMP family, devoid of 
structural features distinctive of the diverse MMP subclasses  but instead 
has a novel cysteine array motif and an immunoglobulin-like C2 type fold 
domain (Pei et al., 2000) and appearing to digest only gelatin (Pei, 1999). 
MMP-28 also named Epilysin belongs to the MMP–19 subfamily of the MMP 




1.4  MMP Regulation 
 
The proteolytic activities of MMPs influence essential cellular processes like 
cell proliferation, migration and adhesion, as well as many fundamental 
physiological events involving tissue remodelling, such as angiogenesis, 
bone development, wound healing, and uterine and mammary involution 
(Page-McCaw et al., 2007,  Rowe and Weiss., 2008). The major function of 
MMPs is the degradation and removal of ECM molecules from tissues and to 
achieve this they must tightly regulated. MMP activity is controlled at four 
different levels including gene transcription, compartmentalisation, 
proenzyme activation and endogenous inhibition. 
 
1.4.1   Transcriptional regulation of MMPs 
 
MMP gene expression is primarily regulated at the transcriptional level, 
which results in most MMPs being expressed in normal tissues at low levels 
but is upregulated during certain physiological and pathological processes. 
Several MMP promoters share several cis-elements in their promoter 
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regions which allows tight control of cell-specific expression by a diverse set 
of trans-activators including AP-1, PEA3, Sp-1, β-catenin/Tcf-4, and NF-κB 
(Benbow and  Brinckerhoff, 1997, Westermarck and  Kahari, 1999, 
Chakraborti  et al., 2003).  Induction or stimulation at the transcriptional level 
is mediated by a variety of inflammatory cytokines, hormones and growth 
factors such as interleukin-1(IL-1), interleukin-6 (IL-6) (Mauviel, 1993), 
tumour necrosis factor-α (TNF-α) (Ito et al., 1990), epidermal growth factor 
(EGF), platelet-derived growth factor (PDGF), basic fibroblast growth factor 
(bFGF) (Fabunmi et al.,1996) and CD40 (Malik et al., 1996).  
Furthermore, extracellular matrix metalloproteinase inducer (EMMPRIN) a 
cell surface protein that induces MMP expression has been identified in both 
normal and diseased human tissues (Spinale et al., 2000). Moreover, other 
factors such as heparin, transforming growth factor- β (TGF-β), interleukin-4 
(IL-4), retinoic acid and corticosteroids have been shown to have an 
inhibitory effect on MMP expression (Mauviel, 1993). 
This response at the transcriptional level occurs several hours after 
exposure to a stimulus which suggests MMP promoters are downstream 
targets within signalling pathways of early response genes, which are 
induced shortly after cellular stimulation. These early response genes 
encode signalling proteins that phosphorylate the different transcription 
factors, which are then able to bind the promoters of MMP genes. These 
signaling intermediates involved in the activation of transcription factors 
include the nuclear factor kappa B (NF-κB), the mitogen activated protein 
kinases (MAPK), the signal transducers and activators of transcription 
(STAT) and the Smad family of proteins (Vincenti et al., 2007).   
Studies have also shown that the p65 subunit of NF-κB can regulate  MMP-
1, MMP-2, MMP-3, and MMP-9 transcription during the initiation and 





1.4.2    Post-transcriptional regulation of MMPs 
 
Although MMPs are mainly regulated at the transcriptional level,  post-
transcriptional gene regulation can be instigated by cytostolic mRNA stability 
mediated  by trans-acting RNA binding proteins that interact with multiple 
AU-rich elements (ARE) mostly located in their 5′- or 3′-untranslated regions 
(UTRs), which are potential targets of different UTR-binding proteins with 
ability to stabilize or destabilize these mRNAs. The expression of MMP-2, 
MMP-9 and MMP-13 has been shown to be regulated through mRNA 
stability as demonstrated by researchers who  found TGF-b increases MMP-
2 and -9 levels by extending the half-life of MMP mRNAs in human gingival 
fibroblasts and prostate cancer cells (Overall et al., 1991; Hsu et al., 1992), 
and inducing MMP-13 expression by both inducing transcription and 




1.4.3   Compartmentalization of MMPs 
 
It is essential that cells are unable to indiscriminately release proteases 
which lead  to the unwanted degradation of proteins. In vitro studies have 
demonstrated significant overlap in the substrates MMPs can cleave within 
the ECM,  although substrate selectivity can be honed by enzyme affinity 
and compartmentalization. (Sternlicht and Werb, 2001). Kinetic studies have 
shown that specific enzymes degrade some substrates more efficiently than 
others. One example was  demonstrated by Mackay et al., (1990)  who 
established that both MMP-2 and MMP-9 act on cleaved collagen more 
efficiently than other MMPs. Compartmentalization refers to where and how 
in the pericellular environment an MMP is released and held and is an 
essential mechanism for regulating the substrate specificity and efficiency of 
any proteinase (Ra and Park, 2007). Secreted MMPs require a cellular 
compartment-specific localization mechanism to function properly. Through 
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their motifs and modules they are directed to extracellular compartments and 
are likely to be anchored to cell membranes which targets their  catalytic 
activity by locating and concentrating them close to  potential substrates 
within the pericellular space (Hadler-Olsen et al., 2011). A number of 
mechanisms have been described to compartmentalize MMPs. In addition to 
the membrane-bound MMPs, several examples of specific cell-MMP 
interactions have been reported, such as the binding of MMP-2 to the αvβ3 
integrin (Brooks et al., 1996) MMP-1 to the α2β1 integrin (Dumin et al., 2001, 
Stricker et al., 2001), MMP-9 to CD44 (Yu and Stamenkovic, 2000) and 
MMP-7 to surface proteoglycans (Yu and Woessner, 2000). All these 




1.4.4  Activation of ProMMPs 
 
Although transcriptional regulation is essential for MMP production, the third 
level of control is the extracellular activation of the secreted latent enzymes 
by cleavage of the propeptide.  
The cysteine residue (Cys73) is present within  the propeptide domain  
which functions as a stabilizer of the inactive form by forming a bond  with 
the active Zn2+ site in the catalytic  domain rendering the enzyme inactive. 
This mechanism has been referred to as the ―cysteine switch‖ The cysteine 
residue is replaced by a water molecule which binds to the Zn2+ ion 
converting it from  non-catalytic zinc to catalytic zinc   and resulting in the 
intermediate active enzyme following which the pro-domain of the MMP is 
removed by autolytic cleavage or by other proteases to produce the fully 








1.4.4.1    Chemical Activation of ProMMPs 
 
MMPs can be activated by a number of proteinases in vivo,  or in vitro by 
non-proteolytic agents such as SH-reactive agents, mercurial compounds, 
reactive oxygen and denaturants (Nagas and Woessner, 1999). These 
agents most likely work through the disturbance of the cysteine-zinc 
interaction of the cysteine switch (Van Wart and Birkedal-Hansen, 1990, 
 Chen et al.,1993). ProMMP-3 activation with a mercurial compound have 
indicated that the initial cleavage occurs within the propeptide and that this 
reaction is intramolecular whilst the subsequent removal of the rest of the 
propeptide is due to intermolecular reaction of the generated intermediates 
(Okada et al., 1988, Nagase et al.,1990).  Interestingly Gu et al., (2002) 
demonstrated the chemical activation of a proMMP in vivo by showing that 
NO activates proMMP-9 during cerebral ischemia by reacting with the thiol 












Figure 7    Example of Chemical Activation of a ProMMP 
Chemical activation of MMPs relies on modification of the cysteine switch sulfhydryl 
(SX) resulting in partial activation of the MMP and intramolecular cleavage of the 
propeptide after which removal of the propeptide by intermolecular processing 
results in full activity of the MMP.  The catalytic domain is depicted as a grey circle, 
the active-site cleft is shown in white containing the zinc binding site (Zn). The 
propeptide is represented as a black line containing the bait region (black filled 
rectangle) and the cysteine switch (C). SH indicates the sulfhydryl of the cysteine  





                                   Intramolecular cleavage    
 
      MMP intermediate 
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 1.4.4.2   Furin Intracellular Activation of ProMMPs 
 
Generally most proMMPs are secreted from cells and activated 
extracellularly. However in 1995, Pei and Weiss demonstrated that proMMP-
11 (stromelysin 3) is activated intracellularly by the Golgi-associated 
subtilisin-like serine proteinase furin and secreted as an active enzyme 
propeptide which is subsequently activated intracellularly before secretion 
Later Sato et al., (1996) established that MT1-MMP expressed in 
Escherichia coli was also activated by furin and proposed that all MT-MMPs 
contained a similar furin recognition sequence RXKR or RRKR and were 
likely to be activated intracellularly although the precise mechanism was 
unknown. About  a third of  MMPs including all membrane-bound MMPs are 
now known to contain a furin recognition sequence at the C-terminal end 
(Marchenko and  Ratvnikov, 2001,  Sternlicht  and  Werb, 2001,  Kang et al., 
2002, Illman et al., 2003). As these MMPs are secreted with enzyme activity,  
regulation by  gene expression or endogenous inhibition is vital to control 
their  proteolytic action.  
 
 
1.4.4.3 Activation of proMMPs by Plasmin  
  
The remaining MMP members are expressed and secreted as inactive pro-
forms, which need to be activated. Proteolytic activation of MMPs is stepwise 
in many cases and the first step usually involves proteinases such as 
plasmin, trypsin, furin, chymase, elastase or kallikrein, of which plasmin 
appears to be the major physiological activator  via the cysteine switch in 
vivo (Wart and Hansen-Birkedal, 1990, Murphy et al., 1994). At the cell 
surface, plasmin is derived from plasminogen by the action of  urokinase 
plasminogen activators (uPAs) and tissue plasminogen activators (tPAs) 
which are both membrane-associated thereby creating localized proMMP 
activation and subsequent ECM turnover. Plasmin is reported to activate 
proMMP-1(interstitial collagenase), proMMP-3 (stromelysin 1), proMMP-7 
(matrilysin), proMMP-9 (gelatinase B), proMMP-10 (stromelysin 2) and 
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proMMP-13 (collagenase 3) and subsequently some may participate in 
processing other MMPs (Eeckhout and Vaes, 1977, HE et al., 1989, Lijnen., 
2001). Activation of proMMP-2 is different, in being a two-step process 
involving hydrolysis of MT1-MMP and generating a 64 kDa intermediate 


















Figure 8    Plasminogen Activation               
 
Tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator 
(u-PA) bound to its cellular receptor (u-PAR) converts plasminogen to the active 
enzyme plasmin. Plasmins  primary role is to convert fibrin in blood clots to soluble 
degradation  products (FDP) but in addition to this has the ability to convert  some 
proMMPs into active MMPs resulting in ECM degradation. The plasminogen 
activators t-PA and u-PA are inhibited by plasminogen activator inhibitors (PAI) and 
plasmin is mostly inhibited by α2-antiplasmin while MMPs are inhibited by tissue 
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1.4.4.4   Activation of proMMPs by MMPs 
 
As well as the plasminogen system a number of MMPs can cleave the 
prodomain of other MMP zymogens leading to activation. In 1994, Sato et al 
cloned a membrane-type MMP (MT1-MMP) and identified it as an activator 
of latent MMP-2.  
 
Since, at least six MT-MMPs have been cloned and demonstrated to 
activate other MMPs including MT1-MMP, MT2-MMP (Butler et al., 1997, 
Takino et al., 1997, MT3-MMP (Takino et al., 1995, Zhao et al., 2004), MT5-
MMP (Llano et al., 1999, Pei, 1999) and MT6-MMP (Velasco et al., 2000). 
Knauper et al.,(1996)  also demonstrated that MMP-2  together with  MT1-
MMP were able to process human procollagenase-3 (MMP-13) to generate 
the fully active enzyme  via an activation cascade mechanism.  MT1-MMP-
mediated activation of proMMP-2 has been studied the most extensively and 
is unique in the fact that TIMP-2 is crucial for MMP-2 activity (Wang et al., 
2000) unlike proMMP-2 activation by MT2-MMP which is direct and 
independent of TIMP-2 ( Morrison et al., 2001).  
 
 
1.4.4.4.1   Cell Surface Activation of ProMMP-2  by MT1-MMP 
 
 ProMMP-2 forms a tight complex with TIMP-2  (Howard and Banda, 1991) 
through their C-terminal domains allowing the N-terminal inhibitory domain of 
TIMP-2 to bind to MT1-MMP on the cell surface which is subsequently 
activated by MT1-MMP that is free of TIMP-2 thus generating an 
intermediate form that is further processed to the fully activated form 
(Strongin et al., 1995, Kinoshita et al., 1998).  
 
Alternatively, MT1-MMP inhibited by TIMP-2 can act as a ―receptor‖ of 
proMMP-2. This MT1-MMP–TIMP-2–proMMP-2 complex is then presented 
to an adjacent free MT1-MMP for activation (Strongin et al., 1995, Butler et 
al., 1998, Cao et al., 1995, Morgunova et al ., 1999). Research has shown 
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that TIMP-2 promotes pro-MMP-2 activation by MT1-MMP through this 
trimolecular complex formed from pro-MMP-2, TIMP-2 and MT1-MMP, 
although excess amounts of TIMP-2 inhibit activation by blocking MT1-MMP 
activity. Therefore in vivo, efficient pro-MMP-2 activation may be dependent 
on the balance between the amounts of MT1-MMP and TIMP-2 (English et 
al., 2006). 
 
Although proMMP-2 activation was expected to occur only at low TIMP-2 
concentrations relative to MT1-MMP, a study by Kudo et al., (2007) showed 
that proMMP-2 was activated by MT1-MMP which was mostly saturated with 
TIMP-2, and as a result TIMP-2 appeared to inhibit cleavage of other direct 
MT1-MMP substrates even at the level that induces proMMP-2 activation. In 
light of these results they speculated that TIMP-2 concentration dictates 























































Figure 9    Cell Surface Activation of ProMMP-2 
A. MT1-MMP on the cell surface acts as a receptor for TIMP-2 which binds via its 
N-terminal domain to the active site of the MT1-MMP. This binary complex then 
acts as a receptor for pro-MMP-2, with the TIMP-2 free MT1-MMP molecule in 
close proximity can then cleave the propeptide of pro-MMP-2, generating an 
intermediate species. Further proteolysis of the propeptide through an autocatalytic 
mechanism results in the generation of the fully active enzyme. Activation of pro-
MMP-2 is only possible if the TIMP-2 concentration is low, with sufficient TIMP-2 to 
generate the trimeric complex but not enough to saturate all the MT1-MMPs 
required for proteolysis of the propeptide.  
B. If high levels of TIMP-2 are present, TIMP-2 will bind to and inhibit all MT1-MMP 
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More recently Otto et al., (2016) looked at aortic stiffness in cardiovascular 
disease using a co-culture model of rat aortic endothelial cells and smooth 
muscle cells  stimulated with Ang ll which resulted in activation of latent pro-
MT1- MMP and pro-MMP-2 exclusively in SMCs when co-cultured with ECs. 
They concluded  that the endothelium under ANGII stimulation acts as a 
novel and key activator of latent pro-MT1- MMP and pro-MMP2 in SMCs of 
rat aorta and  therefore the endothelium may critically contribute to the 
pathophysiology of aortic stiffness which is also a factor in AAA. 
 
 
1.4.5   Endogenous Inhibition of MMPs 
 
In normal healthy tissues MMPs are tightly regulated by naturally occurring 
inhibitors of which TIMPs (tissue inhibitor of metalloproteinases) are the 
dominant source while α2-macroglobulin and tissue-factor pathway inhibitor-
2 (TFPI-2) and calcium-binding proteoglycans inhibit MMPs to a lesser 
extent. Disruption of the balance between the production of active enzymes 
and their inhibition may result in diseases such as arthritis, atherosclerosis, 
tumour growth and metastasis.  
 
1.4.5.1    Tissue-Factor Pathway Inhibitor-2 
 
TFPI-2 is a 32 kDa matrix-associated Kunitz-type serine proteinase inhibitor 
consisting of a short amino-terminal region with three tandem Kunitz-type 
domains and a positively charged carboxy-terminal tail (Chand et al., 2005). 
Research has shown TFPI-2 can diminish the proteolytic activity of MMP-1, 
MMP-2, MMP-9 and MMP-13 (Herman et al., 2001). TFPI-2  can also weakly 
inhibit the coagulation proteins factor Xa and factor VIIa/TF complex in 
addition to its established targets the serine proteins kallikrein, trypsin, 
chymotrypsin, and plasmin, (Sprecher et al.,1994,  Petersen et al., 1996 Rao 
et al., 1999). 
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1.4.5.2    Calcium-binding Proteoglycans 
 
The testicans form a subgroup within the BM-40/SPARC/osteonectin family 
of modular extracellular proteins (Hartmann and Maurer., 2001) and are 
composed of highly conserved, extracellular, calcium-binding, sulfate 
proteoglycans.The Testican family is composed of highly conserved, 
extracellular, calcium-binding, sulfate proteoglycans. Testicans are detected 
in a variety of tissues and family members include Testican-1, Testican-
2,Testican-3 and an amino-terminal splice variant of Testican-3, designated 
NTes. Most Testicans are able to inhibit MT-MMPs thereby inhibiting the 
activity of pro-MMP-2 as shown by Nakada et al., (2001)  who demonstrated 
that N-Tes, testican-1 and testican-3 but not testican-2 are able to inhibit 
MT1- or MT3-MMP mediated proMMP-2. 
 
 
1.4.5.3   α2-Macroglobulin 
 
Blood plasma derived α2-macroglobulin (α2M) is a 772 kDa protein 
comprised of   four nearly identical subunits bound together by -S-S- bonds. 
α2M  is  a broad spectrum proteinase inhibitor of tissue fluids and  blood. 
and  able to inactivate a variety of proteinases including serine, cysteine, 
aspartic acid and MMPs. It is synthesised mainly in the liver by hepatocytes 
but other cell types such as macrophages are also believed to produce α2M. 
Whilst α2M is considered to be the main inhibitor of MMPs in serum/tissue 
fluids, the major tissue inhibitors of active MMPs are thought to be the TIMP 
family where they may act more locally (Cawston and Mercer, 1986, 1987). 
α2-Macroglobulin inhibits endopeptidases by cleaving one or more bonds  in 
the 'bait'  region initiating a conformational change that leads to entrapment 
of the whole enzyme which becomes covalently anchored by   
transacylation,  preventing  interaction with its natural substrates. The α-
macroglobulin/proteinase complex is then quickly cleared  by low density 
lipoprotein receptor-related protein (LDL-RP) mediated endocytosis (Sotturp-
Jensen,1989, Strickland et al.,1990, Birkedal-Hansen et al., 1993). It is 
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probable that MMPs are similarly internalised and degraded by the same 
process as demonstrated by  Barmina et al.,  (1999) who established that 
MMP-13 associates with the LDL-RP through a specific receptor on 
osteoblastic cells and Hahn-Dantona et al., (2001) who showed MMP-9 and 
its TIMP-1 complex could be internalised  by binding to LDL-RP. α2-
Macroglobulin  also plays a role in the irreversible clearance of MMPs as 
macroglobulin/MMP complexes are removed by scavenger receptor-
mediated endocytosis in contrast to TIMPs which inhibit MMPs in a 
reversible manner (Sternlicht and Werb, 2001). 
More recently, Satoh et al., (2013) examined potential serum protein 
biomarkers for aortic aneurysms by comparing protein profiles from pre-
surgical and post-surgical sera in AAA patients. Their findings suggested 
that α2-macroglobulin may be a potential serum biomarker for AAA. 
 
 
1.4.5.4   Tissue Inhibitors of Metalloproteinases (TIMPs) 
 
TIMPs are endogenous inhibitors of MMPs found in most tissues and body 
fluids and by inhibiting MMP activity are consequently important regulators of 
ECM turnover, tissue remodelling and cellular behaviour. Within the aortic 
wall MMPs are able to degrade most proteins of the ECM but are 
counteracted by TIMPs which inhibit MMP activity and restrict ECM 
breakdown and thus play an important role in maintaining the integrity of  the 
healthy aorta. The balance between MMP and TIMP activities is involved in 
both normal and pathological events such as AAA, wound healing, tissue 
remodelling, angiogenesis, tumorigenesis and metastasis (Gomez et al., 
1997) In addition to their primary role of MMP inhibition, recent studies have 
suggested that TIMPs themselves may have roles independent of MMPs 
that include direct modulation of cell growth and differentiation (Lambert et 
al., 2004).  
 
Currently four members of the TIMP family have been identified in humans 
and are designated TIMP-1, 2, 3 and 4 (Brew et al., 2000). They are 
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homologous proteins of 21–29 kDa in size and each TIMP molecule consists 
of around 190 amino acids composed of two distinct domains, a larger N-
terminal and a smaller C-terminal domain, each stabilised by three 
conserved disulfide bonds. The N-terminal domain containing the conserved 
VIRAK amino acid consensus sequence is able  to inhibit MMPs by chelating 
their catalytic zinc atom  whilst The function of the C-terminal domain is not 
fully understood, but it has been shown that it can bind tightly to the 
haemopexin domain of latent MMPs  (Williamson et al., 1990, Murphy et al., 
1991, Nagase, 2002).   
 
In general most mesenchymal and epidermal cells are able to produce 
TIMPs but additionally TIMP-1, 2, and 3 are also produced by white blood 
cells (Rowe et al., 1997).TIMPs form non-covalent 1:1 stoichiometric 
complexes with MMPs most of which can be inhibited by all four TIMPs,  
although differences in binding affinity have been reported (Olson et al., 
1997) and  membrane-type (MT) MMPs form a distinct group  since they are 
bound to the cell membrane and are rarely inhibited by TIMP-1 (English et 
al., 2001, Baker et al., 2002). 
 
X-ray crystallographic studies have shown that TIMP-1 and 2 molecules 
have an elongated wedge-like shape (consisting of the N-terminal and the C-
terminal halves of the polypeptide chains opposing each other) that fits into 
the entire length of the active-site cleft of an MMP just like a substrate 
molecule. Subsequently the conserved cysteine in the N-terminal domain will 
chelate the active-zinc site and expel the water molecule, thereby 
inactivating the MMP protein (Gomis-Rüth et al., 1997). Next, the N-terminal 
domain is folded into a five-stranded β-pleated sheet rolled into a β-barrel 
common   to    the    oligosaccharide/oligonucleotide  binding-fold   (O-B fold)  
found in certain DNA-binding proteins (Williamson et al., 1994).                                                                                                                               
TIMP-1 is a 25 kDa secreted polypeptide that is capable of inhibiting most 
MMPs,  whereas TIMP-2, a 21 kDa nonglycosylated protein is predominantly 
active against MMP-2 although it also appears more effective than TIMP-1 at 
inhibiting MMP-9. TIMP-1 and TIMP-3 expression is inducible, whereas 
TIMP-2 expression is largely constitutive. Often the production of TIMPs is 
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elevated by the same stimuli that promote MMP expression (Thompson et 
al., 2002).  TIMP-1 and TIMP-2  are  not only  able to bind to the active forms 
of MMPs but  TIMP-1 can bind to proMMP-9 and TIMP-2 to proMMP-1 and 
2, inhibiting the intramolecular autoactivation of these proenzymes (Howard 
et al., 1991, De Clerek et al., 1991, Okada et al., 1992). Another important 
feature of TIMP-2 is its role in the activation of proMMP-2  by  MT1-MMP  
which was described earlier in section  1.4.4.4.1  and Figure 9.  
 
TIMP-4 inhibits MMP-1, MMP-3, MMP-7 and MMP-9, showing a particular 
interaction with MMP-2. TIMP-4 transcripts appear abundant in the human 
heart but occur only at low levels in other organs (Liu., 1997).  In mice, 
TIMP-4 mRNA was restricted to neural tissue, Sertoli cells, ovaries, cardiac, 
breast and skeletal muscle tissues which also applied in part to humans 
(Young et al., 2002, Lambert et al., 2004).TIMP-3 appears to be unique in 
that it exists primarily in association with the extracellular matrix (Gomez et 
al., 1997), its ability to form complexes with sulphated glycosaminogens (Yu 
et al, 2000) and its inhibitory action against other metalloendopeptidases 
such as the ADAM family (Amour et al., 1998, Loechel et al., 2000, 
Kashiwagi et al., 2001). Presently there is no evidence that TIMPs are able 
















Table 3    Summary of Common Features of TIMPs 
 
 TIMP-1 TIMP-2 TIMP-3 TIMP-4 
Amino acid 
residues 
184 194 188 194 
Protein kDa 28 22 24/27 22 
Glycosylation 
sites 
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2. Introduction: Vascular Pathology 
 
2.1  The Abdominal Aortic Aneurysm (AAA) 
 
An abdominal aortic aneurysm (AAA) is a swelling (aneurysm) of the aorta 
which is the main artery that leads away from the heart, through the 
abdomen to the rest of the body. The abdominal aorta is the largest blood 
vessel in the body and is usually around 2cm wide.  An abdominal aortic 
aneurysm is defined as permanent and irreversible localised dilation of the 
aorta involving all three layers of the aortic wall that exceeds the normal 
diameter by 50% or greater than 3 cm in total (Johnston et al., 1991). 
Abdominal aortic aneurysm (AAA) represents a common degenerative 
disease of the aortic wall with a life-threatening risk of rupture and is 
generally associated with old age. The most common location of arterial 
aneurysm formation is the abdominal aorta, specifically the segment of the 
abdominal aorta below the renal arteries ending above the bifurcation of the 
iliac arteries and are termed infrarenal abdominal aneurysms (IAAA) and 
typically exhibit a fusiform morphology with symmetrical circumferential 
enlargement of the wall or less frequently a saccular form affecting only part 
of the aortic circumference. Although most aortic aneurysms occur in the 
abdominal aorta, aneurysmal degeneration that occurs in the thoracic aorta 
is termed a thoracic aortic aneurysm (TAA). However, this study will only 
focus on AAAs  and not TAAs for several reasons, including different 
anatomical locations and differing aetiologies which are explained more fully 













Figure 10    Diagrams of the Normal Anatomy of the Aorta and Location 
of an Infrarenal Abdominal Aortic Aneurysm  
 A: The aorta extends upward from the top of the left ventricle of the heart in the 
chest area (ascending thoracic aorta), then curves (aortic arch) downward through 
the chest area (descending thoracic aorta) into the abdomen (abdominal aorta). 
The aorta delivers oxygenated blood pumped from the left side of the heart to the 
rest of the body. B: The location of a typical infrarenal abdominal aneurysm. 
 
2.1.1    Aetiology of Abdominal Aortic Aneurysms (AAAs) 
 AAA formation is not well understood and is a complex multifactorial 
condition involving genetic and environmental factors as well as mechanical 
influences such as turbulent blood flow and hypertension. AAA is 
characterized by destruction of elastin and collagen in the media and 
adventitia, depletion of medial smooth muscle cells with thinning of the 
vessel wall, and transmural infiltration of lymphocytes and macrophages.  
Atherosclerosis is often a common underlying feature of aneurysms and is 
considered a risk factor along with hypertension, cigarette smoking, 







2.1.2    Prevalence of AAA in UK 
 
Screening studies in the UK have estimated  a prevalence of 1.3 - 12.7% 
depending on the age group studied. The incidence of AAA in men is 
approximately 25 per 100,000 at age 50 increasing to 78 per 100,000 in 
those older than 70 years. ( NICE Technology Appraisal Guidance., 2009). 
Men are six times more likely to be diagnosed with AAA than women and 
that likelihood increases with age and other risk factors such as smoking, 
hypertension or having a first degree relative affected by AAA. During 2016 
the NHS Screening Programme also stated that 54 out of every 10,000 men 
screened will eventually have surgery to repair an  aneurysm (NHS AAA 
Screening Programme, 2016).  Interestingly the incidence of ruptured AAA 
rose from the 1970s to 2000 but now appears to be declining  which may be 
attributed to changes in smoking habits and increases in elective AAA repair 
in those aged 75 years and over (Anjum et al., 2012). 
The NHS AAA Screening Programme (NAAASP) screened more than 
260,000 men (65 years of age or over) in the UK during 2013/14 and 
detected nearly 3,700 aneurysms of 3cm or larger which resulted in 491 














2.1.3   Summary of Histological Features of AAA 
 
 
Table 4    Major Histological Features of AAA 
 
Inflammatory infiltrate Koch,1990, 
Freestone,1995 
Extensive extracellular matrix  remodelling Golledge, 2008 
Aortic advential thickening and neovascularisation Holmes,1995 
Thompson,1996 
Thickening of the tunica intima Holmes,1995 
Thompson,1996 
Fragmentation/decrease in aortic medial elastin  Campa,1987, 
Baxter,1992 
Medial  neovascularisation Holmes, 1995 
Fragmented internaI elastic lamina Morimoto, 1993 
Intraluminal thrombus Harter,1982 




2.1.4   Infrarenal Adominal aortic Aneurysm 
The propensity for aneurysms to develop in this part of the aorta is 
multifactorial.  Firstly, the number of elastic lamellae is greatest in the 
ascending aorta, containing approximately 55 to 60 elastic lamellae (elastic 
fibres and interspersed SMCs constitute a ‗lamellar unit‘), which gradually 
decrease in number across the descending thoracic aorta down the length of 
the aorta to reach approximately 26 at the aortic bifurcation (Wolinsky and 
Glagov,1967). Despite this regional variation in medial thickness, there 
appears to be a relatively consistent relationship between the number of 
elastic lamellae and the estimated hemodynamic stress typically placed on 
the vessel wall. This relationship is maintained in a number of mammals 
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however, it is particularly notable that the human, infrarenal aorta represents 
one of the few exceptions to this rule, because it contains fewer elastic 
lamellae than would otherwise be predicted for its estimated haemodynamic 
load, therefore the elastin content is markedly decreased resulting in this 
segment becoming thinner and stiffer (Wolinsky and Glagov, 1969). 
Additionally, with increasing age there is a corresponding decrease and 
degeneration of the elastic lamellae due to elastin synthesis essentially 
ceasing in the adult aorta, and partial replacement with collagen resulting in 
the some of the histological changes listed in Table 4. 
Secondly, the oxygen and nutrient supply to the aortic media is generally 
derived by simple diffusion from the lumen in segments that contain up to 
approximately 29 elastic lamellae (Wolinsky and Glagov, 1967). Aortic 
segments from humans and other mammals that contain a greater number 
of elastic lamellae require an additional nutrient supply which provided by 
vasa vasora that extend from the adventitia to the outer layers of the elastic 
media. The human thoracic aorta contains a rich vasa vasorum, however the 
infrarenal aorta is normally devoid of medial vasa vasorum and as the 
infrarenal aorta may contain more than 29 elastic lamellae, the lack of vasa 
vasorum in this region represents another unique feature of this aneurysm-
prone segment (Zarins et al., 2001). 
Another consideration is localization of increased haemodynamic load in the 
infrarenal aorta due to the distal tapering and  progressive stiffening (due to 
decreased elastin) in this region as well the addictive effects of retrograde 
pressure waves that reflect from the iliac bifurcation combined with incoming 
antegrade pressure waves (Dobrin, 1989 and Newman, 1973). Overall this 
culminates in the infrarenal aorta having a lower capacity to withstand the 
haemodynamic demands placed on it and hence the predisposition for AAAs 





2.1.5   Genetic Associations of AAA  
 
Clustering of AAA in families, raising the possibility of an inherited genetic 
predisposition, was reported as early as 1977 (Clifton, M.A). Numerous 
studies since that time have analysed possible candidate genes, including 
matrix metalloproteinases, and these are summarised in Table 5. 
 
Table 5   Most Significant AAA Associated Candidate Genes 
 




Lipid metabolism rs599839 Jones et al., 2013 
IL6R Inflammation rs7529229 Harrison et al., 2012 
LPA Lipid metabolism rs10455872 
rs3798220 
Helgadottir et al 2012 
AGTR1 Renin-angiotensin 
system 
rs5186 Jones et al ., 2008 
TGFBR2 TGFB signalling rs1036095 Biros et al., 2011 
TGFBR2 TGFB signalling rs764522 Biros et al., 2011 
ACE Renin-angiotensin 
system 
rs4646994 McColgan et el.,2009 
MMP3 Degradation of ECM rs3025058 Morris et al., 2014 
MMP13 Degradation of ECM rs2252070 Saracini et al., 2012 
MTHFD1 Methionine metabolism rs8003379 Giusti et al., 2008 
MTRR Methionine metabolism rs326118 Giusti et al., 2008 
LRP5 Lipid metabolism rs3781590 
rs4988300 
Galora et al., 2013 
 
Human leukocyte antigen (HLA) alleles have also been suggested to act as 
genetic risk factors for AAA and studies involving the HLA-DR B1 locus 
found that the B1*02 and B1*04 subtypes were more prevalent in the 
aneurysm group compared to a control group, although the precise 
mechanism by which the HLA genotype affects susceptibility is unknown 
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(Rasmussen et al ., 2001).  Increased frequency of the HLA-DR2 allele was 
described by Hirose et al., (!998, 1999) who suggested this might be a 
genetic risk factor for AAA, as opposed to HLA-DQ3 which appeared to have 
a protective effect. 
As technology has improved, genome-wide studies have identified certain 
chromosomal regions (susceptibility loci) of the human genome contributing 
to genetic risk for AAA (Krishna et al., 2010, Hinterseheret al., 2011). Within 
these areas, over 1800 target genes have been identified including MMP-9 
(Pahl et al., 2012). 
Whilst there is vast evidence of genetic factors in the development of familial 
AAA, as yet no clear pattern of inheritance has been discovered. Many 
questions remain unanswered although it seems likely to be a complex 
interplay between genetic predisposition and environmental exposure; future 
studies may define subgroups of patients at risk. 
 
 
2.1.6   Autoimmunity in AAA 
 
In nonspecific AAAs infiltration of monocytes, macrophages, B-lymphocytes, 
plasma cells and T-lymphocytes (including both CD4 and CD8 T-cells) are 
commonly observed as well as the presence of Russell bodies (aggregates 
of immunogloblin) in the adventitia and outer media, leading researchers to 
investigate the role of autoimmunity in the pathogenesis of AAA (Koch et al., 
1990). Using immunoglobulin G isolated from human aneurysmal tissue as 
the primary antibody in Western blot analysis of aortic tissue extracts, 
Gregory and colleagues (1996) found antibodies with specific reactivity 
against two major protein bands migrating at 40 kDa and 80 kDa (a dimeric 
form of the predominant 40-kDa species). This initial putative aortic 
autoantigen was designated aortic aneurysm associated protein-40 (AAAP-
40) and found to co-localize with elastin-associated microfibrils. Additional 
studies indicated that AAAP-40 has a high degree of sequence homology to 
microfibril-associated proteins (MAGP), an important component of the 
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elastin-associated microfibrils, fibrinogen beta and vitronectin (Xia et al., 
1996, Hirose et al., 1998). Furthermore, using immunohistochemistry an 80 
kDa collagen-associated protein was observed in the adventitial connective 
tissue and is suggested as another target of an autoimmune response in 
AAA (Chew et al., 2003).  Immunoreactivity against autoimmune proteins 
that co-localize with structural cytoskeletal components could contribute 
towards the pathological features of AAA. 
Molecular mimicry defined as the sharing of common antigenic epitope(s) 
between a microorganism (bacteria or viruses) and self (host) (Oleszaket al., 
2004) is another mechanism which may be responsible for the  generation   
of autoimmunity in AAA. Microorganisms such as Chlamydia pneumoniae, 
Treponema pallidium, herpes simplex virus and cytomegalovirus all share 
variable sequence homology with epitopes of AAAP-40 thereby triggering 
the autoimmune response (Ozsvathet al., 1996., Halmeet al., 1999). 
Certain human leukocyte antigen (HLA) subtypes are associated with 
chronic inflammatory and autoimmune diseases such as rheumatoid arthritis 
and have been studied in relation to aortic aneurysms. The immune 
response within the aortic wall is regulated by the HLA system and 
expression of certain alleles has been associated with susceptibility to 
autoimmunity in AAA and was discussed earlier in section 2.1.5. 
 
2.1.7    Infectious Agents in AAA 
                                                                                                                                                         
Mounting evidence suggests that infectious agents may play a contributory 
role in the pathogenesis of atherosclerosis, particularly cytomegalovirus and 
Chlamydia pneumoniae (Chung and Rivera, 1998). Studies by Tanaka and 
colleagues (1994)  have also indicated that chronic low grade infection may 
be involved in the development of aneurysmal disease after finding evidence 
of cytomegalovirus (CMV) genomic DNA in 65% of degenerative AAA and in 
86% of inflammatory AAA, but in only 31% of normal aortic tissues (Tanaka 
et al., 1994). Furthermore in IAAA, expression of CMV immediate early 
mRNA (signifying active infection) was detected in macrophages, fibroblasts 
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and endothelial cells leading researchers to suggest frequent and active 
infection of CMV in IAAA plays a significant role in the induction of chronic 
inflammatory reaction (Yonemitsu., 1996). However, Satta and colleagues 
(1998) found no evidence for cytomegalovirus in degenerative human AAA 
tissues thus the evidence to date suggests that cytomegalovirus more likely 
plays a role in inflammatory AAAs, whereas the role of chronic viral infection 
in the more common degenerative form of aneurysm disease is open to 
question.  
Chlamydia pneumoniae has also been associated with atherosclerosis as 
well as being detected in SMCs and macrophages located in AAA lesions. 
Petersen et al., (1998) using a nested polymerase chain reaction method 
designed to detect a fragment of the major outer membrane protein gene of 
C. pneumoniae, discovered C. pneumoniae–specific DNA in 35% of patients 
with AAA, but only 5% in non-aneurysmal abdominal aortas. C. pneumoniae 
was also demonstrated in the walls of AAA by Juvonen et al., (1997) using 
immunohistochemistry and PCR and again later by Karlsson et al., (2000) 
using the same methods. In 2001 Lindholt and colleagues during serological 
studies reported a significant correlation between IgG and IgA titres against 
C. pneumoniae and aneurysmal expansion rate,  although previously in 
1998 the Viborg Study in Denmark had failed to find any correlation  
(Lindholt et al., (1999).  Interestingly,  an earlier study by the Lindholt  group 
(1997) had failed to detect any evidence of C. pneumoniae in the walls of 
symptomatic AAA using a nested polymerase chain reaction method. 
Furthermore, chronic obstructive pulmonary disease (COPD) and its 
connection with chronic C. pneumoniae was also considered a possible risk 
factor for AAA  but  Lederle et al., (2000) found no association between 
COPD and AAA. 
The more commonly involved organisms involved in infections of aneurysms 
are Staphylococcus aureus and Salmonella species which can be easily 
identified by culture (Sessa et al., 1997). Less diagnosed is Coxiella burnetii, 
the etiologic agent of Q fever and in 2005 Sessa et al reported on three of 
the known nine cases of this infection in aneurysms, suggesting that 
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underlying cardiovascular disease such as valve defects or aortic aneurysms 
are risk factors for Q fever and can lead to severe complications if untreated 
(Sessa et al., 2005).  
The sexually transmitted disease syphilis caused by the spirochetal 
bacterium Treponema pallidum used to be a common risk factor for AAA if 
left untreated but is now less common due to adequate antibiotic treatment. 
Mycotic aortic aneurysms are unusual, accounting for less than 1% of aortic 
aneurysm repairs and are defined as those naturally occurring aortic 
aneurysms that result from or are secondarily infected by bacteria arising in 
a distant site of infection. In these cases of mycotic aneurysms of 
haematogenous origin,  local invasion of the intima and media gives rise to 
abscess formation and aneurysmal dilation of the vessel caused  by either 
gram-negative or more commonly gram-positive organisms and only rarely 
More recently in 2008, Nyberg and colleagues investigated 119 patients with 
infrarenal AAA and 36 matched controls for specific IgG class antibodies 
against C. pneumoniae, Helicobacter pylori, Cytomegalovirus, and Herpes 
simplex virus. The study demonstrated no significant difference in 
seroprevalence for these infectious pathogens between AAA patients and 
controls and therefore failed to establish a connection between AAA and 
infectious burden (Nyberg et al., 2008). Overall the association between 
infectious agents and the development of AAA remains controversial and 
unresolved and future work may provide new insights. 
 
2.1.8  Atherosclerosis and AAA 
 
In Section 2.1.1 atherosclerosis was described as an important risk factor 
and for many years AAA was considered an end-stage manifestation of 
atherosclerosis, but recently this view has been increasingly questioned and 
the specific relationship to atherosclerosis remains unknown. For many 
years AAA has long been considered an end-stage manifestation of 
atherosclerosis, but in recent years this view has been increasingly 
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questioned and the specific relationship to atherosclerosis still remains 
unknown. Most AAAs occur in association with advanced atherosclerosis, 
and most patients with aneurysm disease exhibit risk factors for 
atherosclerosis which strongly suggests that atherosclerosis and AAAs are 
causally linked; however there are potentially important differences in 
pathophysiology and morphology between the two diseases. 
 
Table 6   Comparison of Features for AAA and Arterial Occlusive 
Disease (AOD) 
 
FEATURES AAA AOD 
Age at onset Approx 10 years later than 
AOD 
Approx 60 years 
Gender Predominantly affects 
males in a ratio approx 5:1 
to females 
Both sexes affected 
equally 
Genetics Family history of AAA is a 
strong risk factor 
 Genetic factors represent 
a  risk  for atherosclerosis 
e.g. Familial 
hypercholesterolemia 
Smoking Risk factors Risk factors 
Hyperlipidaemia Low risk factor High risk factor 
Hypertension Significant risk factor Risk factor 
Diabetes mellitus Negative risk factor High risk factor 
Pathophysiology Dilation of all layers of 
artery wall – loss of elastin 
and SMCs – weakening of 





proliferation of cells 
leading to rigidity and 
stenosis of vessel 
Inflammatory response High proteolytic activity 
and greater infiltration of 
inflammatory cells than 
AOD 
Chronic inflammation 
TNF-α, IL-1β, IL-6 Higher levels of these 
cytokines found in AAA 






Furthermore, results have been contradictory in some areas of this research, 
for example Shteinberg‘s comparison of AAA and AOD found the risk factors 
male gender and smoking high in both groups with no significant difference 
(Shteinberg et al., 2000) whereas LaMorte et al., (1995) found male gender 
a stronger risk factor in AAA than AOD and smoking a stronger risk factor in 
the AOD group. Louwrens et al., (1993) found AAA patients were older with 
higher blood pressure than patients with AOD but no difference in tobacco 
consumption or cholesterol levels contradicting Chan et al., (1996) whose 
AOD patients were older with higher rates of smoking and no difference was 
found in regard to hypertension and lipid levels.  
Recently, a retrospective study demonstrated the atherosclerotic profiles are 
significantly different between patients with thoracic aortic aneurysm (TAA) 
and AAA suggesting mechanisms underlying the development of aortic 
aneurysms may differ in TAA and AAA (Ito et al., 2008). It is also notable 
that aneurysms only rarely occur in certain vessels that are commonly 
affected by occlusive atherosclerosis (such as the carotid and external iliac 
arteries) and that patients without evidence of atherosclerosis may develop 
AAA. Although it is difficult to exclude atherosclerosis as a likely causative 
factor in aneurysm disease it is difficult to define the exact etiologic 
relationship between the two and some researchers  propose that 
aneurysms are a unique disease entity with localized atherosclerosis 
representing a nonspecific secondary response, thus the specific 
pathogenesis of AAA versus AOD remains ill-defined. 
 
2.1.9  Oxidative stress in AAA 
A prominent pathological feature of AAA is the inflammatory response during 
which oxidative stress is invariably increased as well as further contributing 
to the pathophysiology of inflammation. Oxidative stress can be defined as 
tissue damage occurring secondary to increased production and/or 
decreased removal of reactive oxygen species (ROS), the balance of which 
depends on the activity of ROS-generating systems such as NADPH oxidase 
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as well as levels of endogenous cellular antioxidants (McCormick et al., 
2007).  
Oxidative stress is  another proposed main player in AAA and the idea that 
ROS including superoxide anion (O2
-), hydroxyl radical (∙OH) and reactive 
nitrogen species (RNS) such as nitric oxide (NO) and peroxynitrite (ONOO-) 
are associated with the pathologic progression of AAA has long been 
considered by researchers (Yajima et al., 2002). In 1987, Dubick et al 
reported that levels of ascorbic acid, Cu, Zn and superoxide dismutase 
(SOD) activity in tissue samples from patients with AAA and AOD were 
reduced suggesting a role for oxygen radicals or increased lipid peroxidation 
in occlusive and aneurysmal disease of the aorta. More recently, Zhang et 
al., (2003)  established the presence of inducible nitric oxide synthase 
(iNOS) (which catalyzes the production of nitric oxide (NO) in the media and 
adventitia of AAA patients promoting formation and activity of peroxynitrite 
and further contributes to oxidative tissue and cellular injury in AAA. Liao 
and colleagues (2001) also confirmed these findings, that expression of 
iNOS increased significantly in the aneurysm walls of patients with AAA 
compared to the healthy controls and concluded SMCs and inflammatory 
cells were main cellular sources of increased iNOS in AAA. Furthermore NO 
may regulate the development of AAA by inducing the expression of the 
extracellular MMP inducer EMMPRIN thereby modulating the activity of 
MMPs (Johanning et al., 2002, Lizarbe et al., 2009). 
The major vascular cells found in the aortic wall, SMCs, fibroblasts and 
endothelial cells all produce ROS primarily via membrane-associated 
NADPH oxidases, xanthine oxidase (XO) and the multiple isoforms of nitric 
oxide synthase (NOS). Xiong et al., (2009) investigated the hypothesis that 
ROS produced by these enzymes play an important role in aneurysm 
formation by selectively blockading them  in a murine model of AAA. The 
results show that apocynin (the specific inhibitor of  NADPH oxidase) but not 
oxypurinol (XO inhibitor) suppressed experimental aortic aneurysm formation 
in the murine model suggesting that  NADPH oxidase but not XO contributes 
to ROS production. Additionally, they found that CaCl2 treated homozygous 
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iNOS deficient mice were partly resistant to aneurysm induction in 
comparison to wild type mice, signifying a role for both the NADPH oxidase 
and iNOS pathways in AAA development (Xiong et al., 2009). Significantly, 
ROS are reported to activate matrix metalloproteinases (MMPs) 
(Rajagopalan et al., 1996), to inhibit plasminogen activator inhibitor-1 (PAI-1) 
and to induce apoptosis of SMCs (Li et al., 1997) as well as augmenting the 
cycle of inflammation, ultimately resulting in extracellular matrix degradation 
as seen in AAA.  
Recently, Spadaccio et al., (2016) conducted a study which looked at protein 
oxidation and supported the involvement of oxidative stress in the 
pathogenesis of AAA. Using a redox proteomic approach they investigated 
total and specific protein carbonylation and protein-bound 4-hydroxy-2-
nonenal (HNE) in the serum of AAA patients and demonstrated increased 
oxidative damage to protein. Emeto et al., (2016) also highlighted potential 
treatment strategies targeting ROS in AAA but concluded that none of these 
were effective in clinical practice. 
 
2.1.10    Chronic inflammation in AAA 
 
In section 2.1.3, inflammatory infiltrate was described as a major histological 
feature of AAA and additionally can be another factor causing increased 
expression of MMPs in this disease, therefore inflammation and its 
mediators will be discussed in the following sections. 
The specific factors that initiate chronic inflammation in AAA are undefined 
but whatever the factors responsible for initiating aneurysmal degeneration, 
chronic inflammation is one of the common histologic features of established 
AAAs. The inflammatory response includes cells such as polymorphonuclear 
neutrophils (PMN), T cells, B cells, macrophages, mast cells and NK cells 
and is usually transmural in distribution with dense infiltrates largely focused 
in the outer media and adventitia as well as elevated IgG in the tissues 
(Freestone et al., 1990, Satta et al., 1998). A subset of lesions described as 
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"inflammatory AAAs" (accounting for approximately 5% of AAAs) were first 
described by Walker et al in 1972;  these aneurysms are characterized by an 
unusually thick wall with dense retroperitoneal fibrosis extending into 
periaortic tissues. Patients with the inflammatory variant are younger and 
usually symptomatic, largely from back or abdominal pain.  
The pathogenesis of inflammatory AAA appears to involve an immune 
response localized to the vessel wall although the etiology of most 
inflammatory AAA cannot be established (Hellmann et al., 2007). Other 
research groups have suggested that inflammatory AAAs probably represent 
the extreme end of the spectrum of the inflammatory process found in all 
AAAs rather than a separate clinical entity (Witz and Korzets., 2005).  
Meher et al., (2014) examined the role of B cells (B1 and B2 subsets) in the 
development of AAA and found B2 cells in the absence of other B-cell 
subsets,increase splenic regulatory T-cell population and suppress 
 experimental  AAA formation in mice. A study by Wang et al., (2014) 
 established an important role for Immunoglobulin E (IgE) in AAA 
pathogenesis through the activation of CD4+ T cells, mast cells and 
macrophages and proposed neutralizing plasma IgE in the treatment of 
human AAAs. 
More recently, studies by Lai et al., (2016) investigated Toll-like receptors 
(TLRs) which are type I transmembrane proteins that play a key role in 
various inflammatory responses. Their results suggested TLR4 signalling 
contributes to AAA formation by promoting the proinflammatory status of 








2.1.11   Chronic Inflammatory Mediators implicated in   AAA 
 
The infiltrating cells secrete various humoral inflammatory factors such as 
cytokines, chemokines, leukotrienes, ROS and immunoglobulins (Shimizu et 
al., 2006). Inflammatory mediators of particular relevance to this thesis are 
described here. 
 
2.1.11.1    Chemokines 
 
Chemokines   represent   a   superfamily   of  cytokines   (divided into at 
least three structural branches: C, CC and CXC) that function as potent 
chemoattractants and activators of specific leukocytes, playing an important 
role in the inflammatory process associated with aortic aneurysms either in 
the initial stages of the disease or later by amplifying the inflammatory 
response. In 1993 Koch et al demonstrated that the chemotactic molecules, 
monocyte chemoattractant protein-1 (MCP-1) of the CC subgroup and 
interleukin-8 (IL-8) of the CXC subgroup are both expressed in human AAA 
tissue. This was later further confirmed by Middleton et al., (2007) whose 
results established significantly higher levels of the CXC chemokines IL-8, 
epithelial neutrophil activating peptide-78 (ENA-78) and growth related 
oncogene (GRO) and the CC chemokines MCP-1, MCP-2 and RANTES 
(regulated upon activation, normal T-cell expressed and secreted) in AAA 
samples compared with controls. 
Recently Jones et  al., (2016) investigated tissue and plasma samples from 
AAA patients to determinewhether inflammatory cytokines could be used as 
biomarkers for the presence of AAA. Results showed that Eotaxin and 
RANTES, belonging to the C-C family of chemokines, were potentially novel 





2.1.11.2    Elastin derived peptides (EDPs) hypothesis 
 
It has been proposed that the peptide fragments derived from the 
degradation of extracellular matrix components, including elastin, laminin 
and fibronectin may further induce and intensify inflammatory cell 
recruitment by the production of soluble products with chemotactic activity 
within the degenerating aortic wall. Subsequently, Hance and colleagues 
(2002) using in vitro chemotaxis assays found that soluble EDPs in AAA 
tissue can attract mononuclear phagocytes through ligand-receptor 
interactions with their cell surface receptor the 67-kD EBP. Additionally  this 
AAA-derived chemotactic activity can be eradicated by both competition with 
Val-Gly-Arg-Pro-Gly (VGVAPG), a repetitive peptide found in human elastin 
and the presence of lactose which dissociates the 67-kD EBP. 
Dale et al., (2016) using a mouse model of AAA looked at the effect of EDPs 
on macrophage polarization as they are known to  release  proinflammatory 
cytokines,such as TNF-α and IL-1β,  additionally TNF-α has been   shown  
to be required for experimental aneurysm formation in mice (Xiong et. al., 
2009). Results determined that EDPs promoted a proinflammatory 
environment in aortic tissue by inducing proinflammatory M1 macrophage 
polarization which led to AAA dilation which was attenuated by 
 neutralization of EDPs. 
 
 
2.1.11.3    Proinflammatory cytokines 
 
Cytokines are intercellular low molecular weight soluble proteins which 
function as chemical messengers for regulating the immune system and are 
important in the inflammatory process. A large number of cytokines have 
been identified in AAA tissue where they are known to stimulate 
metalloproteinase expression by a number of cell types within the aneurysm 
wall (including macrophages, SMCs and fibroblasts) as well as TIMP 
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reduction and induction of prostagandin synthesis. In 1992,  Pearce et al.,  
first demonstrated increased expression of tumour necrosis factor-alpha 
(TNF-) and interleukin-1 beta (IL-1β) in  aneurysmal tissue and later 
Szekanecz and colleagues (1994) found a significant increase in levels of 
interleukin-6 (IL-6) and interferon-gamma (IFN-) but not IL-2 and IL-4 in 
supernatants of AAA explants compared to controls. A further study by 
Szekanecz et al., (1994) proposed that interleukin (IL)-8 and TNF- ,   
previously found to be present in AAA tissue may be important for 
chemotactic activity responsible for endothelial cell migration and therefore 
might play a role in neovascularization within the aneurysmal wall. More 
recently Liu et al., (2016) utilized an angiotensin II-induced AAA mouse 
model to determine the effect of daidzein on AAA. Daidzein, is a 
phytoestrogen which contains strong anti-inflammatory activity and affects 
various mechanism pathways including the NF-κB, p38MAPK and TGF-β1 
pathways.  The results demonstrated that in angiotensin  II-induced  AAA  
mice, daidzein significantly attenuated incidence of AAA; producing an 
anti-inflammatory effect by inhibiting TNF-α, IL-1β and NF-κB  protein 
expression  in addition to suppressing gene expression of MMP-2, COX-2 
and TIMP-1.  
Unexpectedly, Davis and co-workers (1998) found that in AAA tissue there 
was a significant increase in the level of IL-10 which is a potent inhibitor of 
macrophage pro-inflammatory cytokine production and can affect levels of 
TNF-, IL-6 and IL-1β which ultimately may decrease MMP levels and 
increase TIMP expression. However, pro-inflammatory cytokines were still 
increased within the AAA walls despite the increase in IL-10,  and IL-13 
another anti-inflammatory cytokine was undetectable in both AAA samples 
and controls. Moreover they found levels of TNF- , IL-6 and IL-1β increased 
in AOD in comparison to AAA, which contradicts several other notable 
studies which found higher levels of these cytokines in AAA than in AOD. 
More recently. researchers found that IL-6 was one of the most highly 
secreted cytokines among the 50 pro-inflammatory cytokines analyzed in 
AAA tissues and further research indicated that the IL-6 pathway is critically 
involved in the inflammation of AAA (Nishihara et al., 2013). This was 
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corroborated by Kokje et al., (2016) who tested a role for IL-6 in the initiation 
and progression of AAA using  a murine elastase model. They concluded 
AAA was characterized by increased IL-6 signalling and that IL-6 appeared 
multi-faceted, protective upon acute injury but negatively involved in the 
perpetuation of the disease process. 
 
 
Table 7   Cytokines Present in the Aortic Wall 
                                                                                                                                                                  








Cytokine gene expression 
Proliferation CD4+ cells 
Differentiation of  B cells 









 EC adhesion molecules 
T cell activation induces 
production of cytokines and 









Stimulates production of  B 
cells/neutrophils 





















Upregulation of MHC Class I and 
II 
T and B cell differentiation 
Ig G secretion 







Downregulates MHC Class II 





2.1.11.4    Prostaglandins (PGs) 
 
Prostanoids are a subclass of eicosanoids  consisting of the prostaglandins 
and thromboxane A2 which are important mediators in the regulation of 
cardiovascular functions, including contraction and relaxation of vascular 
smooth muscle, modulation of inflammatory processes and connective tissue 
turnover and there is substantial evidence that they are associated with AAA 
pathogenesis (Dorn et al., 1992). The prostanoid most commonly observed 
in aneurysmal tissue is prostaglandin E2 (PGE2), demonstrated to be 40-fold 
higher than in normal aortic tissue after synthesis by macrophages and 
SMCs and is thought to increase the production of MMPs within the vascular 
wall (Holmes et al., 1997) as well as suppressing vascular SMC proliferation 
and promoting apoptosis (Walton et al., 1999). PGE2-metabolism also 
involves 15-hydroxyprostaglandin-dehydrogenase (15-PGDH) and a study 
by Solà-Villà et al., (2015) examined 15-PGDH expression in human AAA  
and their data showed 15-PGDH is upregulated in AAA and mainly 
expressed in infiltrating leukocytes.  
The production of PGE2 from arachidonic acid (AA) is catalyzed by the rate-
limiting enzyme cyclooxygenase (COX) of which two main isoforms COX-1 
and COX-2 have been identified.    
 
                                                                                                                         
2.1.11.5    Cyclooxygenases 
 
Cyclooxygenase-1 (COX-1)  is a constitutively expressed enzyme involved 
in maintaining low levels of prostglandins (PG) whereas cyclooxygenase-
2 (COX-2) is induced in response to cell activators such as growth factors 
and cytokines suggesting that this enzyme is involved in the generation of 
PG during inflammation and has emerged as a key regulator for PG 
synthesis (Herschman et al., 1996). Walton and colleagues (1999) found 
that aneurysm-infiltrating macrophages consistently stained strongly for 
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COX-2 in aneurysm biopsies whereas expression of COX-1 in this tissue 
was minimal. Experimental models have suggested a role for COX-2 in AAA 
expansion and using rat elastase perfusion models researchers 
demonstrated treatment with the nonselective COX inhibitor indomethacin 
reduced AAA growth (Holmes et al., 1996, Miralles et al., 1999).  A more 
recent study by Gitlan et al., (2007)  attempted to define the role of COX-2 in 
AAA. Using COX-2 deficient mice infused with angiotension II to induce 
aneurysm formation, they showed that,  after 28 days of infusion there was a 
54% incidence of AAA in COX-2 wild-type mice in comparison to no 
detection of AAA in the COX-2 deficient mice. Additionally COX-2 and PGE2  
increase both the release and activation of pro-MMP-2 and pro-MMP-9 
(Cipollone et al., 2001, Shankavaram et al., 2001).           
At present direct evidence to support a role for COX-2 is lacking, but the 
demonstration of COX-2 in the inflammatory infiltrate, a crucial factor in AAA 
development  appears consistent with COX-2 promotion of AAA as well its 
association with revascularization, which could also further AAA  
development (Chapple et al., 2007). 
 
 
2.1.11.6   Angiotensin II 
 
Angiotensin II (Ang II) derived from the precursor angiotensinogen through 
sequential cleavage by renin and angiotensin-converting enzyme (ACE) or 
chymase) (Inoue et al., 2009), is a potent vasoconstrictor that has been 
implicated in vascular inflammation and atherosclerosis.  Animal studies 
have consistently shown the ability of Ang II during infusion to promote the 
formation of AAAs although the mechanism of this is presently undefined 
(Daugherty et al., 2004).  Huang et al., (1996)  demonstrated that Ang II can 
alter the integrity of the aortic wall from studies using Brown Norway rats, a 
strain known to be susceptible to rupture of the internal elastic lamina that 
was abrogated by administration of ACE inhibitors or angiotensin receptor 
antagonists. Ang II is also known to stimulate the release of PGs in various 
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cells and tissues so Ohnaka and colleagues (2000) investigated whether 
Ang II regulates COX-2 (a key regulator of PG synthesis) expression in 
cultured rat VSMCs and subsequently discovered Ang II did indeed regulate 
COX-2 and PG production through p42/44 MAPK and p38 MAPK signalling 
pathways and mediated cell growth and proliferation of VSMCs.  
Additionally Ang II promotes vascular inflammation by ROS production 
through nuclear factor kappa B (NF-κB) mediated induction of pro-
inflammatory genes and downregulation of peroxisome proliferator-activated 
receptors (PPARs) a family of transcription factors that modulate vascular 
inflammation. Furthermore Ang II via activation of NF- κB increases 
secretion of IL-6, one of the principal inflammatory cytokines found within the 
aneurysm wall (Tham et al., 2002). 
Recently Wang et al., (2016) demonstrated that baicalein (BAI) an alcohol 
soluble flavonoid known for its anti-inflammatory effect attenuates the 
incidence and severity of AAA in Apoe -/- mice infused with AngII by inhibiting 
inflammatory cell accumulation and AngII-induced activation of MMP-2 and 
MMP-9 to maintain elastin content in vivo. Additionally BAI also  to blocks 




2.1.11.7   NF- κB and Ets-1 
 
The NF- κB transcription factor has a major role in regulating pro-
inflammatory genes implicated in atherosclerosis and AAA, including 
adhesion molecules, cytokines, chemokines, interferons, growth factors and 
other mediators such as iNOS and COX-2 (Tham et al., 2002). NF- κB also 
regulates the transcription of MMP-1, MMP-2, MMP-3 and MMP-9 (Bond et 
al., 1999, Takeshita et al., 1999, Kim et al., 2000), inhibits transcription of 
elastin and collagen (Kuang et al., 2002, Kouba et al., 1999) and is important 
for VSMC proliferation (Bellas et al., 1995). Miyake et al., (2007) 
demonstrated its importance by successfully inhibiting the progression of 
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AAA in rat and rabbit models using chimeric decoy oligodeoxynucleotides 
(ODNs) to inhibit both NF- κB and Ets-1 simultaneously leading to the 
inhibition of a number of MMPs which play a role in human AAA.  
Ets-1, the founding member of the Ets oncogene family is another 
transcription factor that mediates vascular inflammation and remodelling and 
is induced in VSMCs in response to a variety of inflammatory factors 
(Hultgardh-Nilsson et al., 1996). The induction of the chemokine MCP-1, the 
adhesion molecule vascular cell adhesion molecule-1 (VCAM-1), and 
plasminogen activator inhibitor-1 (PAI-1) by Ang II is largely dependent on 
Ets-1 (Zhan et al., 2005). Ni et al., (2007)  identified a novel role for Ets-1 as 
a transcriptional mediator of Ang-mediated ROS generation by regulating the 
expression of NAD(P)H oxidase subunits such as p47phox. Although the role 
of Ets-1 in the development of AAA has not yet been clarified,  Ets-1 is an 
important regulator of several MMPs including MMP-2 and MMP-9 and 
therefore plays a substantial role in extracellular matrix turnover, is essential 
for angiogenesis and is involved in vascular inflammation which are all 




2.2   Proteolytic Breakdown of the Aortic Wall 
 
One of the major pathophysiological features of AAA is considered to be the 
destruction of the medial elastin and collagen degradation by increased 
proteolysis within the aortic wall and it is now well established that among 
the numerous potential proteinases MMPs (with special emphasis on MMP-2 
and MMP-9) play the principal role in aneurysm formation (Vine and Powell, 
1991, Thompson and Parks, 1996). Other enzymes that that may participate 
in degeneration of connective tissue include plasmin, the plasminogen 
activators urokinase plasminogen activator (u-PA) and tissue plasminogen 
activator (t-PA) (Reilly et al., 1994), their inhibitor plasminogen activator 
inhibitor-1 (PAI-1) (Allaire et al., 1998),  serine elastases (Wassef et al., 
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2001) and cysteine proteases particularly cathepsins S, K and L (Sukhova 
and Shi, 2006).   Serine proteases have been hypothesized to play a role in 
AAA due to their potent elastase activity but currently there is no evidence to 
support this except for those from the plasminogen activator family which are 
known to activate MMPs. Cysteine proteases also appear to play a role in 
AAA formation.  including cathepsins a class of lysosomal proteases  which 
have been found to be overexpressed in human AAAs compared to normal 
aortic tissue. The protease activity of the cathepsins is normally balanced by 
endogenous inhibitors such as cystatin C which is normally constitutively 
expressed but  has been found to be significantly decreased in tissue from  
human AAAs (Shi et al., 1999). 
Impaired   elastogenesis  by   adult   VSMCs   limits   regenerative   repair   
of  elastic fibres but Swaminathan et al., (2014, 2016) recently demonstrated 
significant elastogenesis by bone marrow mesenchymal stem cell-derived 
SMCs (BM-SMCs) and their pro-elastogenesis and antiproteolytic effects on 
rat aneurysmal SMCs. Following on from the earlier study they are currently 
investigating the effects of super paramagnetic iron oxide nanoparticle 
(SPION) labelling of BM-SMCs necessary to magnetically guide them to the 
AAA wall. Results indicate the SPION labelling is noncytotoxic and  does not 
change the ability of the BM-SMCs to stimulate elastin regeneration and 




2.2.1   Role of MMPs in AAA 
 
The structure and function of MMPs has been discussed earlier in Chapter 1 
in relation to their natural physiological  role within the ECM and therefore 




2.2.1.1   Gelatinases 
 
 MMP-2 and MMP-9 both have elastolytic and collagenolytic properties and 
appear to play a particularly critical role in AAA formation. MMP-2 is 
constitutively produced and expressed in small aneurysmal aortas and 
therefore is thought to be significant in the initiation of abdominal aortic 
aneurysms (AAA) whilst the inducible MMP-9  is expressed at higher levels 
in large aneurysms has a significant role in aneurysm expansion and rupture 
(Freestone et al, 1995). Sakalihasan et al., (1996)  found activated MMP-9 
and MMP-2 levels were raised in aneurysmal aortic walls. Davis et al., 
(1998)  reported that MMP-2 (mRNA) and protein levels were significantly 
higher in AAAs than in controls whilst  Yamashita et al., (2001)  additionally 
demonstrated levels of  both MMP-2 and MMP-9 mRNA were increased in 
the AAA group compared with normal subjects and that the gelatinolytic 
activity of both MMPs was elevated in all AAA tissues examined. McMillan et 
al., (1997) measured aneurysmal MMP-9 mRNA levels using RT-PCR to 
define the relationship between AAA size and MMP-9 expression. Results 
demonstrated that MMP-9 mRNA expression was significantly higher in 
moderate-diameter AAAs (5.0cm to 6.9 cm) than either small (<4.0 cm) or 
large (>7.0 cm) AAAs and led researchers to summise that increased MMP-
9 expression  may  account for the propensity of AAAs  to  continue  to   
expand  in contrast to smaller aneurysms. (McMillan et al.,1997). Later, 
immunohistochemical techniques were used by Papalambros  and collegues 
(2003) to  investigate the expression of MMP-2 and -9 in AAA tissues. 
Findings revealed MMP-9 levels were significantly higher in large AAAs but 
there that was no relation between AAA size and levels of MMP-2,  leading 
them to propose that immunohistochemical expression of MMP-9  in AAA is 
correlated to the size of the aneurysm. The role of MMP-9 on AAA formation 
has also been studied using MMP-9 deficient mice where MMP-9 deficiency 
attenuated elastase-induced AAAs and reduced calcium chloride-induced 
AAAs in mice (Pyo et al., 2000, Longo et al., 2002). Interestingly, infusing 
macrophages from wild-type mice reversed the protection of MMP-9 
deficiency in the calcium chloride model of AAA indicating that macrophage-
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derived MMP-9 is required for AAA development. By contrast, infusion of 
competent WT macrophages into MMP-2 deficient  mice did not reconstitute 
the aneurysms (Longo  et al., 2002). 
 
Yang et.al. (2014) also  investigated the molecular mechanism underlying 
the role of monocyte chemoattractant protein-1 (MCP-1) in the formation and 
development of AAA. Results demonstrated that MCP-1 stimulates secretion 
of MMP-9 directly through the ERK1/2 and p38 MAPK mediated pathways in 
HASMCs  and might be a potential therapeutic target in the treatment of 
AAA. Later studies looked at mesenchymal stromal cells (MSCs) found 
within the aneurysmal wall and found they too contribute towards increased 
levels of MMP-9  in AAA (Ciavarella et. al., 2015).   
 
More recently,  in 2013, TefÃ-Silva et al., used an experimental model in rats 
to induce AAA by combining two potential causes of MMP secretion, 
inflammation and turbulent blood flow. Results of morphological examination 
of sections of aorta included considerable destruction of elastin fibres and 
deposition of collagen which they concluded were directly related to the 
dramatic increase of the levels of MMP-2 and -9 throughout the experiment. 
Researchers have also speculated that the MMP-2 gene may be a candidate 
gene after investigating its promoter region and documenting six 
polymorphisms associated with differential promoter activity which may be 
responsible for early elastolysis and aneurysmal degeneration in AAA (Price 
et al., 2001 Goodall et al., 2001). 
 
Smoking is known to be a significant risk factor in AAA and Ghosh et al., 
(2015) hypothesized that cigarette smoke may increase MMP2 and MMP9 
secretion through the Jak/Stat pathway in the aorta.  Treating rat VASMCs 
with an aqueous extract of cigarette smoke  resulted in a significant increase 
in pro-MMP-9 and a modest increase in pro-MMP-2 which was significantly 
reduced after transfection of the cells with small interfering RNAs (siRNAs) 
for Jak2, Stat3, or both Jak2 and Stat3  leading them to conclude that 
inhibiting the Jak/Stat pathway could be a potential therapeutic approach in 
the treatment of AAA. 
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Recently Li et. al. (2016) investigated the role of  cold-inducible RNA-binding 
protein (CIRP),  a recently identified  pro-inflammatory  cytokine,  in  the  
progression  of  AAA. CIRP mRNA and protein expression was upregulated 
significantly  in  human AAA tissue and anti-CIRP antibody treatment 
significantly suppressed the dilation of experimental AAA in rats and 
significantly attenuated the expression of  MMP-2 and MMP-9 demonstrating 
its potential as a novel target against AAA progression. Additionally, 
Bumdelger et al., (2016) reported on the possible involvement of 
osteoprotegerin(OPG) in the prevention of AAAs through inhibition of tumour 
necrosis factor-related apoptosis-inducing ligand (TRAIL). Results 
suggested both the TRAIL-induced expression of MMP-9 in SMCs and the 
chemoattractive effect of TRAIL on SMCs were inhibited by OPG which may 




2.2.1.2   MT1-MMP 
 
MT1-MMP which  is involved in the processing of the MMP-2 pro-enzyme is 
also expressed in the aneurysm wall by both infiltrating macrophages and to 
a lessor extent smooth muscle cells in a similar pattern to MMP-2  and plays 
a dominant role in macrophage-mediated elastolysis (Xiong et al., 2009) 
Thompson et al.,1996).  Significantly higher levels of  MT1–MMP mRNA 
have also  been detected in AAAs in comparison to normal aortas 
(Nollendorfs et al., 2001). 
 
 
2.2.1.3  MMP-12  (Human macrophage elastase)    
                                                                              
MMP-12 is reported to be predominately produced by infiltrating 
macrophages within the aortic media of aneurysmal tissue subsequently 
binding with high affinity specifically to residual elastin fibres (Curci et 
al.,1998). Although researchers have confirmed increased MMP-12 in AAA 
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compared to normal aorta, results of animal studies involving  MMP-12 
deficient mice found the animals still developed elastase induced aneurysms 
(Pyo et al., 2000). Later, animal studies by  Savio et al., (2008) established 
that inhibition of MMP-12 reduces the severity of AngII-induced AAAs in 
apoE–/– mice  (Luttun et al., 2004). 
Zheng et al., (2015) examined  the link between phosphatidylinositol 3-
kinases δ (p110δ) which regulates immune function and aneurysm 
development.They demonstrated that p110δ inactivation promotes 
aneurysm development by inducing macrophage migration and upregulating 
the activator protein-1/MMP-12 pathway in macrophages. 
 
 
2.2.1.4   MMP-3 (Stromelysin-1) 
 
Immunohistochemical studies have localized the expression of stromelysin-1 
in AAA to macrophages within the aortic wall (Newman et al., 1994). 
Additionally Carrell et al., (2002) also demonstrated that MMP-3 and TIMP-3 
were overexpressed in the wall of AAAs using reverse transcriptase–
polymerase chain reaction (RT-PCR). They hypothesized that the increased 
MMP-3 expression may arise from a combination of genetic and 
environmental factors. This was supported by a Finnish study suggesting 
that a polymorphism (5A MMP3 allele) may be a genetic risk factor for AAA 
(Yoon et al., 1999). MMP-3 (stromelysin-1) not only breaks down collagen 
and other structural proteins of the aortic wall, but it also activates other pro-
MMPs such as interstitial collagenase,matrilysin, and gelatinase B by 




2.2.1.5   MMP-13 (Collagenase -3) 
 
Collagen degradation is important in the latter stages of AAA development 
as resistance to further expansion and rupture is dependent upon the  
tensile strength of the interstitial collagens (Tilson et al., 1990). MMP-13  is a 
collagenase degrading enzyme with  limited  tissue distribution  and a  highly 
regulated pattern of expression. Mao et al., (1999) using RT-PCR and 
Southern blotting detected increased expression of MMP-13 in AAA samples 
and athersclerotic aorta (ATH) but not in normal aorta. They also found 
higher levels  of MMP-13 in AAA samples compared to ATH and that MMP-
13 was localised to SMCs in close spatial proximity to collagen. 
 
 
2.2.1.6   MMP-1 (Interstitial collagenase-1) 
 
Irizarry et al., (1993) demonstrated increased immunoreactivity of MMP-1 
localized in the adventitia of AAAs. MMP-1 is secreted primarily by a variety 
of mesenchymal  and epithelial cell types but invading inflammatory cells 
within the aneurysm can also constitute a  source of MMP-1,  although its 
role appears more related to tissue repair than disease processes (Welgus 
et al., 1985, Parks et al., 1998).   It is particularly selective in cleaving the 
triple-helix domain characteristic of types I and III collagen but it has little 
activity against type II collagen, gelatins, or other matrix proteins (Welgus et  
al., 1980, 1981, 1985). 
 
 
2.2.1.7   MMP-8 (Neutrophil collagenase) 
 
MMP-8, also known as collagenase-2 is a product of polymorphonuclear 
neutrophils (PMNs), where the protein is stored  in granules and released 
upon cellular activation (Lazarus et al., 1968, Hasty et al., 1990). Studies  
98 
 
have indicated that chondrocytes, synovial fibroblasts and vascular 
endothelium can all express MMP-8 (Cole et al., 1996, Hanemaaijer et al., 
1997). Wilson et al., (2005) examined the expression of the potent type-I 
collagenase MMP-8 in AAA and normal aorta using enzyme-linked 
immunosorbent assays  and immunohistochemical techniques. Results  
demonstrated  MMP-8 levels were significantly raised in AAA tissues in 
comparison to normal aorta and that  MMP-8 was localised to the 
mesenchymal cells  of the adventitia of the aortic adventia (Wilson et al., 
2005). Additionally Reeps et al., (2009) also identified MMP-8 in the 
inflammatory infiltate of AAA tissue using immunostaining methods. Mao et 
al., (1999) using RT-PCR and Southern blotting concluded that because 
MMP-8 was inconsistently expressed in AAA and ATH tissue and since 
neutrophils are not a prominent component of the chronic inflammatory 




2.2.2   The Role of TIMPs in AAA 
 
Despite early reports that suggested that the amount of TIMP present in 
human AAA tissue might be decreased (McMillan et al, 1995), there is now 
substantial evidence that the production of TIMPs is actually increased 
within the aneurysm wall.  Studies carried out by Tamarina et al., (1997) who 
found TIMP-1 mRNA levels in AAA tissue were in molar excess in 
comparison to the metalloproteinases studied, while Elmore et al., (1998) 
identified a small but statistically significant increase in TIMP-2 mRNA in 
AAA tissue although for TIMP-1, mRNA levels were not significantly 
different. Nishimura and colleagues (2003) also discovered TIMP-1 was 
highly expressed in the walls of AAA arteries compared with to the controls.  
Eskandari et al., (2004) demonstrated the protective effects of TIMP-1 by 
inhibiting the effects of MMPs in an experimental AAA model where TIMP-
1−/− mice developed significantly larger aneurysms compared to TIMP-1+/+ 
mice. Additionally, Allaire et al., (1998) found local overexpression of TIMP-1 
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prevented aortic aneurysm degeneration and rupture in a rat model. Plasma 
TIMP-1 has also been demonstrated to be considerably elevated in patients 
with AAA compared to patients with aortoiliac atherosclerosis or in healthy 
individuals (Nakamura et al., 2000).  
Bumdelger et al., (2013) found TNF-alpha significantly activated both MMP-9 
and TIMP-1 expression in cultured VSMCs, which was blocked by a Jun 
kinase inhibitor (SP600135) and surmised inflammatory cytokines, including 
TNF-alpha, may simultaneously induce MMPs and TIMPs leading to 
remodelling of the aortic medial layer in AAA. Most recently, Bumdelger et 
al., (2016)  determined that tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL) served as an inducer of MMP-9 and TIMP-1 
transcription via the JNK and/or nuclear factor-kappaB (NFkB) pathways 
leading to aortic medial thickening and breakdown of the aortic ECM. 
 
Baker et al., (1998) compared the effects of overexpressing TIMP-1, 2 and 3 
on invasion, proliferation and death in rat aortic SMCs. Their findings 
established that TIMP-1 overexpression did not affect cell proliferation but 
TIMP-2 caused a dose-dependent reduction in proliferation and interestingly 
TIMP-3 overexpression induced DNA synthesis and promoted SMC death by 
apoptosis, a common feature of AAA.  Basu et al., (2012) also investigated 
the causal role of Timp3 in  a mouse model of AAA and demonstrated the 
regulatory function of Timp3  is critical in preventing adverse vascular 
remodelling and loss of the Timp3 gene leads to  AAA formation. 
 
2.3   Hypoxia Within the Aortic Wall 
 
Inside the body internal O2 concentrations are maintained within a narrow 
range and changes in oxygen tension can result in differential expression of 
specific genes with physiological or pathological consequences (Faller, 
1999). The oxygen supply of the inner aortic media depends largely on 
diffusion from the endothelium as the infrarenal aorta is normally devoid of 
medial vasa vasorum (Zarins et al., 2001)  and therefore conditions which 
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increase wall thickness affecting oxygen diffusion or reduce oxygen 
transmissibility produce hypoxia and steep pO2 gradients within the vessel 
wall. Arterial wall hypoxia has been investigated in other conditions such as 
atherosclerosis, intimal hyperplasia and myointimal hyperplasia. 
Atherosclerosis is often associated with AAA, Björnheden and colleagues 
(1999) using the hypoxia marker 7-(4'-(2-nitroimidazol-1-yl)-butyl)-
theophylline,  demonstrated that hypoxic zones do exist in the arterial wall in 
rabbits in vivo, within atherosclerotic plaques when lesions exceed certain 
dimensions and at a depth that is also readily reached in humans. Heughan 
et al., (1973)  induced experimental atheromata in rabbits by a combination 
of injury and high cholesterol diet which resulted in the transmural oxygen 
tension being markedly different from normal. The lowest mean values were 
recorded immediately adjacent to the lumen and measured 18 mm Hg at five 
weeks compared with the mean low point of 22 mm Hg measured 60% of 
the distance from the outer surface in normal aortas. In experimental 
atheromata some individual low point values reached as low as 10 and 12 
mm Hg which is far lower than any measured in normal aorta. Studies with 
experimental hypertension (which is a high risk factor in aneurysmal 
disease), hyperlipidaemia and balloon injury also produced medial hypoxia 
with steep pO2 gradients within the vasculature (Crawford and Blankenhorn., 
1991).                      
In 1996, Vorp et al., first hypothesized that intraluminal thrombus (ILT) may 
be important in the natural history and pathology of AAA as a result of poor 
diffusion of oxygen through the ILT. Approximately 80% of AAA have ILT 
resulting in increased inflammation, a thinner wall underlying the thrombus 
and greater risk of rupture (Satta et al, 1996, Kazi et al, 2003).  Later studies 
concluded that ILT within an AAA caused localised hypoxia so that aortic 
wall pO2 differed between aneurysmal and normal aortic tissue and may lead 
to increased localized mural neovascularisation, inflammation and regional 
wall weakening. (Vorp et al, 2001). Hu et al., (2004) studied the expression 
of hypoxia-inducible factor-1 alpha (HIF-1α) and related genes in 
aneurysmal and normal specimens. The global oxygen sensor HIF-1α 
responds to low tissue oxygen by up-regulating hypoxia responsive genes 
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(Laderoute, 2005). They found the expression of HIF-1alpha mRNA and 
protein product were significantly higher in AAA tissue than in normal aorta, 
furthermore, the expression of VEGF and caspase-3 were also higher in 
AAA tissue and both had a significantly positive relationship with HIF-1alpha 
expression (Hu et al., (2004). 
More recently Xu et al., (2016) investigated the serum concentration of HIF-
1α and VEGF in patients with aneurysms at different stages and discovered 
that serum concentrations of HIF-1α in the early stage group were 
significantly higher than those in the normal group and that the late stage 
group were significantly higher than those in the early or mid-term group. 
They concluded from the results that serum HIF-1α and VEGF has clinical 
value of early diagnosis and assessment of disease severity.  A study by 
Strauss et al., (2015) identified polymorphisms in the HIF1A and VEGF 
genes as potential genetic markers that indicate the predisposition to AAA  
including the HIF1A 1772T allele which seems to be a genetic risk factor that 
determines sensitivity to cigarette smoke exposure.  
 
 
2.3.1  Hypoxia-inducible factor -1alpha (HIF-1α)    
 
The transcription factor Hypoxia-inducible factor-1α is a heterodimeric 
protein composed of the hypoxia inducible 120 kDa HIF-1 subunit and the 
constitutively expressed 91-94 kDa HIF-1 subunit also known as the aryl 
hydrocarbon nuclear translocator (ARNT). HIF-1α functions as a master 
regulator of mammalian oxygen homeostasis, controlling the expression of 
over seventy genes involved in intracellular adaptive responses to hypoxia, 














Figure 11   HIF-1 alpha and HIF-1 beta Subunits 
 
HIF-1α and HIF-1β contain one basic-helix-loop-helix (bHLH) domain and two PER-
ARNT-SIM (PAS1/PAS2) domains in their N-terminal regions. The positions of post-
translational hydroxylation (OH) of the proline residues (P402/P564) and acetylation 
(OAc) of lysine (K532) of HIF-1α are shown. This occurs within the oxygen-
dependent degradation (ODD) domain (residues 401-603) close to the N-terminal 
transactivation domain (NTAD) and confers recognition by pVHL (von Hippel-
Lindau tumour suppressor gene) leading to degradation of the subunit. At the C-
terminal domain (CTAD) hydroxylation at N803 inhibits recruitment of coactivators 
required for HIF-1α transcriptional activity. HIF-1β contains one transactivation 




The closely related proteins HIF-2α (also known as endothelial PAS protein), 
HIF-like factor (HLF), HIF-related factor (HRF), and member of the PAS 
superfamily 2 (MOP2) have also been identified (Ema et al, 1997; Flamme et 
al., 1997; Hogenesch et al., 1997; Tian et al.,1997). In contrast to 
ubiquitously expressed HIF-1α, HIF-2α is predominantly expressed in the 
lung, endothelium, and carotid body (Ema et al, 1997; Tian et al, 1997). HIF-
3α which was discovered more recently is expressed in a variety of tissues 
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2.3.2 HIF-1α under Normoxic Conditions (Oxygen-dependent) 
 
At normal oxygen levels the prolyl-hyroxylases PHD1, PHD2 and PHD3 
hydroxylate the key proline residues (Pro402/ Pro564) within the HIF-1α 
ODD domain (Epstein et al., 2001).  PHDs are dioxygenases that utilize 
oxygen as co-substrate providing the molecular basis for the oxygen-sensing 
function of these enzymes but 2-oxoglutarate ascorbate and iron are also 
required as cofactors for the prolyl hydroxylation reaction (Cioffi et al., 2003). 
Asparagine hydroxylase FIH (factor inhibiting HIF-1) hyroxylates Asp803 
inhibiting recruitment of the aforementioned coactivators required for HIF-1α 
transcriptional activity. Once hydroxylated HIF-1α interacts with an E3 
ubiquitin-protein ligase complex composed of pVHL, elongin B, C and Cullen 
2, targeting it for polyubiquitylation and rapid degradation by the 26S 
proteosome (Salceda and Caro, 1997, Maxwell et al., 1999, Cockman et al., 
2000). 
HIF-1α also contributes to other cellular processes that occur under 
normoxic conditions. Many growth factors  and cytokines are known to 
induce and activate HIF-1α, including insulin–like growth factors, 
transforming growth factor, platelet-derived growth factor, epidermal growth 
factor and interleukin -1β (Felser et al., 1999, Hellwig-Burgel et al., 1999,  
Stiehl et al., 2002, Haddad and Land, 2002). Nitric oxide has also been 
reported to promote HIF-1α expression under normoxia (Kasuno et al., 
2004) along with vascular hormones such as endothelin, angiotensin II,  
thrombin (Richard et al., 2000, Gorlach et al., 2001, Page et al., 2002, 
Pisarcik et al., 2008), During non-hypoxic induction of HIF-1α the main 
mechanism implicated in these processes seems to be an increase in HIF-
1α protein translation rather than stabilization, and this increase alone 
appears sufficient to shift the balance between synthesis and degradation 





2.3.3    HIF-1α under Hypoxic Conditions 
 
During hypoxia HIF-1α is not hydroxylated because oxygen is unavailable 
allowing the unmodified protein to escape the VHL-binding and subsequent 
ubiquitination and degradation by the proteosome. HIF-1α can then dimerize 
with HIF-1β (ARNT) to form the HIF-1α transcription complex which binds to 
its target DNA sequence within the hypoxia response element (HRE) of 
target genes, recruiting the coactivators p300 and CREB binding protein 
(CBP) to activate transcription (Semenza., 1996, Ebert and Bunn., 1998). 
Interestingly, PHD2 and PHD 3 are HIF targets themselves and markedly 
induced by hypoxia,  suggesting they may participate in a negative feedback 
loop to suppress the HIF response to prolonged hypoxia (Marxsen et al, 
2004, Appelhoff et al., 2004, Aprelikova et al., 2004, Dery et al., 2005,Stiehl 
et al., 2006). 
Baek et al., (2016) recently identified a new methylation-based regulation of 
 HIF-1α stability in the nucleus in response to cellular oxygen levels which is 
independent of previously identified mechanisms. This mechanism is based 
on the collaboration between the SET7/9 methyltransferase and the LSD1 
demethylase. SET7/9 adds a methyl group to HIF-1α which triggers 
degradation of the protein by the ubiquitin-proteasome system whereas 
LSD1 removes the methyl group, leading to stabilization of HIF-





















Figure 12. HIF-1 Alpha Regulation by Proline Hydroxylation 
A: In normoxia, HIF-1α is hydroxylated by proline hydroxylases (PHD1, 2 and 3) in 
the presence of O2, Fe
2+, 2-oxoglutarate (2-OG) and ascorbate. Hydroxylated HIF-
1α (OH) is recognised by pVHL (the product of the von Hippel–Lindau tumour 
suppressor gene), which together with the E3 multisubunit ubiquitin ligase complex 
tags HIF-1α with polyubiquitin allowing recognition by the proteasome and 
subsequent degradation. Acetylation of HIF-1α (OAc) also promotes pVHL binding. 
B: In response to hypoxia proline hydroxylation is inhibited. VHL is no longer able to 
bind and target HIF-1α for proteasomal degradation leading to HIF-1α accumulation 
and translocation to the nucleus. HIF-1α then dimerises with HIF-1α, binds to 
hypoxia-response elements (HREs) within the promoters of target genes and 
recruits transcriptional co-activators such as p300/CBP for full transcriptional 
activity. Abbreviation: CBP (CREB-binding protein), Ub (ubiquitin) (Adapted from 


















































Table 8   Factors Stabilizing HIF under Normoxic Conditions 
 
     REGULATOR FUNCTIONS/PATHWAY CONSEQUENCE      REFERENCE 
Nickel (Ni
2+
) Decreases cellular Fe level 
Inhibits PHDs 
Increased HIF-1α Davidson et al., 2005 
 Down-regulates exp of 
FIH-1 and ARD1 
 Ke et al., 2005 
 Depletes intracellular 
ascorbate 
 Salnikow et al, 2004 
 P13K/Akt  Li et al., 2004 
Cobalt (Co
2+
) Replaces Fe Increased HIF-1α Yuan et al., 2003 
 Down-regulates exp of 
FIH-1 and ARD1 
 Ke et al.,2005 
 Depletes intracellular 
ascorbate 
 Salnikow et al., 2004 
 P13K  Gao et al., 2004 
Arsenite ROS Increased HIF-1α Duyndam et al., 2001 
 p38MAPK  Duyndam et al., 2003 
Chromium ROS, p38MAPK Increased HIF-1α Gao et al., 2004 
 ROS, P13K/Akt Increased HIF-1α Gao et al., 2002 
Vanadate AMP-activated protein 
kinase (AMPK) 
Increased HIF-1α Hwang et al., 2004 








ROS Increased HIF-1α Feldser et al., 1999 
Foetal calf serum ROS Increased HIF-1α Richard et al., 2000 
Angiotensin II 
(AngII) 
ROS Increased HIF-1α Gorlach et al., 2001 





ROS/p44/42 MAPK Increased HIF-1α Gorlach et al., 2001 
Page et al., 2002 
Nitric oxide (NO) MAPK, P13K Increased HIF-1α Kasuno et al., 2004 








 interleukin-1β (IL- 
Increased HIF-1 DNA 
binding 
Increased HIF-1α Hellwig-Burgel et 
al.,1999 






2.3.4  The Role of Hypoxia and HIF-1α in the Expression of 
MMPs  
The involvement of MMPs in the pathogenesis of AAA is well documented 
but what is unknown is the potential role of  hypoxia and HIF-1α in the 
regulation of MMPs in AAA, although in many other research areas HIF-1α is 
known to modulate MMPs. In HCT116 human colon carcinoma cells HIF-1α 
is shown to regulate the expression of many genes involved in the 
pathophysiology of invasion including MMP-2 (Krishnamachary et al., 2003). 
A later study into colon adenoma and colon cancer also looked at the 
expression of MMP-2, HIF-1alpha and VEGF and their results showed a 
positive correlation between levels of HIF-1α mRNA expression and MMP-2 
and VEGF mRNA (Shin et al., 2007). Ahn et al., (2008) examined the 
contribution of HIF-1α to hypoxia-induced MMP and cytokine production in 
rheumatoid fibroblast-like synoviocytes transfected with a HIF-1α 
overexpression vector and found a significant increase in MMP-1 and MMP-
3. Lolmède and colleagues (2003), during obesity studies, subjected 3T3-
F442A adipocytes to hypoxia or hypoxia mimics which stimulated the HIF-1 
pathway and markedly enhanced the expression of leptin, VEGF and MMP- 
2 and MMP-9. Bovine cartilage disks subjected to mechanical overload (a 
causative factor in osteoarthritis) were strongly immunopositive for HIF-1α, 
additionally MMP-1, MMP-3 and MMP-13 were  detected in pressure-treated 
disks whereas staining in controls was low or undetectable (Pufe et al., 
2004). The degradation or remodelling of the ECM may play role in the 
pathogenesis of temporomandibular joint (TMJ) disorders, Yamaguchi et al., 
(2001) found hypoxia and IL-1β induced MMP-1, MMP-2, MMP-3 MMP-9 
and MMP-13 mRNA in (TMJ) disc cells but concluded MMP induction was 
due largely to hypoxia and the involvement of HIF-1α. An interesting study 
by Ahn et al., (2008) was conducted to determine the contribution of HIF-1α 
to hypoxia-induced MMP and cytokine production in rheumatoid fibroblast-
like synoviocytes (FLS).  Results demonstrated that hypoxia-induced MMP-3 
expression is exclusively regulated by HIF-1α, and hypoxia-induced MMP-1 
or IL-8 expression appeared to have salvage pathways other than the HIF-1α 
pathway. Most recently, in 2010 Sun et al., determined the effect of hypoxia 
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and specifically HIF-1a on expression of CXCR4 and MMP-1 and their role in 
chondrosarcoma cell invasion, finding that hypoxia and specifically HIF-1a 
increased CXCR4 and MMP1 expression in a chondrosarcoma cell line and 
this increase  could be inhibited by siRNA directed at HIF-1a or CXCR4.  
Wang et al., (2015) investigated  the effect of hypoxia on the proliferation 
and expressions of HIF-1α, VEGF MMP-9 in keratinocytes obtained from 
oral lichen planus (OLP) lesions.The results demonstrated that hypoxic 
conditions can promote the protein expression of HIF-1α and both the mRNA 
and protein expression of its downstream targets VEGF and MMP-9 in 
keratinocytes. 
Conversely, other researchers have reported different findings, Miyoshi et 
al., (2006), in cancer studies concluded that hypoxia accelerated metastasis 
by hepatoma cells by upregulating MMP expression in a HIF-1α independent 
manner. Hong et al., (2005) using pulmonary artery endothelial cells (PAEC) 
and smooth muscle cells (PASMC) also found hypoxia could inhibit the 
secretion and activity of MMP-2 and MMP-9 in PAEC and PASMC and 
proposed the HIF-1 pathway might contribute to hypoxia-induced down-
regulation of MMP-2 and MMP-9. However, Herget et al., (2003) found that 
rats exposed to chronic hypoxia demonstrated upregulation of collagenolytic 
MMP activity which promoted pulmonary vascular remodelling and 
hypertension. Furthermore these hypoxia-induced increases in collagenolytic 
activity in pulmonary vessels could be inhibited by treatment with Batimastat, 
a MMP inhibitor.     
 
2.3.5  HIF-1α Target Genes 
The transcription factor HIF-1α acts as a master regulator of oxygen-
regulated gene expression. It is responsible for the induction of genes that 
facilitate adaptation and survival of cells and the whole organism from 
normoxia  (~21% O2) to hypoxia (~ 1% O2) (Wang et al., 1995, Semenza, 
1998). HIF-1α protein has a short half-life (t½ ~ 5 min) and is highly regulated 
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by oxygen (Salceda and Caro, 1997) in contrast to the transcription and 
synthesis of HIF-1α which are constitutive and seem not to be affected by 
oxygen (Wang et al., 1995, Kallio et al., 1997,  Wiesener et al., 1998). HIF-
1β is constitutively expressed and its mRNA and protein are maintained at 
constant levels regardless of oxygen availability (Kallio et al., 1997)  
During normoxia HIF-1α proteins are rapidly degraded (Wang et al., 1995) 
but exposure to hypoxia  causes HIF-1α become stabilized and translocates 
from the cytoplasm to the nucleus where it dimerizes with HIF-1β and 
becomes transcriptionally active (Huang et al., 1996,  Kallio et al., 1997). 
The activated HIF complex then associates with HREs in the regulatory 
regions of target genes and binds the transcriptional coactivators to induce 
gene expression (Lando et al., 2002). 
More than 60 putative HIF-1 target genes have been identified including 
secreted signalling proteins, angiogenic growth factors, cell surface 
receptors, extracellular matrix proteins, transcription factors,cytoskeletal 












Table 9   HIF-1 Alpha Target Genes 
 
     Function                  Gene or Abbreviation                       Reference 
Cell proliferation Cyclin G2, IGF2, IGF-BP1,2 and 3, 
WAF-1, TGF-α, TGF-β3 
Feldser et al, 1999, 
Krishnamachary et al, 2003, 
Wykoff et al, 2000 
Cell survival ADM, IGF2, IGF-BP1,2 and 3, 
NOS2,  TGF-α,  
Cormier-Regard et al, 
1998,Feldser et al, 1999, 
Krishnamachary et al, 2003,  
Apoptosis Bcl-2/adenovirus EIB 19kD-
interacting protein 3 (BNip3), 
iNip3-like protein X (NIX), RTP801                                    
Carrero et al, 2000, Bruick, 
2000, Shoshani et al, 2002 
Erythropoiesis Erythropoietin (EPO) Semenza et al, 1991 
Angiogenesis VEGF, EG-VEGF, Leptin (LEP), TGF-
β3, LRP1, ENG 
Levy et al, 1955, LeCouter et 
al, 2001, Grosfield et al, 
2002, Scheid et al, 2002, 
Wykoff et al, 2000, 
Bernhardt et al, 2006 
Vascular tone NOS2, Heme oxygenase, ET1, 
ADM, α1β-adrenergic receptor 
Melillo et al, 1995, Lee et al, 
1997, Hu et al, 1998, Nguyen 
and Claycomb, 1999, Eckhart 
et al, 1997 
Matrix metabolism MMPs, PAIs, , uPAR CATHD, 
Fibronectin 1 (FN-1) 
Ben-Yosef et al, 2002, 
Kietzmann et al, 1999, 
Takahashi et al, 2000, 
Krishnamachary et al, 2003, 
Glucose metabolism AK-3, ALD-A and C, ENO1, LDHA, 
CA9 and 12, GLUT1 and 3, GAPDH, 
HK1 and 2, , PKM, PFKL, PGK1, 
PFKFB3 
O’Rouke et al, 1996, 
Semenza et al, 1996, Wykoff 
et al, 2000, Chen et al, 2001, 
Graven et al, 1999, 
Mathupala et al, 2001, 
Semenza et al, 1994, 
Minchenko et al, 2002 
Iron metabolism Transferrin, transferrin receptor, 
Ceruloplasmin 
Rolfs et al, 1997, Bianchi et 
al, 1999, Lok and Ponka, 
1999, Chinmay et al, 2000 
Drug resistance Multidrug resistance 1(MDR1) Comerford et al, 2002 
Cell adhesion Microneme protein 2 (MIC2) Wykoff et al, 2000 
Motility LRP1, c-MET, TGF-α, autocrine 
motility factor (AMF) 
Wykoff et al, 2000, 
Pennacchietti et al, 2003, , 
Krishnamachary et al, 2003, 
Niizeki et al,  2002 
Aa metabolism Transglutaminase 2 Wykoff et al, 2000 
Cytoskeletal structure Keratin 14, 18 and 19, vimentin Krishnamachary et al, 2003, 
Semenza et al, 2003 
Transcriptional 
regulation 
ETS-1,DEC1 and 2, NUR77 Oikawa et al, 2001, Miyazaki 
et al, 2002, Choi et al, 2004 
Nucleotide 
metabolism 
Adenylate kinase 3, Ecto-5’-
nucletidase 
O’Rouke et al, 1996, 
Synnestvedt et al, 2002 
HIF activity P35srj Bhattacharya et al, 1999 





























Figure 13   Overview of the Pathogenesis of AAA 
This flow diagram gives a simplified overview of some of the main factors involved 


























MMP activity increase 

















TIMP activity decrease 
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2.4  Diagnosis of AAA 
 
Most patients with AAA are asymptomatic and are often diagnosed during 
procedures such as  x-rays or ultrasound scans carried out for other 
reasons. Sometimes an abdominal aneurysm  may be discovered during a 
routine physical examination where a pulsatile mass is palpable in the 
abdomen, or  through ultrasound screening programs for AAA.  As the 
aneurysm expands,  symptoms may occur  and patients commonly present 
with abdominal, back,  flank or groin pain. The risk of rupture is high in  
symptomatic aneurysms and mortality from AAA rupture is around 90% with 
65 to 75 % of patients dying before arrival at the hospital (Brown and  
Powell, 1999). 
 
2.4.1 AAA Screening 
 
The NHS AAA Screening Programme was set up in England in 2009 and 
has been offered throughout the UK since the end of 2013. All men aged 
over 65 are  invited to undergo an ultrasound scan to check the diameter of 
their abdominal aorta. An ultrasound scan is a painless procedure that uses 
high-frequency sound waves to create an image of part of the inside of the 
body. An ultrasound probe is used  which gives off high-frequency sound 
waves which bounce off different parts of the body and create "echoes" that 
are picked up by the probe and turned into a moving image which is 
displayed on a monitor while the scan is carried out as shown in Figure 14. 
 
Men with a normal sized abdominal aorta (less than 3cm in diameter) are not 
invited back whilst those with a small (3.0-4.4cm) or medium (4.5-5.4cm) 
AAA will be invited back for regular scans to check the size of the aneurysm, 
known as 'watchful waiting'. Annual scans are carried out for patients with 
small aneurysms and three monthly scans for patients with medium 
aneurysms. Patients are also given advice on diet, stopping smoking, 
weight, exercise and medication which may help to prevent the aneurysm  
increasing  in diameter.  Patients found to have a large aneurysm (5.5cm or 
113 
 










Figure 14    Example of  an Ultrasound Scan of AAA 
Longitudinal view of the abdominal aorta demonstrating a focal area of 




2.4.2 Surgical Intervention 
 
Prior to surgical intervention further imaging of the AAA may be carried out  
to provide greater detail for the vascular surgeon to plan surgical repair of 
the aneurysm. These tests may include computerized tomography (CT)  or 
magnetic resonance imaging (MRI) scans. Also if these scans are performed 
with the addition of contrast medium it provides greater detail to enable 
enhanced evaluation of the vasculature and is known as CTA (computerized 
tomographic angiogram) or MRA (magnetic resonance angiogram). 
Occasionally a procedure known as aortography (aortogram) is carried out to 
evaluate the aorta, aneurysm and how the aneurysm affects the branches of 







Figure 15    Computed Tomographic Scan and Computerized 
Tomographic Angiogram of AAA 
 
A: Computed tomographic scan of the abdominal aorta at the level of the 
kidneys (outline arrows) showing an aneurysm (arrows) with a small amount of 
mural thrombus along the posterior and lateral walls. B: Reconstructed 
computerized tomographic angiogram scan in the frontal projection demonstrating 
the bilobed infrarenal aortic aneurysm (arrow heads). The renal arteries are well 
visualized  (small arrows), revealing a severe stenosis of the proximal right renal 
artery (outline arrow) and the proximity of the aneurysm neck to the renal arteries. 
The relationship of the aneurysm to the iliac arteries and the aneurysmal dilatation 
of the right common iliac artery (outline arrow head) are also well displayed. CTA is 
accomplished by combining all of the axial slices to produce a three-dimensional 
reconstructed image of the AAA which can be rotated into any plane that best 





















Figure 16   Aortogram of AAA 
Early arterial phase of a posteroanterior abdominal aortogram using iodinated 
contrast. medium to demonstrate a bilobed aneurysm  (arrows) originating just 













Figure 17   Magnetic Resonance Angiogram of AAA 
MRA demonstrating an abdominal aneurysm  below the level of the kidneys in the 
infrarenal aorta (www.radiopaedia.org). 
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2.4.2.1  Open Surgical Aneurysm Repair 
 
Open repair of  an AAA  is a major operation involving an incision from just 
below the breastbone to the top of the pubic bone to allow the surgeon to 
clamp the aorta and replace the dilated segment of the vessel with an aortic 
graft which can be sewn or 'stented' in place. The graft is sutured to the 
aorta connecting one end of the aorta at the site of the aneurysm to the 
other end of the aorta.The graft is made of a strong, durable, man-made 
plastic material such as Dacron (textile polyester synthetic graft) or 
polytetrafluoroethylene (PTFE) a non-textile synthetic graft. Subsequently 
the  aortic clamps are removed to restore bloodflow once again. Following 
surgery complications that may occur include risk of haemorrhage, cardiac 




Figure 18. Diagram and Photograph Taken During Open Surgery for 
AAA 
A: Diagram illustrating how the weakened segment of aorta is replaced with the 
artificial graft. B: Photograph  taken  during open surgical  AAA intervention 








2.4.2.2  Endovascular aneurysm repair (EVAR)  
 
EVAR was first pioneered in the early 1990s and is now widely used for the 
treatment of AAA.  EVAR is performed by inserting a stent graft via the 
femoral artery (using x-ray images) for guidance into the lumen of the 
aneurysmal portion of the aorta.  The endovascular  stent graft consists of a 
graft that provides a conduit for blood flow and a stent that anchors the graft 
to the aorta and provides structural support for the graft material. The aim is 
to divert blood flow into the graft in order to  bypass the aneurysm.  The 
advantages of endovascular repair over open repair is that it is less invasive 
than open surgery and has a lower mortality rate and length of post-
operative care in hospital is reduced. Disadvantages include the need for 
life-long follow-up imaging and the long-term durability of graft material is yet 
to be proven. 











Figure 19. Diagram of Endovascular Aneurysm Repair (EVAR) 
Diagram illustrating  A:  A catheter wire inserted via the common femoral artery and 
the stent graft passed up over the catheter wire into the aorta. B: The stent graft 






2.5  Medical Treatment of AAA 
 
Patients diagnosed with a small aneurysm are given advice on diet and life 
style but additionally if they are hypertensive they will be prescribed 
medication such as angiotensin-converting enzyme (ACE) inhibitor to lower 
blood pressure which is a high risk factor for AAA. In addition,  if they are 
diagnosed with high cholesterol they will also be prescribed statins  (a group 
of cholesterol lowering medicines) as having a high level of LDL cholesterol 
is potentially dangerous as it can lead to a hardening and narrowing of the 
arteries and is also a risk factor for AAA. Statins reduce LDL by blocking the 




2.6  Pharmacological research for Medical Treatment 
of AAA 
 
Existing treatment of AAA involves routine screening for early detention of 
aneurysms, surveillance of small and medium sized AAAs and surgical 
intervention for larger aneurysms. Currently there are no proven 
pharmaceutical treatments for preventing the expansion and rupture of AAA, 
although many scientists are carrying out studies and clinical trials involving 
potential targets against AAA. 
  
2.6.1 Theraputic Targets for Treatment of AAA 
 
2.6.1.1 Pro-inflammatory Mediators 
 
Reactive oxygen species play a role in AAA  possibly as  pro-inflammatory 
mediators. Two animal studies found  α-Tocopherol (vitaminE), a lipid-
soluble antioxidant, was found to significantly attenuate the formation of AAA 
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(Nakahashi et al., 2002, Gavrila et al., 2002). On the contrary a large 
randomized study reported that long-term supplementation with vitamin E 
did not reduce the rate of AAA rupture (Tornwall et al., 2001). 
 
 
2.6.1.2  17β-Estradiol 
 
Female reproductive hormones, such as estrogen may play protective roles 
against the development of AAA. Rats treated with 17β-estradiol exhibited 
less macrophage infiltrate, lower MMP-9 levels and developed smaller 
aneurysms after elastase infusion compared to controls (Ailawadi et 
al.,2004). Martin-McNulty et al., (2003) also found in an Ang II-induced AAA 
model,  treatment with 17β-estradiol reduced expression of MCP-1, activity 
of NF-κB, and aneurysm size. 
 
 
2.6.1.3  Inhibitors of Renin-Angiotensin System (RAS) 
 
Angiotensin-converting enzyme (ACE) inhibitors are widely used in the 
treatment of  hypertension, congestive heart failure and other cardiovascular 
disorders. The ACE inhibitors captopril, lisinopril, and enalapril all prevented 
the development of AAA created by elastase infusion in rats (Liao et al., 
2001). Fujiwara et al., (2008) reported that treatment with Valsartan (an 
angiotensin II type 1 (AT1) receptor antagonist) prevented AAA development  
and infiltration of macrophages and suppressed NF-κB activation and MMP-
9 expression in elastase-induced AAA in rats. In contrast, another  study 
found AT1 receptor blockers did not prevent AAA rupture (Hackman et al., 
2006) and furthermore Sweeting et al., (2010) reported an association with 





2.6.1.4  Statins 
 
The group of cholesterol-lowering drugs (3-hydroxy-3-methylglutaryl 
coenzyme A)(HMG-CoA) reductase inhibitors  more commonly known as 
statins have been  suggested as a possible therapy for AAAs based on their 
pleiotropic actions, independent of their lipid lowering effects ( Takemoto and 
Liao, 2001, Schonbec. and Libby, 2004). Steinmetz et al., (2005) found that 
simvastatin suppressed aneurysm formation in elastase-infused C57BL/6 
wildtype and hypercholesterolemic ApoE−/− mice and in elastase-induced 
AAA in rats where it also reduced levels of MMP-9 and NF-κB ( 
Kalyanasundaram et al., 2006). Other studies suggested treatment with 
atorvastatin prevented AAA development, macrophage infiltration and 
supression of MMP-9 and MCP-1(Shiraya et al., 2009, Yoshimura and Aoki., 
2012). Dunne et al., (2014)  reviewed the clinical evidence regarding the role 
of statins in the medical management of small AAAs and refuted the claim 
that statins attenuate AAA growth and that further studies with stringent 
identification, verification of statin usage and a standardised method of 
estimating AAA growth rates were required.  
 
In contrast to this, research by Yoshimura et al., (2015) indicated 
that statins preferentially inhibit the Rac1/NF-κB pathway to suppress MMP-
9 and chemokine secretion in human AAA and could attenuate AAA 
progression.  Further studies by Piechota-Polanczyk et al., (2015)  found 
statin treatment in patients with AAAs may influence the concentration of 
proteases and their inhibitors (TIMPs) in aneurysmal wall tissue and 
intraluminal thrombi (LTs). Interestingly, Pafili et al., (2015) looked at the 
effect of pharmacological agents used for the treatment of patients with 
diabetes mellitus on AAA formation and results showed  statins, angiotensin 
converting enzyme inhibitors, angiotensin receptor blockers, fenofibrate, 
antibiotics and some hypoglycemic agents are now been suggested to have 




2.6.1.5  Mast Cell Stabilizer 
 
Mast cells are an inflammatory type of cell found in  the walls of  human  
AAA which, when activated,  leads to the release of pro-inflammatory 
cytokines such as IL-6 and IFN-γ. In elastase-induced AAA in mice, 
disodium cromoglycate (DSCG) a mast cell  stabilizer, significantly reduced 
AAA expansion, preserved  the elastic  lamina, decreased mast cell and 
macrophage infiltration,  reduced  IFN-γ, IL-6 and MMP activity (Sun et al., 
2007). Tsuruda et al., (2008) using a different mast cell stabilizer known as  
tranilast, stated that, in calcium chloride-induced rodent models of AAA, 
tranilast attenuated AAA formation . Despite the interest in these drugs no 
clinical trial results are yet available to fully understand how effectively they 
might reduce AAA expansion. 
 
More recently,  Sillesen et  al., (2015) undertook a randomised clinical trial to 
investigate whether the mast cell inhibitor, pemirolast, could retard the 
growth of medium-sized AAAs but there was no significant difference in 
growth between patients receiving the placebo and those receiving 
pemirolast and they concluded that treatment with pemirolast did not retard 
the growth of medium-sized AAAs. 
 
 
2.6.1.6  Intracellular Signaling Pathways 
 
Signaling pathways may be effective in treating experimental AAA, including 
the Rho/Rhokinase,NF-κB, and JNK pathways. Treatment with fasudil, a 
Rhokinase inhibitor resulted in reduction of both the incidenceand severity of 
Ang II-induced AAA in apolipoprotein E-deficient mice in addition to inhibiting 
VSMC apoptosis and proteolysis by MMP-2 and 9(Wang et al, 2005). NF-κB 
inhibition by pyrrolidine dithiocarbamate (PDTC) suppressed development  
of elastase-induced AAA in mice (Parodi et al., 2005). Pharmacological 
inhibition of c-Jun N terminal kinase (JNK) with SP600125, a specific JNK 
inhibitor, has been reported to prevent  or regress AAA in CaCl2-induced 
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mouse AAA and AngII-induced ApoE-/- mouse AAA models suppressing 
MMP activity and migration of inflammatory cells (Yoshimura et al., 2005).  
 
Vorkapic et al., (2016) investigated the importance of tyrosine kinase 
pathways in the development of aneurysms using Imatinib, a selective 
inhibitor of several tyrosine kinases, in a mouse model of AAA. Treatment 
with Imatinib decreased aortic diameter and vessel wall thickness indicating 
tyrosine kinase inhibitors may be useful in the treatment of pathological 
vascular inflammation and remodelling in AAA. 
 
 
2.6.1.7  Enzymes for ECM Metabolism 
 
MMPs are well known for their role in the progression of AAA and therefore 
are possible targets for pharmacological intervention. Treatment with 
doxycycline, a tetracycline derivative reduced MMP-9 production and caused 
a significant reduction in the incidence of AAA induced by elastase infusion 
in rats (Petrinec et al., 1996). Since then many studies using doxycycline 
have been carried out under a variety of different experimental conditions 
that have supported Petrinec's research (Curci et al., 1998, Huffman et al., 
2000, Prall et al., 2002, Manning et al., 2003, Kaito et al., 2003, Sho et al., 
2004, Bartoli et al., 2006,  Vinh et al., 2008). A number of studies into the 
effect of doxycycline on human AAA have also been carried out. 
Preoperative treatment with doxycycline  was found to decrease MMP-9 
expression in aneurysm tissue (Curci et al., 2000). Doxycycline was also 
found to slow down AAA expansion in comparison to patients treated with a 
placebo during a randomized trial (Mosorin et al., 2001). Another clinical trial 
demonstrated the safety of doxycycline and its ability to reduce MMP-9 
plasma levels ( Baxter et al., 2002). Lindeman et al., (2009) also reported 
that doxycycline inhibited infiltration of neutrophils and cytotoxic T cells in the 




Systemic treatments of MMP inhibitors have shown effectiveness in animal 
models, but often did not translate to clinical success either because of the 
low doses used or due to systemic side effects of MMP inhibitors. Nosoudi  
et al., (2015) proposed a targeted nanoparticle (NP) - based delivery 
of MMP inhibitors at low doses to the AAA site for preventing expansion of 
aneurysms in patients without systemic side effects.Intravenous injections of 
elastin antibody-conjugated BB-94 (MMP inhibitor batimastat) - loaded NPs 
targeted to the site of aneurysms in a rat model of AAA  resulted in 
inhibited MMP activity, elastin degradation, calcification and aneurysmal 
development in the rat aorta. 
 
Baxter et al., (2016) are currently enrolling patients into their Non-Invasive 
Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA3CT) which is a 
Phase llb randomized, placebo-controlled clinical trial testing doxycycline to 
determine if it reduces the growth of small AAAs and systemic markers of 
inflammation over a 24 month time period. They predict the outcome will 
demonstrate at least a 40% reduction in aneurysm growth rate. 
 
 
2.6.1.8  Anti-inflammatory agents 
 
Prostaglandins act as a class of biological mediators in the inflammatory 
process,  and   are  converted  from   arachidonic   acid  by   cyclooxygenase 
(COX). The expression of COX-2  but not COX-1 is upregulated in human 
AAA tissue (Holmes et al., 1997). King et al.,  (2006) using the selective 
COX-2 inhibitor celecoxib found it decreased the incidence and severity of 
AAA formation in Ang II-induced ApoE-/-mouse AAA models, whereas 
selective COX-1 inhibition had no effect on AAA formation.  Additionally,  the 
incidence of Ang II-induced AAA was reduced in COX-2-deficient mice in 
comparision to wild-type mice (Gitlin et al., 2007). 
 
Inflammation has an important role in AAA progression and several studies 
have attempted to attenuate aneurysm formation by targeting inflammatory 
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cells such as  macrophages. Iida et al., (2013)  demonstrated the ability of 
the peptide CXCL4-CCL5 heterodimer inhibitor MKEY to both suppress 
experimental AAA initiation and stabilize existing aneurysms in murine 
models through the impaired infiltration of mural monocytes/macrophages. 
 
Yan et  al., (2016) investigated the effects of zinc which is known to have an 
anti-inflammatory action (Bao et al., 2010) on AAA progression and its 
related molecular mechanisms in a rat model of AAA. The results showed 
that zinc supplementation significantly suppressed the CaCl2-induced 
expansion of the abdominal aortic diameter, preserved aortic medial elastin 
fibres, attenuated macrophage and lymphocyte infiltration and reduced 
MMP-2 and MMP-9 production. This study also demonstrated that treatment 
with zinc could prevent the development of rat experimental AAA by 
induction of A20 (a zing-finger transactivating factor) - mediated inhibition  of 
the NF-κB canonical signalling pathway. Kortekaas et al., (2014) evaluated  
the  anti-inflammatory potential  of  ACE (angiotensin-converting-enzyme) 
inhibitors (independent of their blood pressure lowering effect) in AAA 
patients who were treated with ramipril 2-4 weeks preceding surgery. Post-
surgical analysis of AAA tissues showed ACE inhibition quenched multiple 
aspects of vascular inflammation in AAA but this did not translate into 
reduced aneurysm growth. An earlier study by Takai et al., (2013) had also 
looked at the effect of ACE inhibitors against elastase-induced AAA 
progression in mice and concluded MMP-9 inhibition by imidapril might 













3.  General Methodology 
 
3.1 Cell Culture 
 
3.1.2    Materials List 
 
 HASMCs (TCS Cellworks and Caltag Buckingham, UK. 
 Dulbecco‘s Modified Eagles Medium (DMEM) Invitrogen, Paisley, UK)  
 Foetal calf serum (FCS) (GlobePharm LTD. UK). 
  Penicillin/Streptomycin (Invitrogen. Paisley, UK) 
  Phosphate Buffered Saline (Invitrogen. Paisley, UK) 
  Accutase (Innovative Cell Technologies Inc.). 
  L-Glutamine (Sigma Aldrich. Dorset, UK). 
  Smooth Muscle Cell Complete Medium (Caltag. Buckingham, UK)  
 Glass cover slips (VWR International Ltd. Dorset, UK). 
  T25, T75, T150 filter-cap flask and 6/12 well plates (Triple Red Ltd. 
Oxfordshire, UK).  
 Lab-Tek Chamber slides (Nalgene Nunc International). 
 
 
3.1.3    Cell Culture Protocol 
 
The primary HASMC culture was seeded into T25 flasks and routinely grown 
in DMEM supplemented with 10% foetal calf serum, 2mM L-glutamine, 100 
units/ml penicillin and 100μg/ml streptomycin or Smooth Muscle Cell 
Complete Medium  which was replaced every two to three days.  The cells 
were kept in 5% CO2, 95%. air at 37C in a humidified Jencons Millenium 
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incubator (Jencons Ltd. Bedfordshire, UK). Upon reaching confluence (100% 
monolayer covering flask base) the cells were split 1:5 into T75 flasks. 
HASMCS were washed in PBS then dissociated from the flasks using 2mls 
Accutase /T25 and incubated at 37ᴏC for approx 2-5 minutes.  DMEM was 
added to inactivate the Accutase and the cells were brought out of 
suspension by centrifugation at 1600rpm for 5 minutes. The supernatant was 
removed and the pellet resuspended in fresh DMEM. For hypoxia studies 
cells were passaged into 6-well plates or for cell staining experiments grown 















Figure 20   Laminar Flow Cabinet 
All cell culture work was carried out under aseptic conditions inside a laminar flow 
cabinet which was switched on 10 minutes prior to use to allow air flow to reach 





3.1.4    HASMC Cell Storage and Resurrection of Cells 
 
Cell stocks were routinely stored in liquid nitrogen. Confluent T25-flasks 
were harvested using Accutase solution, following which the cell pellet was 
then resuspended in a freeze-down medium, consisting of 50% FCS, 40% 
growth medium and 10% DMSO. 1ml volumes of freeze-down medium were 
used to resuspend the pellet from each T25 flask of cells. Cell suspensions 
were stored in NUNC Cryo-tubes and frozen to -70ºC at -1ºC per min in the 
Cryo 1°C Freezing Container and then placed into liquid nitrogen storage.  
Cells were resurrected rapidly by placing NUNC Cryo-tubes under warm 
running water. Cells were washed once by centrifugation of the cell 
suspension at 1600rpm for 5mins and the subsequent pellet resuspended in 
normal DMEM-based medium.  
 
 
3.1.5  Trypan Blue Exclusion Cell Viability Counts 
 
The Trypan Blue exclusion test is used to determine the number of viable 
cells present in a cell suspension. It is based on the principle that live cells 
possess intact cell membranes that exclude certain dyes such as Trypan 
blue which cannot permeate viable cells and appear clear under the light 
microscope, dead or compromised cells take up the Trypan blue dye and 
appear blue in colour. 
 
3.1.6    Materials List 
 
 Accutase (TCS Cellworks LTD. Buckinghamshire, UK), 
 Trypan Blue (Sigma Aldrich Company Ltd. Dorset, UK).  
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3.1.7   Trypan Blue Exclusion Cell Count Protocol  
 
Cells grown in 12-well plates or T25-flasks were dissociated by incubation 
with 500μl or 2000μl Accutase, respectively, per well/flask at 37ºC, 5%CO2 
for  5-10 minutes. The cell suspension was mixed 1:1 with Trypan blue and 
cells were counted using a Neubauer double rhodium coated counting 
chamber (Fisher Scientific UK Ltd). Approximately 15μl of the cell/Trypan 
blue mixture was applied to the counting chamber and blue (dead) and clear 
(viable) cells were counted from five of the nine 1mm2 squares on the 
counting chamber (as indicated in Figure 21). The average number of cells 
per square was used in the calculation of the number of cells per ml of the 
starting cell suspension, as shown below: 
 
Viable cells/ml = Mean cells per square * 2 * 10,000 
 
 *2    (Dilution factor of Trypan blue). 
 *10,000  (Volume correction from volume of 1mm square under  
cover slip, 10-4ml  to 1ml). 
 
 
The percentage of viable cells can be calculated after repeating the above 













                                
 
Figure 21   Cell Counts Using a Haemacytometer 
The typical grid layout of the haemocytometer, divided into nine 1mm squares. Cell 
counts were taken from the five numbered squares (as indicated in A). Only cells in 





3.2  Hypoxia Studies 
 
Human aortic smooth muscle cells (HASMCs) were passaged into 6-well 
plates and grown to sub-confluence under normal conditions in the presence 
of 10% FCS in DMEM with additions of 2mM L-glutamine, penicillin (10,000 
IU/ml) and streptomycin (10,000 IU/ml). The cells were then maintained in 
serum-free medium under severe hypoxia (5%CO2, 94%N2 and 1%O2) 
inside a sealed Minimac hypoxia chamber (Figure 22) at 37oC for up to 72 
hours. Controls were maintained throughout the 72 hour period in an 
incubator at 37C in 95% air, 5%CO2. Conditioned media and cell lysate 
samples were collected at the termination of allotted time points and stored 
at -80o for later analysis. Additionally cells were also grown on 13mm 






for immunostaining purposes or under normal oxygen levels for comparison 











Figure 22    Don Whitley Minimac Hypoxia Chamber 
This workstation was used to maintain the HASMCs under severe hypoxic 
conditions (1% hypoxia) fully incubated at 37 oC. The‗rapid lock‘ manually-operated 
portholes allow both access for the operator‘s arms and the transfer of samples in 
and out of the chamber with the automatic gas refill system for the sleeves, 
ensuring the internal atmosphere is not compromised by the transfer of oxygen 
through the ports to provide a strict hypoxic environment.  
 
 
The ability to manipulate samples under hypoxic conditions without 
compromising the chamber atmosphere is important as some proteins, 
especially those in the HIF-1 family are rapidly degraded once the cells 
become normoxic again, therefore it is vital to collect the proteins without 
having to expose the cells to normal oxygen levels. 
To further ensure that a strict hypoxic environment was being maintained, a 
calibrated oxygen sensor (Analox Oxygen Analyser) shown in Figure 23 
below was placed inside the hypoxia chamber to monitor oxygen levels at all 
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times but especially important during the manipulation and removal of 












3.3  Immunostaining 
 
Immunohistochemistry (IHC) is a technique widely used in all areas of 
research and refers to the process of detecting antigens within cells of a 
tissue section by the interaction of antibodies tagged with a visible label 
targeted against and binding specifically to specific antigens. Correct 
processing of the tissue section allows the ultra structure of the tissue to be 
maintained prior to IHC which subsequently enables visualisation of the 
distribution and immunolocalisation of specific cellular antigens within the 
proper tissue context.   
Antibody-mediated antigen detection techniques are separated into direct 
and indirect methods. For this study the more sensitive indIrect method was 
employed involving an unlabelled primary antibody that binds to the target 
antigen and a labelled secondary antibody that reacts with the primary 
antibody. The secondary antibody must be raised against the IgG of the 
animal species in which the primary antibody has been raised and results in 
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signal amplification due to the binding of several secondary antibodies to 
each primary antibody. IHC target antigens can be detected through 
fluorescent or chromgenic techniques which envolve enzymatic activity 
resulting in the production of a coloured precipitate. In this case a 
commercially available kit based on the biotin/avidin system was used in 
most of the immunostaining procedures. Avidin, a large 68,000 molecular 
weight glycoprotein can be labelled with alkaline peroxidase and has a very 
high affinity for the low molecular weight vitamin biotin which can be 













Figure 24   The Avidin-Biotin Complex  
An unlabelled primary antibody reacts with its  target antigen and a biotinylated 
secondary antibody which is raised againt the IgG of the primary antibody. The 
biotin molecule is easily conjugated to antibodies and enzymes. In the avidin-biotin 
complex (ABC) method secondary antibodies are conjugated to biotin and function 








3.3.1 Fast Red Staining of HASMCs and Fibroblasts 
 
3.3.2  Materials List 
 
 Phosphate buffered saline ((Invitrogen. Paisley, UK). 
  Methanol (VWR International Ltd. Dorset, UK), Acetone VWR 
International Ltd. Dorset, UK).  
 Tween-20 (polyoxyethylene-sorbitan monolaurate) (Sigma Aldrich. 
Dorset, UK). 
  Horse serum (Sigma Aldrich. Dorset, UK). 
 Alkaline phosphatise-conjugated avidin biotin complex, antimouse 
IgG (VECTASTAIN® ABC-AP kit (Vector Laboratories Ltd. 
Peterborough, UK).  
 Levamisole Soln (Vector Laboratories Ltd. Peterborough).  
 Naphthol AS-MX phosphate/Fast red TR Fast TM (Sigma Aldrich. 
Dorset, UK).  
 Superfrost Plus Microscope Slides (VWR International Ltd. Dorset, 
UK).  
 Aquamount (VWR International Ltd. Dorset, UK). 
 Primary and secondary antibodies  
 
3.3.3  Fast Red Staining Protocol 
 
HASMCS and fibroblasts were grown on 13mm diameter coverslips in 6 or 
12-well plates for characterisation purposes. Conditioned media was 
aspirated from the wells, cells were washed with PBS which was 
subsequently removed and replaced with ice-cold acetone/methanol (50:50) 
for fixation. After incubation the fixative was aspirated, the cells washed in 
PBS and then incubated for 30 minutes in blocking buffer (0.5% Tween-20 
and 1.5% horse serum in PBS) at room temperature. The blocking buffer 
was removed and cells incubated in primary antibodies for 2 hours at room 
temperature. Excess 1ᴏ antibody was removed by washing cells in PBS 
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three times for five minutes after which the secondary antibody biotinylated 
horse anti-mouse IgG.(VECTASTAIN® ABC kit) was applied for 30 minutes 
to one hour at room temperature and subsequently removed by a repeat of 
the previous wash steps. The cells are then incubated in the ABC reagent 
solution (prepared according to the manufacturer‘s instructions) for 30 
minutes at room temperature and the previous wash steps repeated. 
Visualisation of positively stained cells was obtained using Napthol AS-MX 
phosphate/Fast red TR Fast during which Levamisole (125mM) can be 
added to the solution to inhibit any endogenous alkaline phosphatase 
activity. The reaction was followed under the microscope and when optimal 
staining was achieved the reaction was stopped by rinsing in running water 
followed by counterstaining with Mayer‘s Haematoxylin for approximately two 
minutes. Finally the coverslips holding the stained cells were removed from 
the 6 or 12-well plates and placed cell-side down onto glass slides using 
Aquamount mounting medium and allowed to dry at room temperature. 
Samples were viewed under a Zeiss Axioscope microscope and images 




































Figure 26 Phase Contrast Microscope 
This microscope enabled living cells to be visualised and photographed. Also it 
allowed daily monitoring of proliferating cells for growth progression and to check if 
cells are free from infection.  
 
 
3.4  Bradford Assay     
 
Protein concentration prior to sample analysis  was determined by Bio-Rad 
protein assay (Bio-Rad Laboratories, Hertfordshire, UK). 
 
The principle underlying Bradford assay is the binding of the Coomassie 
Blue G250 dye to proteins which can be utilized  to measure the 
concentration of total protein in a sample.This method actually measures the 
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presence of the basic amino acid residues, arginine, lysine and histidine  
which contributes to formation of the protein-dye complex and under acidic 




3.4.1 Bradford Assay Protocol 
 
The Biorad microtitre plate protocol was used (96-well plate). Serial dilutions 
of  samples (10µl) were placed in triplicate into separate wells. Biorad dye 
reagent was diluted 1:5 with dH2O and then filtered through watman paper. 
200µl of the diluted dye reagent was added to each sample and allowed to 
incubate  for  at  least 5  minutes at  room temperature.   Following  this,  
absorbance (OD) was measured spectrophotometrically at 595nm in a plate 
reader. 
Biorad bovine serum albumin (BSA) was used as a standard (1.4mg/ml 
stock). Doubling dilutions of the BSA were prepared to a concentration of 
0.01µg/µl and 10µl of each dilution was added to wells in triplicate.  Dye 
reagent was added as before and absorbances read at 595nm. Prism 
software was used to create a standard curve from which the unknown 







Chapter 4. Analysis of MMP-2 and 
MMP-9 Levels in HASMCs Exposed 





4. Analysis of MMP-2 and MMP-9 levels in HASMCs 




Increased matrix metalloproteinase (MMP) activity is implicated in aneurysm 
formation through elastin destruction and collagen degradation. MMP-2 is 
thought to play an important role in the initiation of aneurysm formation 
formation and is the dominant gelatinase in early aneurysms, whilst MMP-9 
has significant role in later aneurysms (Freestone et al., 1995). 
The aorta contains several different cell types such as fibroblasts, smooth 
muscle cells (SMCs) and endothelial cells but SMCs are considered the 
principal cell type in the tunica media of the aorta. Crowther et al., (2000) 
demonstrated SMCs derived from aneurysmal aorta produce increased 
levels of MMP-2 and are the primary source of MMP-2 in AAA whilst 
macrophages are the primary source of MMP-9 in aneurysms (Hibbs., 1992).  
The mechanism for AAA induction has not been fully elucidated but arterial 
wall hypoxia has been proposed as a candidate for the initiation of aneurysm 
formation. Animal models of AAA have demonstrated evidence of low 
oxygen tension within aortic media (Bjornheden et al.,1999) which amongst 
other things may alter smooth muscle cell function resulting in aortic 
degradation and potential aneurysm formation (Vorp et al., 1996). 
Furthermore, research has shown that hypoxia exists in vivo in aneurysms of 
patients with intraluminal thrombus, a common feature of AAA which 
contributes to arterial wall hypoxia and weakening (Vorp et al., 1998, 2001). 
 
Previous   research  by   our  Group  (Erdozain  et  al.,  2011)   demonstrated 
significant increases in MMP-2 and MMP-9 in HASMC conditioned media 
after exposure to sequential decreases in oxygen tension (5-1%) over a 96 
hour time period. However, cell viability assays (lactate dehydrogenase) 
carried out on all hypoxic and normoxic samples found NADH production in 
supernatants from cells exposed to hypoxia for longer than 72 hours, 
therefore,  evaluation of samples at 1% oxygen tension which were beyond 
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this time-point were not carried out.  In light of these results, the aim of this 
further investigation was to assess HASMC MMP secretion and induction 
times after exposure to constant severe hypoxia (1%) over a 48 hour time 
period rather than the previous sequential decreases. Previously, cells were 
maintained in media containing foetal calf serum (FCS) throughout the 
period of hypoxia and therefore in these experiments, in order to rule out 
foetal calf serum as a confounding factor, cells were maintained in serum-
free media 24 hours prior to and during exposure to hypoxia. 
 
 
4.2 Chapter Aims 
 
The hypothesis suggests that levels of MMP-2 and MMP-9 protein will be 
increased during exposure to severe hypoxia.  
 
The aim of the chapter will be: 
 
1. To culture stocks of HSMCs to generate sufficient cells for the 
experimental hypoxia study and characterisation. 
2. To culture human neonatal fibroblast cells for immunocytochemical 
characterisation control purposes. 
3.  To determine whether MMP-2 and MMP-9 has been secreted into the 
HSMC conditioned media after exposure to prolonged 1% hypoxia or normal 
oxygen levels using zymography techniques. 
4. To determine if there  are differences in secreted MMP levels between the 
hypoxic and normoxic samples. 
5. To corroborate the identity of the MMPs present in the culture supernatent 
by immunoblotting. 
6. To perform cell viability assays on HASMCs exposed to severe hypoxia. 
7. To carry out inhibition assays to further identify sources of gel proteolysis. 
8. To confirm the localisation of MMP-2 and MMP-9 in control and 





4.3 HASMC Characterisation 
 
Prior to any experimentation cell lineage of all cultures were confirmed by 
immunostaining for SMC - specific α-actin (SMA) which is a 42 kDa protein 
and one of the six isoactins expressed in mammalian cells. SMA is the most 
abundant of all the isoforms constituting 40% of total cell protein and over 
70% of total actin content (Fatigati et al, 1984). Additionally HASMCs were 
probed with antibodies against the 55 kDa intermediate filament protein 
desmin. Fibroblasts are the primary contaminating cell type in VSMC 
cultures therefore neonatal skin fibroblasts were also established under 
exactly the same culture conditions as for HASMCs to use as a comparison 
and provide negative controls. 
 
 
4.3.1 Fast Red Staining of HSMCs and Fibroblasts 
 
HASMCS and fibroblasts were grown to subconfluence on 13mm diameter 
coverslips placed in 6-well plates. After fixation in ice-cold acetone/methanol 
(50:50) cells were incubated in blocking buffer (0.5% Tween-20 and 1.5% 
horse serum in PBS) for 30 minutes followed by a 2 hour incubation in the 
following primary antibody solutions (all supplied by DAKO Ltd.
Cambridgeshire, UK) monoclonal mouse anti-human smooth muscle actin 
(1:100) monoclonal mouse anti- Aspergillus niger glucose oxidase (negative 
control) (1:100), mouse monoclonal anti-prolyl 4-hydroxylase (1:100), mouse 
monoclonal anti-human desmin (1:50) and monoclonal mouse anti-human 
smooth muscle myosin heavy chain (1:50). A biotinylated horse anti-mouse 
IgG secondary antibody was applied for one hour at room temperature 
followed by incubation for 30 minutes in Vectastain‘s ABC reagent solution.  
Visualisation of positively stained cells was obtained using Napthol AS-MX 
phosphate/Fast red and the reaction followed under the microscope until a 
pink/red precipitate appeared. After counterstaining in Mayer‘s haematoxylin 
for approximately 2 minutes, cells were mounted cell-side down onto 
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microscope slides and viewed under a Zeiss Axioscope microscope and 
images were captured using the Zeiss KS300 program (Carl Zeiss Ltd. 
Hertfordshire, UK). The full protocol has been described earlier in Chapter 3: 
General Methodology.  
 
4.3.2 HSMC Characterisation Results 
 








Figure 27   Living Fibroblasts in Cell Culture 
Living fibroblasts were viewed under phase contrast microscopy (Nikon Eclipse 
TS100. Nikon Instruments UK) and images were captured using a Nikon Coolpix 
digital camera (Nikon UK Ltd. Surrey, UK). A and B show sub-confluent and 









Figure 28   Living HASMCs in Cell Culture 
Living HASMCs were viewed under phase contrast microscopy. A. Sub-confluent 
HASMCs. B. HASMCs after being subjected to Accutase treatment and losing 
adhesion from the flask ready for subculture respectively (Bar = 50μm). 













Figure 29   Immunstaining of HASMCs and Fibroblasts 
HASMCs (A) and fibroblasts (B) grown on glass coverslips were labelled with anti-
human prolyl 4-hydroxylase (fibroblast) primary antibody (1:100 dilution) and 
biotinylated anti-mouse IgG secondary antibody (1:200 dilution) then visualised 





















Figure 30   Immunostaining of HASMCs and Fibroblast with Alpha Actin 
 
HASMCs (A) grown on glass coverslips were labelled with anti-human SMC- 
specific α-actin (SMA) primary antibody 1:100 dilution. Fibroblasts (B) were also 
probed with SMA for comparison 1:100 dilution A biotinylated anti-mouse IgG 
secondary antibody (1:200 dilution) was applied to all samples. Nuclei were 
counterstained using Mayers Haematoxylin. Localisation of α-actin was visualised 
using Fast Red and viewed under a Zeiss Axioscope microscope, images were 






Under phase contrast microscopy, cultured HASMCs revealed a typical 
spindle-shaped morphology containing an oval shaped nucleus which grew 
to  form regularly oriented parallel bundles  attaining  the characteristic 
smooth muscle ―hill and valley‖ pattern on reaching 100% confluence 
(Chamley-Campbell et al., 1979 ) However a few cells  exhibited a more 
spread out flattened morphology  which is not unusual in cultured smooth 
muscle cells (Kocher and Gabbiani,1987).  
Fibroblasts generally have a more flattened appearance than smooth muscle 
cells and contain a large rounder shaped nucleus containing more nucleoli 
(Chamley-Campbell et al, 1979) Immunocytochemical staining of the HSMCs 
for αSMA showed a very positive pinkish red cytoplasmic stain at the 1:100 
dilution In comparison, the fibroblasts were negative for SMA staining as 
expected but positive for prolyl 4-hydroxylase. 
 The cells were also probed for desmin (not shown)  but gave negative or 
very weakly positive  results which correlates with the findings of Absher et 
al., (1989)  who noted that although in vivo desmin is the intermediate 
protein expressed, in culture SMCs can very rapidly alter their cytoskeletal 
protein profile and express vimentin  rather than desmin.  
All controls slides gave negative results with no staining observed when 
primary antibodies were omitted or after probing with  the Aspergillus niger 






4.4 Gelatin zymography 
 
4.4.1 Principles of Zymography 
 
Expression of MMP-2 and MMP-9 in conditioned media from HASMCs after 
exposure to severe hypoxia for up to 48 hours was studied using the 
technique gelatin zymography. 
Zymography is a sensitive method for examining matrix metalloproteinases. 
Gelatin is the most commonly used substrate and is useful for demonstrating 
the activity of the gelatinases such as MMP-2 and MMP-9. This technique is 
a modification of SDS-PAGE (sodium dodecylsulphate polyacrylamide gel), 
based on the incorporation of an in situ enzymatic substrate (gelatin) into the 
electrophoretic gel at the time of polymerization. Proteolytic activity is 
reversibly inhibited by SDS during electrophoresis and recovered by 
incubating the gel in the appropriate buffers delaying proteolysis until the 
sample proteins have been resolved into bands of concentrated activity.  
The advantage of this system is the detection of both the proenzyme and 
active forms of MMPs, which can be distinguished on the basis of molecular 
weight and is possible because the proenzymes are activated in situ as the 
latent MMP unfolds due to action of SDS.  The zymogram is subsequently 
stained with Coomassie Brilliant Blue where areas of digestion appear as 
clear bands against a darkly stained background where the substrate has 
been degraded by the enzyme allowing the visualization of gelatin-degrading 
enzymes. 
 
4.4 2  Gelatin Zymography Protocol 
 
MMPs were separated on a vertical 7.5% polyacrylamide resolving gel 
containing 1% gelatin and 4% polyacrylamide stacking gel. Electrophoresis 
was performed at 125 V and allowed to run until the gel-front neared the end 
of the resolving gel, followed by incubation for 1.5 hours in 2.5% Triton X-
100 at room temperature to renature the proteins, with subsequent 
146 
 
incubation at 37°C in development solution (50Mm CaCl2, 0.5M Tris-HCL pH 
7.6) for between 24-48 hours. Thereafter the gels were stained with 0.2% 
Coomassie Brilliant Blue R-250 for approximately one hour and then 
destained in methanol, glacial acetic acid and dH2O (4:1:5, v/v/v) following 
which the zymogram was left for 48 hours in water to enhance band 
resolution. Gelatinolytic activity was demonstrated as clear bands against a 
blue background of stained gelatin. Purified human MMP-2 and MMP-9 
protein were used as standards to identify the protein bands. 
Semiquantitative image analysis was carried out using Scion Imaging 
Software (version 4.0.2; www.scioncorp.com) to evaluate the relative 
enzymatic activity in ADU (Arbitrary Density Units)/ml-1mg cellular protein. 
 
 
4.4.2.1 Dilution of samples 
 
After equally loading and running several gels it became clear that to obtain 
decent bands at all time-points was not possible. The early time-points 
required sufficient cell culture supernatant in order to digest the gelatin 
contained within the polycrylamide gel and produce bands of lysis, but for 
the later time points this resulted in very intense bands due to the high levels 
of MMP-2 enzymatic activity which were also prone to merge into one 
another making an accurate densitometric analysis very difficult.  Additionally 
loading too much protein can also result in smears or streaking across the  
polyacrylamide gel. In order to rectify this problem the culture supernatants 
appertaining to the later time-points were diluted and these dilutions taken 
into account during the final analysis and calculations. Figure 31 shows an 
















Figure 31   Comparison of Diluted and Undiluted Samples 
 
Slides A and B show bands of lysis from HAMC culture supernatant samples at 
time-points: 30 hours (lanes 1 and 2) and 48 hours (3 and 4). Lanes containing 
hypoxic samples are annotated in red and normoxic samples annotated in black. 
Slide A: Demonstrates how difficult it is to visually detect the difference between the 
undiluted samples in lanes 2 to 4.  
Slide B: Shows the same samples after dilution which produced much clearer 
separate bands of lysis making density analysis far more accurate as there is more 
contrast for the imaging programme to detect and no merging at the outer regions 
























4.4.2.2    Results of Gelatin Zymography 
 





   
 
 
                                  
   
 
 
Figure 32   Representative Zymography Gels Showing  Analysis of 
MMP-2 and MM-9 Levels in HASMC Supernatant. 
 
Culture supernatants from HASMCs exposed to 1% hypoxia or normoxia  for 48 
hours were equally loaded onto 7.5% polyacrylamide gels containing 1% gelatin. 
Electrophoresis was performed at 125V after which the proteins were renatured in 
2.5% Triton-X solution  followed by a 24 hour incubation in development solution 
and subsequent staining with 0.2% Coomassie Blue R-250 and destaining in 
methanol, glacial acetic acid and dH2O (4:1:5, v/v/v). Purified human MMP-2 and 9 
standards (Chemicon Europe Ltd. UK) served as positive controls and sample 
buffer as a negative control. 
Slide A: 1: Negative control (sample buffer) 2: Positive control (Purified human 
MMP-2) 3: 1hrN 4: 1hrH 5: 3hrsN 6:3hrsH 7: 6hrsN 8:6hrsH 9: RSM10: Positive 
control (Purified human MMP-2).  
Slide B: MMP-2 enzymatic digestion of the gels gave very intense bands at the 
latter time-points (30 hrs, 48 hrs) therefore for more accurate analysis to the culture 
supernatant relating to these time-points was diluted before loading and then 
adjusted for in the final calculations. 1: Positive control (Purified human MMP-2) 2: 
30hrsN 3:30 hrsH 4: 48hrsN 5: 48hrs H 6: RSM. (N: Normoxia, H: Hypoxia, RSM: 
Rainbow size marker). 


























Figure 33    Analysis of MMP-2 Activity in HASMC Culture Supernatant 
A: Bar graph and B: Scatter plot showing levels of MMP-2 in HASMC conditioned 
media after exposure to hypoxia (1%) or normoxia for 48hrs assessed by 
densitometric analysis. Hypoxia (filled bars) compared to normoxia (open bars).  
Results expressed as ADU (Arbitrary Density Units)/mg ml-1 cellular protein. Data 
expressed as mean ± SEM of triplicate values. Results are from three independent 
experiments repeated in triplicate. n = 3. Statistical analysis was performed using 
Student's t-tests and statistical significance was indicated by p values < 0.05. 
 
Results of gelatin zymography evaluation revealed that hypoxia for 1 hour 
led to a significant increase in secreted pro and active MMP-2 species (p < 
0.01). Significant increases were also noted at 3 hours (p< 0.05), at 6 hrs (p 
< 0.05) and at 30 hrs (p < 0.05). Analysis at 48 hours showed sustained 
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elevations, but no statistical significance was found. MMP-9 was not 




4.5    Assessment of HASMC Lysate Samples for 
MMP-9 
 
Lysate from HASMCs exposed to 1% hypoxia or normoxia was assessed 
using gelatin zymography to determine  if any MMP-9 was present inside the 
cells as secreted MMP-9  was not detected in HASMC conditioned media. 
However, in our previous study (Erdozain et al., 2011)  MMP-9 was detected 
in conditioned media from HASMCs exposed to decreasing levels of hypoxia 
over a 72 hour time period (Erdozain et al., 2011).  A maximum of 7μg of 
protein per well was loaded onto the gels which were incubated in 
development buffer for 48 hours rather than the usual 24 hours to give the 










                      









Figure 34    Analysis of MMPs in HASMC Cell Lysate 
 
Lysate from HASMCs exposed to hypoxia or normoxia for 48 hours was overloaded 
onto a 7.5% gel and assessed using gelatin zymography. Incubation was carried 
out over a two day time period in order to maximise enzymatic activity. 1: 1hr N 2: 
1hr H 3: 3hrs N 4:3hrs H 5:6hrs N 6: 6hrs H 7: 30hrs N 8: 30hrs H 9: 48hrs N 10: 
48hrs H. H (HASMCs exposed to hypoxia) N (HASMCs cultured under normoxic 
conditions to serve as controls). 
 
 
Bands of a higher molecular weight than MMP-2 can be seen on the above 
gel which could be consistent with MMP-9. In order try and identify these 
bands the  gel was repeated and the sample size decreased to reduce the 
streaking apparent on the above gel. Additionally the incubation period was 
reduced and MMP-2 and MMP-9 positive controls included along with a 
molecular weight ladder. 
 
 
1 2 4 3 5 7 10 9 8 6 
MMP-9 ? 


















                                                                                                                                                                                                                                                                                                                                   
 
Figure 35    Repeat HASMC Lysate Analysis for MMP-9 
 
Lysate (3μg) from HASMCs exposed to hypoxia or normoxia for 48 hours was 
loaded onto a 7.5% gel and assessed using gelatin zymography. Incubation was 
carried  out overnight.                                                                                            
Slide A:  1: MMP-2 positive control  2: 1hr N 3: 1hr H 4: 3hrs N 5: 3hrs H 6: 6hrs N 
7: 6hrs H 8: 30hrs N 9: 30hrs H 10: 48hrs N 11: 48hrs H 12: RSM.                             
Slide B: 1: MMP-9 positive control  2: 1hr N 3: 1hr H 4: 3hrs N 5: 3hrs H 6: 6hrs N  
7: 6hrs H 8: 30hrs N 9: 30hrs H 10: 48hrs N 11: 48hrs H 12: RSM. H (HASMCs 
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After reducing the protein concentration from 7μg down to 3μg MMP-9 was 
undetected in both normoxic and hypoxic lysate samples in both gels shown 
Figure 35. Therefore these results make the bands seen on the gel in Figure 
34 seem less likely to be MMP-9, unless of course MMP-9 concentrations 
within the samples were so small that only larger sample volumes would 
allow detection. 
 
4.5.2   Zymographic Control Gels 
 
During our earlier study Erdozain et al., (2011) had maintained the cells in 
media containing 10% FCS prior to and during the period of decreasing 
hypoxia levels. FCS is known to effect the expression of some proteins 
therefore controls maintained in 10% FCS media were set up for comparison 
purposes to rule out foetal calf serum as a potential confounding factor  All 
other experiments during this study used cells maintained in serum-free 











Figure 36    10% FCS Control Gel 
Levels of MMP-2 in culture supernatants containing 10% FCS from HASMCs 
exposed to hypoxia or normoxia for 48 hours and assessed using gelatin 
zymography.  Purified human MMP-2 was used as a standard to identify the bands. 
1: MMP-2 positive control  2: 1hr N 3: 1hr H 4: 3hrs N 5: 3hrs H 6: 6hrs N 7:  6hrs H 
8: 30hrs N 9: 30hrs H 10: 48hrs N 11: 48hrs H 12: RSM. (N: normoxia, H: hypoxia). 














Figure 37    Levels of MMP-2 in 10% FCS Control Gel 
 
Levels of MMP-2 in conditioned media containing 10% FCS from HASMCs exposed 
to 1% hypoxia (filled bars) or normoxia (open bars) for 48 hours. Results expressed 
as arbitrary density units (ADU) per unit standardised total protein. Results are from 
one experiment repeated in triplicate. n = 1.  
 
 
A further control zymography gel  (FIgure 38) was set up with only 2 lanes, 
containing freshly prepared medium including 10% FCS (Lane 1) and 
conditioned media with 10% FCS (Lane 2). This was to determine if MMP-2 
was present in the medium containing FCS, any MMP-2 present in this 
sample must originate from the FCS. MMP-2 is expected to be present  in 
the conditioned medium sample containing FCS as this supernatent was 



























Figure 38  Control Gel Demonstrating MMP-2 in FCS 
Zymographic analysis of MMP-2 levels in FCS. Lane 1 was loaded with 20µl of 
freshly prepared medium including 10%  FCS and Lane 2 loaded with 20µl of 
HASMC conditioned medium also containing 10% FCS and incubated overnight at 
37°C. The band in Lane 2 corresponds to MMP-2 as confirmed by the molecular 
weight marker (not shown) and Lane 1 also shows a significant band corresponding 
to MMP-2. The wells were equally loaded.  The results seem to indicate that FCS 
does contain significant amounts of MMP-2 as the medium to which it was added 
was not conditioned by HASMCs and therefore the FCS must be the source of 
MMP-2 seen in Lane 1. Although a negative control was not included this time, 
previously, in all earlier zymographic analysis, freshly preprepared medium not 
containing FCS has been run on a gel and has never produced a band of lysis.  
 
 
The earlier results of gelatin zymography evaluation shown in Section 
4.4.2.2 Figures 32 and 33, revealed that hypoxia for 1 hour led to a 
significant increase in secreted pro and active MMP-2 species (p< 0.01). 
Significant increases were also noted at 3 hours (p<0.05), at 6 hours (p< 
0.05) and at 30 hours (p< 0.05). Analysis at 48 hours showed sustained 
elevations but statistically were not significant. In the control samples the 
elevations for MMP-2 within the HASMC culture supernatant were probably 
due to constitutive expression of MMP-2 accumulating in the conditioned 
media, especially in the latter time-points where nutrient depletion induced 






Freestone et al., (1995) demonstrated that MMP-2 was the dominant 
elastolytic enzyme in the initiation of small aneurysms and findings in this 
study have shown that 1% hypoxia can upregulate MMP-2 activity in 
HASMCs which is also consistent with other research findings.  In 2006 
Miyoshi et al., (2006) reported that hypoxia upregulated MMP expression in 
hepatoma cells during cancer studies and Ben -Yosef et al., (2002) found 
that prolonged hypoxia of endothelial cells appeared to enhance MMP-2 
production and secretion.   
 
Although it is well documented that MMP-9 is implicated in AAA, in particular 
as the diameter of the aneurysm increases (Freestone et al, 1995), and also 
has been demonstrated in AAA tissue. During the present study,  my results 
showed secretion of MMP-9 was not detected in normoxic or hypoxic 
samples after the 48 hour exposure to 1% oxygen. This data appears to 
correlate with  earlier findings by our Group  (Erdozain et al., 2011) where a 
significant increase in MMP-9  was only seen at 2% hypoxia after 72 hours 
of decreasing O2 levels suggesting the driving force behind MMP-9 release 
is a sustained sequential decrease in O2 over time and which also seems 
more comparable to the chronic hypoxic conditions found within the 
aneurysm. Furthermore Thompson et al., (1995) identified macrophages as 
the primary source of MMP-9 in human AAA tissue, therefore in my study 
where they were obviously absent, may account for the lack of MMP-9 within 
the conditioned media but does not discount the possible effect of hypoxia 
on MMP-9 secretion within the real environment of an aneurysm. 
Additionally, a variety of tumour cell lines were examined by Himelstein and 
Koch, (1998) for induction of MMP-9 and MMP-2 under hypoxic conditions. 
Hypoxia did upregulate MMP-9 in one alveolar rhabdomyosarcoma cell line 
but they were unable to demonstrate a consistent hypoxia-mediated 
increase in MMP-9 suggesting that MMP-9 expression may not directly 
affected by exposure to hypoxia in vitro.  
Section 4.5.2 described control zymograms (Figures 36 and 37) which had 
been set up to assess MMP-2 levels in conditioned medium containing 10% 
FCS from HASMCs which been subjected to 48 hours of experimental 1% 
hypoxia. During an earlier study by our Group (Erdozain et al., 2011), the 
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cells were maintained in medium containing 10% FCS prior to and during a 
96 hour period of decreasing hypoxia levels. FCS is known to effect the 
expression of many genes and may also lead to unwanted stimulation of the 
cells during experimentation. Therefore, controls maintained in 10% FCS 
media were set up for comparison purposes to rule out foetal calf serum as a 
potential confounding factor. FCS is routinely used as a supplement to basal 
growth medium in culturing most cells and is vital to enable in vitro 
proliferation and healthy maintenance of cells. Bovine serum albumin is a 
major component of FCS but it also provides a wide variety of other 
components including hormones, attachment factors, carrier proteins, amino 
acids, sugars, lipids and importantly, numerous growth factors.  
During the culturing of HASMCs prior to hypoxia exposure, 10% FCS was 
routinely added to the culture medium as it provides optimal conditions for 
growth. However, 24 hours prior to the start of any hypoxia study, FCS was 
withdrawn and the cells maintained in serum-free media during the 48 hour 
experimental period apart from the aforementioned controls which did 
contain 10% FCS.  'Serum starvation' is commonly used in experiments  as 
the poorly defined complex and variable composition of FCS represents an 
important and undesirable confounding factor while performing bioassays, 
therefore elimination of serum from culture medium provides more 
reproducible experimental conditions (Pirkmajer and Chibalin, 2011). 
Additionally it is common to serum starve the cells to enable cell 
synchronization and ensure they enter quiescence (non-dividing state) to 
better represent physiological conditions found in vivo. 
 
Results from these control samples demonstrated unusual findings as the 
normoxic HASMC conditioned media samples containing FCS contained 
higher levels of MMP-2 protein at all time-points in comparison to the 
hypoxic HASMC conditioned media samples (Figures 36 and 37). These 
control results were the complete reverse of results found in all HASMC 
conditioned media samples where cells had been kept in serum-free media 
prior and during exposure to hypoxia.The HASMCs were grown to and used 
at sub-confluence for the start of all hypoxia studies. One explanation for 
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these opposing results is firstly, the cells in the control samples containing 
FCS would still have had the capacity to proliferate in comparison to the 
cells maintained in serum-free media with the resulting effects of serum 
starvation, as explained earlier. Secondly and importantly, in several other 
areas of research it has been demonstrated that proliferation of cultured 
cells under hypoxic conditions can be reduced. Ray et  al. (2008) studied 
oxygen regulation of human arterial SMC proliferation and survival, 
demonstrating that in HASMCs incubation at 1% O2 reduced cell 
proliferation, delayed G1/S interphase transition and increased apoptotic cell 
death. Similarly, Cogo et al., (2003) looked at the effects of hypoxia on rat 
airway SMC proliferation and showed that exposure to 1% O2 for 72 hours 
decreased cell proliferation by up to 21%. More recently, Mamede et al., 
(2013) looked at the effects of 2% hypoxia in a human hormone-independent 
prostate cancer cell line (PC3) and their results showed a decrease of 64%-
68% in cell proliferation in hypoxia in comparison to cells kept under 
normoxic conditions. Therefore, it seems probable that all the HASMCs 
maintained in FCS-containing medium continued to proliferate, but 
proliferation of cells kept under hypoxic conditions was significantly reduced 
in comparison to those maintained under normoxia leading to significantly 
lower cell numbers in hypoxic FCS-containing conditioned media samples. 
Lower cell numbers in hypoxic samples could explain why MMP-2 levels 
were reduced, even at pO2 levels where MMP-2 levels are generally 
increased, in comparison to the much higher cell numbers of the normoxic 
samples which were able to constitutively secrete MMP-2. 
 
Additionally and of relevance here, some genes contain one or more serum 
response elements (SREs) in their promoter regions which are activated by 
serum response factors (SRFs). Zhe et al., (2003) determined that in human 
and mouse lung fibroblasts MMP-2 and MMP-14 were among the genes 
modulated by SRF, and this could explain increased MMP-2 protein levels in 
these HASMC samples maintained in medium-containing FCS. FCS can 
modulate gene expression, either positively or negatively, therefore it 
interesting to find that MMP-2 expression may have been altered in 
response to FCS and modified in the two different experimental conditions 
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(hypoxia and normoxia) to increase MMP-2 gene expression under normoxia 




4.6 Inhibitory Profile of  MMPs 
 
To further confirm that results obtained  in Figure 32 were due to the effects 
of MMP-2 and not from the participation of other proteolytic enzymes such 
as serine, cysteine and aspartic acid proteases, the inhibitory profile of the 
gelatinases was assessed by the performing the normal gelatin zymography 
protocol but with the addition of the following inhibitors to the reaction buffer 
prior to incubation. 10mM of the calcium chelator ethylenediaminetetraacetic 
acid (EDTA), 2mM  of the zinc chelator 1,10-phenanthroline, 1mM of the 
serine protease inhibitor phenylmethylsulfonyl fluoride (PMSF), 1μM 
leupeptin (serine /cysteine inhibitor) and 1μM pepstatin A (aspartic acid 
inhibitor). MMPs are zinc and calcium dependent proteases therefore one 
would expect that the metal chelating inhibitors EDTA and 1,10-
phenanthroline should abolish all MMP activity resulting in the absence of 
bands from treated gels. 
 
4.6.1 Materials List 
 
All materials were obtained from Sigma Aldrich, Dorset, UK. unless stated 
otherwise. 
 
 Ethylenediaminetetraacetic acid (EDTA). 
 1,10 phenanthroline. 
  Leupeptin.  
 Phenylmethylsulfonyl fluoride (PMSF). 
  Pepstatin A  
160 
 


















Figure 39   Inhibition of MMP-2 Gelatin Zymography Gels 
Conditioned media from HASMCs exposed to 1% hypoxia or normoxia were 
assessed using the normal zymography protocol but with the addition of inhibitors 
to the reaction buffer. Positive control (MMP-2 standard) and RSM(Rainbow size 
marker) were applied.                                                                                           
Slide A: Zymogram after incubation with 1mM PMSF, 1μM leupeptin and 1μM 
pepstatin A.                                                                                                            
Slide B: After incubation with 10mM EDTA.  
Slide C: Incubated with 2mM 1, 10-phenanthroline. 
 
 
Inhibition assays performed to verify the identity of MMP-2 demonstrate that 
gelatinase activity was completely ablated by calcium chelation (EDTA) in 
A B 
C 




Slide B and zinc chelation (1, 10 phenanthroline) in Slide C by chelating and 
removing the calcium and zinc ions essential for MMP activity thus 
preventing bands of lysis appearing on the gels. The inhibitors of serine, 
cysteine and aspartic acid proteases had no effect on gelatinase activity in 
Slide A  and therefore bands of lysis were present on this gel. This means it 
is reasonable to assume that it is indeed MMP-2 responsible for these bands 
and not due to the aforementioned proteases which would have been 
inhibited by the PMSF, leupeptin and pepstatin A if present.   
 
4.7   Expression of MMP-2 protein 
 
MMP-2 immunoblot analysis was carried out to further corroborate that 
MMP-2 protein was present in the HASMC culture supernatant and verify the 
increases in enzymatic activity seen in the hypoxic HASMC samples in 
comparison to normoxic samples was due to MMP-2 activity and not other 
proteases. 
 
4.7.1 Materials list 
 
 ECLTM  Western Blot Detection Reagents (G.E. Healthcare) 
 ECLTM Advance Western Blot Detection Reagents (G.E. Healthcare) 
 HybondTM-C extra nitrocellulose (Amersham Biosciences UK Ltd. 
Buckinghamshire, UK).  
 Kodak BioMax XAR Film (VWR International Ltd. Dorset, UK). 
 Polyoxyethylene sorbitan monolaurate (Tween 20) (Sigma Aldrich 
Company Ltd. Dorest, UK).  
 Mouse monoclonal anti-human MMP-2 (8B4) (Abcam Plc., 
Cambridge, UK). 
 Polyclonal horseradish peroxidise-conjugated goat anti-mouse IgG 




4.7.2  Western and Dot Blot  
 
The immunodetection of MMP-2 protein was assessed using the Western 
Blot and Dot Blot techniques.The Western Blot protocol has been described 
in detail in Chapter 7, section 7.3.2. All materials and recipes for sample 
buffer, running buffer, blotting buffer, washing buffer, blocking buffer, the 
stacking gel and resolving gel are shown in Appendix 1. 
 
4.7.2.1 Levels of MMP-2 Assessed by Western Blot 
 
Samples standardised for protein (7μg) were loaded onto 7.5% SDS PAGE 
gels, then transferred onto nitrocellulose membranes, blocked with 4% non-
fat milk and probed with mouse monoclonal anti-human MMP-2(1:200) 
overnight at 4°C. Unbound primary antibody was removed in washing buffer 
and then replaced with a polyclonal horseradish peroxidase-conjugated goat 
anti-mouse secondary antibody (1:10000) (Dako UK Ltd.,Ely, UK) prepared 
in blocking buffer for 1 – 2 hours.  
Proteins were visualised using an Amersham ECL Advance TM Western 
blotting detection kit (GE Healthcare Life Sciences,Buckinghamshire, UK) 
instead of the basic ECL kit which proved not to be sensitive enough to 
detect the amount of MMP-2 present in the samples. When using ECL 
Advance it was necessary to increase the dilution of secondary antibody 
from 1:200 to 1:10000 and increase the length of time the membrane was 
immersed in washing buffer in order to reduce the background signal. Also, 
exposure of the nitrocellulose membrane to x-ray film in order to measure 


























Figure 40  Levels of MMP-2 Protein 
Levels of MMP-2 protein in culture supernatants from HASMCs exposed to hypoxia 
(1%) or normoxia for 48hrs were assessed by immunoblotting.  Samples were 
equally loaded and subsequently probed with monoclonal mouse anti-MMP-2 
antibody (1:200) and a HRP-conjugated goat anti-mouse immunoglobulin 
secondary antibody (1:10000)  
Slide A: 1: Purified MMP-2 2: Negative (dH2O) 3: Negative (Lysis buffer) 4:1hr N 
5:1hr H 6: 3hrs N 7: 3hrs H 8: RSM. 
 Slide B: 1: Purified MMP-2 2: 6hrs N 3: 6hrs H 4:30hrs N 5:30hrs H 6: 48hrs N 7: 
48hrs H 8: Negative 9: RSM. N (Normoxia) H (Hypoxia). 
A 
1 2 3 4 5 6  7 8 
1 2 3 4 5 6 7 8 9 
164 
 
It was relatively easy to detect the enzymatic activity of MMP-2 using the 
zymography even if MMP-2 levels were low as this technique is very 
sensitive, but to detect the protein using immunoblotting was more 
problematic especially at the earlier time-points. Therefore, the first two 
earlier time-points were analysed using the dot blot method as well so that 
increased volumes of conditioned media could be analysed in conjuction 
with the more sensitive ECL Advance to allow visualisation of MMP-2 
protein.  
 
4.7.2.3 The  Dot Blot Method 
 
The Dot Blot technique is a simplification of the Western Blot method for 
detecting and identifying proteins.The main difference between the two 
techniques is the method of protein transfer onto the nitrocellulose as in a 
Dot Blot the proteins are not first separated by electrophoresis but instead 
are applied as dots directly onto the membrane through the circular template 
of the Dot Blot apparatus (Jencons Ltd. Bedforeshire, UK) which is attached 
to a vacuum pump. The advantage of this method is that it is significantly 
quicker and proteins can be concentrated onto one small area but has the 
disadvantage of being unable to identify the molecular weight of the protein. 
To aid the transfer of protein onto the nitrocellulose membrane the blotting 
paper and membrane were soaked in transfer buffer prior to assembling the 
dot blot apparatus. After transfer of proteins onto the nitrocellulose 
membrane the membrane was blocked for approximately one hour in 4% 
non-fat milk at room temperature followed by overnight 4°C incubation in 
mouse monoclonal anti-human MMP-2 primary antibody (1:250) (Abcam 
Plc., Cambridge, UK) followed by a two hour incubation in polyclonal 
horseradish peroxidase-conjugated goat anti-mouse secondary antibody 
(1:200) (Dako UK Ltd.,Ely, UK) at room temperature. See Western Blot 


























Figure 42     MMP-2 Levels at 1 hr and 3 hr Time-points 
 Levels of MMP-2 protein in culture supernatants at the 1 hr and 3 hr time-points 
from HASMCs exposed to hypoxia (1%) or normoxia for 48hrs were assessed 
bythe dot blot method.  Samples were equally loaded in triplicate and subsequently 
probed with monoclonal mouse anti-MMP-2 antibody (1:250) and a HRP-
conjugated goat anti-mouse immunoglobulin secondary antibody (1:200) Proteins 
were visualised using standard ECL reagent.  
Lane 1: Purified MMP-2, Lane 2: Negative control (Lysis buffer), Lane 3: 1hr N Lane 
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Figure 43  Bar and Scatter Graphs Showing Analysis of  MMP-2 Protein 
Levels in HASMC Supernatant 
Levels of MMP-2 protein in HASMC conditioned media after exposure to hypoxia 
1% ( filled bars) or normoxia (open bars) for 48hrs and assessed by immunoblotting 
followed by densitometric analysis. Results expressed as arbitrary density units 
(ADU) per unit standardised total protein. Data expressed as means ± SEM of 
triplicate values.* p < 0.05; ** p < 0.01. Results are from three independent 
experiments repeated in triplicate. n = 3. Statistical analysis was performed using 







6 3 1 
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MMP-2 immunoblot analysis corroborated that MMP-2 protein was present in 
the HASMC culture supernatant and that there were differences in MMP-2 
protein levels between the hypoxic and normoxic samples. At the 1-hour 
time-point there was no significant difference in levels of MMP-2 protein 
between the hypoxic and normoxic samples, but after 3, 6 and 30 hours, a   
significant rise    (p <0.01, p < 0.01 and p < 0.05, respectively)   in   protein 
levels was evident. The 48-hour time-point also showed an increase in 






















Figure 44    Protein Content of HASMC Whole Cell Lysate from 

































On completion of the hypoxia study  the total protein content of hypoxia and 
normoxia samples was assessed by Bradford assay. Analysis of the 
averaged results showed higher protein levels in the normoxic samples in 
comparison to  hypoxic samples. This was not surprising as during hypoxia 
you might expect none essential protein transcription to be switched off in 
order to cope with hypoxic stress and nutrient depletion. 
 
 
4.8  Lactate Dehydogenase Assay (Marker of Cell 
Damage) 
 
This assay was carried out in order to ensure that any gelatinase activity 
present in the HASMC conditioned media was due to secretion from the 
cells rather than released from compromised cells damaged by prolonged 
hypoxia or a treatment that was cytotoxic. The cytoplasmic enzyme lactate 
dehydrogenase (LDH) is present within all mammalian cells.  The normal 
plasma membrane is impermeable to LDH but damage to the cell membrane 
results in a change in membrane permeability and subsequent leakage of 
LDH into the extracellular fluid (Rae, 1977). In vitro release of LDH from cells 
provides an accurate measure of cell membrane integrity and cell viability.  
Any release of LDH into culture supernatant correlates with the amount of 
cell death and membrane damage providing an accurate measure of any 
cellular toxicity induced by hypoxia or a cytotoxic treatment and can be used 
to assess cell viability. This assay is based upon the ability of LDH to 
catalyze the chemical reaction below:         
 






4.8.1 Materials List 
 
All items were obtained from Sigma Aldrich Company Ltd. Dorset, UK unless 
stated otherwise.  
 
 Allopurinol 
  Nicotinamide adenine dinucleotide (NAD+) 
  Sodium Lactate  Diphenyliodonium Chloride (DPI) (ICN Biochemical 




4.8.2  Protocol  for Lactate Dehydogenase (LDH) Assay 
 
Conditioned media or lysate was assayed for LDH activity with 1.5mM 
sodium lactate, 1mM NAD+, 1μM diphenyliodonium chloride (DPI), 10μM 
allopurinol and phosphate buffered saline (PBS) which was added to a 
cuvette and allowed to incubate at 37°C in the spectrophotometer for 4-5 
minutes.  
The generation of NADH was followed by measuring the absorbance change 
at wavelength 340nm over time using a Hitachi U-2010 spectrophotometer. 
The change in NADH concentration was calculated using Beers Law and the 
extinction coefficient of NADH 6.22 x103 -1cm- 1 . Cell lysate served as a 





















Figure 45   Analysis of HASMC Cell Viability After Exposure to 1% 
Hypoxia 
1.5mM sodium lactate, 1mM NAD+, 1μM diphenyliodonium chloride (DPI), 10μM 
allopurinol and phosphate buffered saline (PBS) was added to sample in the 
cuvette, incubated  at 37°C  and the generation of NADH was followed by 
measuring the absorbance change at wavelength 340nm over time. Cell lysate 
served as a positive control,  PBS and time zero samples served as negative 
controls. 
 
As anticipated the test samples all demonstrated negative values showing 
that no LDH was present in the conditioned media samples ensuring that the 
severe hypoxia had not destroyed the cell membranes allowing MMP protein 
to be released by any other method other than secretion. The positive 
control cell lysate presented high positive values as also expected as LDH 
would have been released at the time of lysis. Negative controls also 


















































With local ethics approval, AAA tissue was obtained from consented patients 
undergoing elective surgical repair. Sections were taken from the proximal, 
distal and body of aneurysm tissue from 5 consenting patients removed 
during surgery. Normal tissue free from signs of aortic disease  was  
obtained from the aortic cuff of 5 x renal transplant donors for control 











Figure 46   Section of Aneurysmal Sac 
 
 
4.9.1.1  Paraffin Wax Embedded Sections 
 
 At the time of retrieval tissue samples were immediately fixed in 0.9% NaCl 
(10%v/v) histological formaldehyde for approximately 48 hours and 
subsequently processed using a Shandon Hypercentre II firowax-embedding 
station (Shandon Inc., Pennsylvania, USA).   
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Figure 47   Shandon Hypercentre Wax-embedding Station used to 
process Harvested Tissue 
 
 
4.9.1.2  Cutting and Mounting  Sections 
 
After processing the paraffin blocks were trimmed back to an optimal cutting 
surface and then 5 µm sections were cut using a sledge microtome. The 5 
µm thickness was chosen as the optimal size as thicker slices did not 
produce such good detail after immunostaining. Next the sections were 
placed in a 40°C water bath to allow them to expand and flatten out before 
being floated onto superfrost microscope slides (being careful to avoid air 
bubbles getting under the tissue section) and then allowed to air dry. The 





                  
 
                 
Figure 48    Sledge Microtome used to Cut Paraffin-embedded Sections 
 
 
4.9.1.3  Deparaffinization and Rehydration of Paraffin 
Embedded Sections 
The sections were dewaxed in two changes of xylene for 5 minutes before 
being put through a graded series of ethanol.  To complete the rehydration 
process the sections were immersed twice in dH2O for 5 minutes each 




4.9.1.4  Immunohistochemistry 
 
4.9.1.5  Materials List 
 
 Mouse monoclonal anti-human MMP-2 (Abcam, Cambridge, UK). 
 Alkaline phosphatase-conjugated Avidinbiotin complex, anti-mouse 
IgG (ABC) kit (Vector Laboratories, Vectastain® ABC-AP reagent, 
AK-5001, Peterborough, UK). 
 Mouse monoclonal IgG1 negative control (DAKO) 
 Napthol AS-MX phosphate/Fast red TR Fast™ (Sigma-Aldrich Ltd., 
Dorset, UK). 
 Levamisole (Vector Laboratories, SP-5000).   
 
 
4.9.1.6  Immunohistochemistry Protocol 
 
Tissue sections were incubated for 20 minutes with diluted normal blocking 
serum originating from the species in which the secondary antibody was 
made (horse serum). Excess serum was removed from the sections before 
an overnight incubation at 4°C in the primary antibody diluted in blocking 
solution. Unbound primary antibody was removed by washing for 5 mins in 
1x PBS followed by a 30 minute to 1 hour incubation at room temperature in 
biotinylated anti-mouse IgG secondary antibody diluted in blocking solution. 
Slides were then washed for 5 minutes in 1x PBS before being incubated for 
30 minutes at room temperature with VECTASTAIN® ABC-AP reagent 
which was prepared according to the manufacturer‘s instructions 30 minutes 
prior to use. The wash steps were repeated proceeded by a 30 minute 
incubation in alkaline phosphate substrate solution with the addition of 
Levamisole to inhibit any endogenous alkaline phosphatase activity. The 
reaction was followed under a light microscope until the desired stain 
intensity had developed, after which the reaction was stopped by bringing 
the slides to tap water. Sections were then counterstained with Mayers 
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Haematoxylin for approximately 1 – 2 minutes and given a final rinse in 
running tap water before coverslips were mounted onto the slides using 
Aquamount mounting medium. Slides were viewed under a Zeiss Axioskop 2 
microscope and images captured using the Zeiss KS300 program. (Carl 




















Figure 49    Photomicrograph Showing the Distribution of MMP-2 (red) 
















Figure 50   Photomicrograph Showing the Distribution of MMP-2 (red) 









                                                                                                                                                           
 
 
Figure 51 Photomicrograph Showing the Distribution of MMP-2 (red) in 
Human AAA Tissue (x252)  (Figure 49 at  Higher Magnification) 
Sections of human aneurysmal tissue were probed with mouse anti-human MMP-2 
(1:200) followed by a biotinylated horse anti-mouse secondary antibody (1:200) and 
counterstained with Mayers haematoxylin. Figures 49 – 51 demonstrate the 
immuno-localisation of MMP-2 within the body region of the aneurysm taken from 












Figure 52    Photomicrograph Showing the Distribution of MMP-2 in 
Human AAA Tissue   A: (x126)   B: (x 31.5)   
 
Sections of human aneurysmal tissue were probed with mouse anti-human MMP-2 
(1:200) followed by a biotinylated horse anti-mouse secondary antibody (1:200) and 
counterstained with Mayers haematoxylin. Slide A: shows localisation of MMP-2 to 
the medial smooth muscle cells and the inflammatory infiltrate seen on the left of 
the section from within the body region of the aneurysm. Slide B: demonstrates the 
difficulties presented when trying to cut sections of aneurysmal aorta as the tissue 
is very friable or brittle and tears very easily. A typical fold in the tissue is also 
apparent in this section which can sometimes present false positivity. (n = 5) 




























Figure 53 Photomicrograph of Control Sections of Human Aorta 
 
Sections of human placenta and normal aortic tissue were used as positive and 
negative controls respectively.  The placental positive control was probed with 
mouse anti-human MMP-2 (1:200) x126) (A) and control aortic tissues were probed 
with monoclonal mouse IgG1 directed against Aspergillus niger glucose oxidase 
(1:200) x126 (B) or mouse anti-human MMP-2 (1:200) x63 (C) and x126 (D) all 
followed by a biotinylated horse anti-mouse secondary antibody (1:200) and 
counterstained with Mayers haematoxylin.  (n = 5) 
 
All control aortic sections stained negatively for Aspergillus niger glucose 
oxidase (an enzyme not present in mammalian cells) or if the primary 
antibody was omitted. Control  or 'normal aortic' tissue was obtained from 





















Figure 54 Photomicrographs Showing Localisation of MMP-2  (shown 
in red) in AAA Tissue  
Sections were probed with mouse anti-human MMP-2 (1:200) followed by a 
biotinylated horse anti-mouse secondary antibody (1:200) and counterstained with 
Mayers haematoxylin. The distribution of MMP-2 can be seen within the medial 
regions of  aneurysmal aortae. Slide A: (x126) shows inflammatory infiltrate and 
hemosiderin in the body region of the aneurysm. Slide B: (x126) and D: (x252) 
shows medial localisation of MMP-2 in the distal region of the aneurysm at different 
magnifications. Slide C: (x126) and E: (x 126) both demonstrate loss of medial 
SMCs and overall disorganization of medial elastin structure. Slide F: (x63) 
demonstrates medial MMP-2 distribution within the proximal region of the 






Figures 49 - 52  and Figure 54 demonstrate the presence of MMP-2 in AAA 
tissue in comparison to the control aortic tissues which were free of 
aneurysmal disease. MMP-2 immunopositivity was observed in the vascular 
smooth muscle cells (VSMCs) within the region of Tunica media and the 
inflammatory infiltrate of the AAA sections. These findings correspond with 
work carried out by earlier researchers who determined that aneurysmal 
aortic medial SMCs were the primary source of MMP-2 in AAA (Crowther et 
al., 1996, 2000., Patel et al., 1996). All the aneurysmal sections studied 
appeared to show decreased medial SMCs which would be consistent with 
SMC apoptosis a common feature of AAA. 
 
4.9.2  Haematoxylin and Eosin (H and E) Staining of Normal 
and AAA Sections 
 
H and E staining is one of the most commonly used in histology, Eosin is 
an acidic dye that is negatively charged  and It stains basic or acidophilic 
structures red or pink such asthe cytoplasm of a cell. Haematoxylin can be 
considered as a basic dye and it stains acidic or basophilic structures a 
purplish blue and therefore will stain  the cell nucleus blue. 
 
4.9.2.1    Tissue Preparation and H and E Stain 
 
4.9.2.2    Materials List 
 
All materials were from VWR Int. Ltd, Dorset, UK unless stated otherwise. 
 DePeX Mounting Medium  
 Iso-pentane  
 Superfrost Plus Microscope Slides  
 Tissue-Tek (Sakura. Berkshire, UK)  
 Harris Haematoxlin, Eosin (Sigma Aldrich Company Ltd. Dorest, UK). 
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4.9.2.3  Tissue Preparation Protocol 
 
A beaker of iso-pentane was chilled in liquid nitrogen. Tissue-Tek was 
spotted onto a cork disk and was submerged in the iso-pentane for 
approximately 5 minutes after which time the Tissue Tek was sufficiently 
hardened. The cork disk was removed and a tissue sample, approximately 
0.5cm2, was pressed into the set Tissue-Tek. The sample was then covered 
in Tissue-Tek and was incubated in the chilled iso-pentane for about 5mins, 
or until all Tissue-Tek was solidified. Following this preparation, the sample 
mounted onto the cork-disk was stored at -70°C for several hours to ensure 
the sample was completely frozen. 
Using a Cryostat (Bright Instruments Company Ltd, Huntingdon, UK) the 
frozen samples were sectioned into 5μm slices which were immediately 
placed onto microscope slides. Sections were then stained with 
Haematoxylin and Eosin using the protocol given in Appendix I. Samples 
were viewed under a Zeiss Axioscope microscope and images were 












Figure 55    Cryostat Used for  Cutting  Frozen Sections of Tissue 
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Figure 56   Photomicrographs of the AAA body Region Stained with 
Haematoxylin and Eosin 
Slide A:  (x 63) H and E staining of the body region of the aneurysm shows dense 
inflammatory infiltrate  within the medial region and reduced VSMC.  
Slide B: (x 31.5) Inflammatory infiltrate is also present in this section, additionally 
hemosiderin can be seen at the outer edge of the media as a yellowish brown 



















Figure 57    Photomicrograph of Control Aortic and AAA Tissues 
Stained with Haemotoxylin and Eosin 
A range of control or 'normal' aortic tissue was stained using haematoxylin and 
eosin for comparison with AAA tissue. A: (x 31.5) B: (x 126) C: (x 63). Additionally 
AAA tissue from different regions of the aneurysm is shown demonstrating the 
structural disorganisation and loss of SMC. D: (x 126) AAA body, E: (x 63) proximal 










Chapter 5. Investigation into the 
Potential Expression of MMP-7 in 






5. Investigation into the Potential Expression of  
MMP-7 in HASMCs Exposed to Severe Hypoxia. 
 
5.1   Introduction 
 
MMP-7 known also as Matrilysin was first described  by Sellers and 
Woessner (1988) in postpartum rat uterus. Distinguished by its low 
molecular mass (28 kDa) and its lack of a C-terminal domain, it is the 
smallest member of the MMP-family.   It is located on chromosome 11 q22 
and like the other members of the MMP family it is a zinc and calcium-
dependent endopeptidase and is secreted as a zymogen requiring activation 
brought about by cleavage of the propeptide (Thompson and Parks, 1996). 
Once activated, MMP-7 has a broad proteolytic activity against a variety of 
extracellular matrix substrates, including gelatin, collagens, proteoglycans, 
elastin, laminin, fibronectin and casein (Woessner and Taplin, 1988, 
Miyazaki et al., 1990, Wilson and Matrisian, 1996). In addition, MMP-7 has 
several other functions including proMMP-2 and proMMP-9 activation, 
regulation of bioactive molecules controlling inflammation, cell proliferation, 
apoptosis, angiogenesis and is thought to play an important role in the early 
steps of tumour progression (Ii et al., 2006).  
 
Research has demonstrated increased levels of MMP-7 in the aneurysm wall 
of AAA, seemingly expressed by cells within the aortic wall such as SMCs 
(Fontaine et al., 2002, Kazi et al., 2005) and suggesting that MMP-7 may 
play a late role in aneurysm progression though promotion of continued 
cellular attrition within the aortic wall (Ikonomidis et al., 2007). Furthermore 
Burke et al ., (2003)  identified a putative HRE containing HIF-1 binding 
sequences within the promoter of the MMP-7 gene which also could mark it 
as a candidate for hypoxic induction.  
 
In our earlier study (Erdozain et al., 2011),  Multiplex PCR analysis revealed 
significant transcriptional up-regulation of MMP-7 mRNA (p 0.001) from 
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HASMC lysate after the HASMCs in culture were exposed to hypoxia for 48 
hours in comparison to control samples. 
 
Therefore, since MMP-7 has been implicated in tumour metastasis and 
inflammation, has broad substrate specificity and is expressed in SMC under 
hypoxic conditions, MMP-7 may be a controlling factor in aneurysm 
development and progression. It was deemed important to determine 
whether the significant increases seen in MMP-7 mRNA also translated at 





5.2   Heparin-enhanced Gelatin Zymography 
 
In contrast to the gelatinases (MMP-2 and MMP-2) MMP-7 is difficult to 
detect at low levels in conventional casein or gelatin zymography and 
therefore the technique heparin-enhanced gelatin zymography described by 
Yu and Woessner  (2000) was employed to assess any expression of MMP-
7.  The addition of heparin to samples enables MMP-7 to be detected at 
much lower levels, possibly by inducing a conformational change that 
increases activity, facilitating refolding, reducing autolysis or by helping 
anchor the enzyme in the gel during the overnight incubation (Yu and 
Woessner., 2001). Casein is often used for MMP-7 but  gelatin can also be 
used, as it too is a substrate of matrilysin. 
 
Vertical 12% SDS-polyacrylamide gels were copolymerized with 1mg/ml of 
pig type A gelatin (Sigma  Aldrich Co. Ltd. Dorset, UK) overlaid with water-
saturated propan-1-ol (Fisher Scientific UK Ltd. Leicestershire, UK) to obtain 
a level gel surface and allowed to set at room temperature for approximately 
30 minutes. Upon setting, the water-saturated propan-1-ol was rinsed off 
with distilled water and a 4% polyacrylamide stacking gel was applied on top 




A final concentration of 0.3mg/ml heparin (porcine intestinal mucosa from 
Sigma) was added to the HASMC samples in non-reducing buffer prior to 
loading onto the gels. For heparin to produce its enhancing effect it is 
necessary for the heparin to run to the same region of the gel as the 
enzyme, which fortunately for MMP-7,  movement of heparin and enzyme is 
almost equal ((Yu and Woessner, 2001). 
 
10μl of a heat-denatured Rainbow size marker (Fisher Scientific UK Ltd. 
Leicestershire, UK) was used as a molecular weight marker. Human 
placental homogenate was used as a positive control. Non-reducing loading 
buffer or lysis buffer provided negative controls. Electrophoresis was carried 
out in electrophoresis/running buffer at the slightly higher voltage of 150V 
which is crucial for heparin-enhanced SDS-Page and allowed to run until the 
dye-front neared  the bottom of the gel. The gels then underwent three thirty 
minute washes in 2.5% Triton X-100 renaturing solution before incubation at 
37°C in Zymogram development solution (50mM Tris, pH 7.6, 5mM Ca Cl2). 
Finally the zymograms were stained with Coomassie Brilliant Blue R-250 
solution and destained with 40% methanol/10% glacial acetic acid. A 
complete list of protocols and reagents used can be found in Appendix 1. 
 
 
5.2.1 Troubleshooting heparin-enhanced gelatin zymography 
 
In order to maximise MMP-7 detection in the HASMC samples it was 
necessary to fill gel wells to their maximum volume presenting an unusual 
problem in that the samples had a tendency to ‗float‘ back out of the well and 
diffuse into the running buffer resulting in some loss of sample. This had not 
happened with other samples without heparin therefore it seemed that the 
heparin was causing this anomaly.  
 
To rectify this problem, the best solution was to increase the concentration of 
glycerol in the non-reducing buffer whenever heparin was included in the 
samples. This solved the issue by increasing the density of the sample and 
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allowing maximal loading of the wells. Incubation times can be very 
important when using zymography in order to achieve the best possible 
results, therefore incubation at 37°C was increased from overnight to forty 
eight hours  to allow as much enzymatic digestion as possible,  due to the 
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Figure 58  Representative Zymography Gel of  MMP-7 Analysis by 
Heparin-enhanced Zymography 
Culture supernatants from HASMCs exposed to hypoxia (1%) or normoxia for 48hrs 
were equally loaded onto 12% gels and analyzed  using heparin enhanced gelatin 
zymography (heparin at a final concentration of 0.3mg/ml was  included in the 
sample buffer).  
A: Negative (lysis buffer) B: Negative (KPO4 buffer in MilliQ water) 1: Positive 
control (human placenta homogenized in potassium phosphate KPO4 plus 
inhibitors) 2: 1hr N 3: 1hr H 4: 3hrs N 5: 3hrs H 6: 6hrs N 7: 6hrs H 8: 30hrs N 9: 
30hrs H 10: 48hrs N 11:48hrs H 12: RSM (N: Normoxia, H: Hypoxia, RSM: 








5.2.3 MMP-7 Increased Sample Volume Analysis and Results 
 
Initially it appeared as though some MMP-7 bands of lysis may be present 
on the polyacrylamide gel as these ‗bands‘ corresponded the molecular 
weight of pro MMP-7  (approximately 30 kDa) but because the movement of 
heparin and MMP-7 is almost equal on the gel  the presence of heparin in 
the samples appeared to be causing  the results to be ambiguous. 
To try to rectify this problem, larger size combs for the gel plates were used 
thereby significantly increasing the HASMC conditioned media sample 
volumes applied. 
 







Figure 59   Representative Zymography Gel of MMP-7  Analysis by 
Heparin-enhanced Zymography  (Increased Sample Volume)  Gel 1 
 
Significantly increased volumes (30µl) of culture supernatants from HASMCs 
exposed to hypoxia (1%) or normoxia for 48hrs were equally loaded onto 12% gels 
and analyzed using heparin enhanced gelatin zymography (heparin at a final 
concentration of 0.3mg/ml was included in the sample buffer) 1: 1hr N 2: 1hr H 3: 





                                                                                                                                        









Figure 60   Representative Zymography Gel Analysis of MMP-7 using 
Heparin-enhanced Zymography   ( Increased Sample Volume)  Gel 2 
 
Significantly increased volumes (30µl) of culture supernatants from HASMCs 
exposed to hypoxia (1%) or normoxia for 48hrs were equally loaded onto 12% gels 
and analyzed  using heparin enhanced gelatin zymography (heparin at a final 
concentration of 0.3mg/ml was included in the sample buffer). 1: Positive control 
(human placenta homogenized in potassium phosphate KPO4 plus inhibitors) 2: 
30hrsN 3: 30hrsH 4: 48hrsN 5:48hrsH  6: Negative control: sample buffer plus 
0.3mg/ml heparin  (N: Normoxia, H: Hypoxia).      
 
 
The heparin enhanced zymography failed to find any MMP-7 present in the 
HASMC conditioned media despite the sample volume being significantly 
increased to  improve the chance of detecting low levels of the enzyme. 
Bands of opacity were present on the gels corresponding to the molecular 
weight of MMP-7 but this appears to be an anomaly caused by addition of 
heparin to the samples as it was also present in the negative control in Lane 
6 of Gel 2 (Figure 60) which obviously did not contain any sample but 
contained the same concentration of heparin as the conditioned media 
samples.  The heparin box is annotated in Figure 60 showing the region on 






As a final control the heparin-enhanced zymography was repeated with the 
same HASMC conditioned medium and the gels subsequently incubated in 
the MMP inhibitor 10mM EDTA which was added to the zymogram 
development solution prior to incubation at 37ºC. 
 






                                                                                                          
 
Figure 61   Representative  Zymography Gel of  MMP-7 Analysis 
(Inhibition Assay) 
Culture supernatants from HASMCs exposed to hypoxia (1%) or normoxia for 48hrs 
were equally loaded onto 12% gels and analyzed  using heparin enhanced gelatin 
zymography (heparin at a final concentration of 0.3mg/ml was included in the 
sample buffer) After electrophoresis gels were incubated in 10mM EDTA which was 
added to the reaction buffer.1:Positive control (human placenta homogenized in 
KPO4 buffer plus inhibitors) 2: 1hr N 3: 1hr H 4: 3hrs N 5: 3hrs H 6:6hrs N 7: 6hrs H 
8:30hrs N 9: 30hrs H 10: 48hrs N 11: 48hrs H 12: RSM (N: Normoxia, H: Hypoxia, 
RSM: Rainbow size marker).   
 
 
5.2.4  Analysis of HASMC Lysate for MMP-7 using Heparin 
enhanced Zymography 
 
Finally, although results had shown that no detectable MMP-7 had been 
secreted into the HASMC supernatant during the hypoxic period, further 




exposure to 1% hypoxia for 48 hours to assess if any detectable MMP-7 was 
present inside the cells. Cells were lysed using ice-cold lysis buffer 
composed of 0.5% Nonidet, 100mM NaCl, (Sigma  Aldrich Co. Ltd. Dorset, 
UK), (10mM Tris HCL (pH 7.5)( Fisher Scientific UK Ltd. Leicestershire, UK). 
 






Figure 62     Representative Zymography Gel Analysis of HASMC Cell 
Lysate for MMP-7 
 
Total cell lysate samples(7μg protein) from HASMCs exposed to hypoxia (1%) or 
normoxia for 48hrs were loaded onto 12% gels and analyzed  using heparin 
enhanced gelatin zymography (heparin at a final concentration of 0.3mg/ml was 
included in the sample buffer).  
1:Positive control (human placenta homogenized in KPO4 buffer plus inhibitors) 2: 
1hr N 3: 1hr H 4: 3hrs N 5: 3hrs H 6:6hrs N 7: 6hrs H 8:30hrs N 9: 30hrs H 10: 
48hrs N 11: 48hrs H 12: RSM (N: Normoxia, H: Hypoxia, RSM: Rainbow size 
marker).   
 
 
5.2.5  Omission of Heparin from HASMC Lysate Samples 
 
The gel shown overleaf in Figure 63 was prepared exactly as before except 





as a control to ensure that no bands of lysis were present on the gel apart 
from the positive control. 
 
 








Figure 63   Analysis of HASMC Lysate Samples (Minus Heparin) for 
MMP-7 
Total cell lysate samples minus heparin (7μg protein) from HASMCs exposed to 
hypoxia (1%) or normoxia for 48hrs were loaded onto 12% gels and analyzed using 
gelatin zymography.                                                                                                   
1: Positive control (human placenta homogenized in KPO4 buffer plus inhibitors) 2: 
1h N 3: 1hr H 4: 3hrs N 5: 3hrs H 6:6hrs N 7: 6hrs H 8:30hrs N 9: 30hrs H 10: 48hrs 
N 11: 48hrs H 12: RSM (N: Normoxia, H: Hypoxia, RSM: Rainbow size marker).     
 
                                                                                                                       
This gel confirms that no bands of MMP-7 lysis are present on the gel. The 
positive control sample which like all the other samples did not contain 
heparin is also not showing clear bands of lysis unlike in Figure 62 where 
bands are clearly evident,  which seems to support research which proposes 







Chapter 6: Analysis of Tissue 
Inhibitor of Metalloproteinases 
(TIMPs) -1 and 2 levels in HASMCs 





6. Analysis of TIMP -1 and TIMP- 2 levels in HASMCs 
exposed to severe hypoxia. 
 
6.1   Introduction 
 
Matrix metalloproteinases (MMPS) are known elastolytic mediators of 
abdominal aortic aneurysm degeneration, and their activity is tightly 
regulated by the presence of tissue inhibitors of MMPs (TIMPs). They play 
an important role in maintaining the integrity of the healthy aorta and 
imbalances in this system may be instrumental in compromising the arterial 
wall integrity leading to pathological events such as AAA. TIMP-1 is a 28kDa 
secreted polypeptide that is capable of inhibiting most MMPs, whereas 
TIMP-2 (24kDa) is predominantly active against MMP-2. Often the 
production of TIMPs is elevated by the same stimuli that promote MMP 
expression (Thompson et al., 2002), therefore,  if it is established that 
hypoxia is a factor in increasing expression of MMPs it would seem prudent 
to analyse TIMP-1 and TIMP-2 levels in HASMC conditioned media from 
cells exposed to severe hypoxia (1%) over a 48 time period. Furthermore our 
earlier study (Erdozain et al., 2011) found significant transcriptional up-
regulation of TIMP-1 mRNA using PCR analysis in HASMC lysate after 
exposuring SMCs to hypoxia for up to 48 hours.  
 
Another important feature of TIMP-2  is  its role in the activation of proMMP-
2,  which forms a tight complex with TIMP-2 through the hemopexin domain 
interactions with the non-inhibitory C-terminal domain of the inhibitor 
allowing proMMP-2 activation by MT1-MMP on the cell surface (Itoh and 
Seiki., 2006). If hypoxia is found to increase or decrease TIMP-1 or TIMP-2 
levels this obviously would have consequencies on the production of some 
MMPs especially MMP-2. 
A technique known as reverse zymography will be used to evaluate the 
HASMC conditioned media samples. 
197 
 
6.2   Reverse zymography 
 
Reverse zymography is an electrophoretic technique described by Oliver et 
al ., (1997) which is very similar to regular zymography but is used to identify 
TIMP inhibitory activity within acrylamide gels. Reverse zymography is much 
more sensitive than Western blot analysis and useful where it may be 
difficult to acquire antibodies sensitive enough to detect small quantities of 
TIMPs (Snoek-van Beurden and Von den Hoff, 2005). Additionally it has the 











Figure 64    Overview of Reverse Zymography 
A: Shows an example of reverse zymography demonstrating dark  blue bands 
representing areas of TIMP inhibition.                  
B: A diagrammatic overview of a reverse zymogram with incorporated gelatin and 
purified MMP-2. Black bands represent TIMP activity. Section 1 contains only 
gelatin and section 2 contains MMP-2 and digested gelatin. (Adapted from Hawkes 












6.2.1    Reverse Zymography Protocol 
 
Vertical 12% SDS-polyacrylamide gels were copolymerized with 1mg/ml of 
pig type A gelatin (Sigma Aldrich Co. Ltd. Dorset, UK) and also an MMP 
(usually MMP-2) was incorporated into the gel which was overlaid with 
water-saturated propan-1-ol (to obtain a level gel surface) and allowed to set 
at room temperature for approximately 30 minutes. Upon setting, the water-
saturated propan-1-ol was rinsed off with distilled water and a 4% 
polyacrylamide stacking gel was applied on top of the resolving gel into 
which the gel combs were inserted to create wells. The samples were run at 
constant voltage of 125 V for approximately 1 hr until the dye front 
approached the end of the resolving  gel, followed by incubation for 1.5 
hours in 2.5% Triton X-100 at room temperature to renature the proteins with 
subsequent incubation at 37°C in development solution (50Mm CaCl2, 0.5M 
Tris-HCL pH 7.6) for between 24-48 hours. Thereafter the gels were stained 
with 0.2% Coomassie Brilliant Blue R-250 for approximately one hour and 
then destained in methanol, glacial acetic acid and dH2O (4:1:5, v/v/v). 
During incubation,  the MMP-2 only digests the gelatin in areas where TIMPs 
are absent therefore, after staining the gel will be colorless except for the 
TIMP bands. In these bands, the TIMPs will inhibit MMP-2 activity by the 
formation of a 1:1 complex, and the gelatin will not be digested (Staskus et 
al. 1991, Riley et al., 1999) .This results in blue TIMP bands against a 
colourless background (Hawkes et al., 2001). The SDS in the gel dissociates 
any TIMPs bound to MMPs, and thus the total amount of TIMPs in the 
sample is detected (Riley et al., 1999). A complete list of recipes and 
materials used can be found in Appendix 1. 
 
6.2 2 Trouble-shooting reverse zymography 
 
Optimization of the gelatin and gelatinase concentration is required because 
this can dramatically increase the sensitivity of the reverse zymogram. 
Initially it seemed more likely that using the highest concentration of MMP 
with a lower concentration of gelatin would give the optimum results. 
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However after testing a combination of different concentrations of gelatinase 
and gelatin, suprisingly it seemed that using a much lower concentration of 
gelatinase in combination with a higher concentration of gelatin incorporated 
into the gel gave the best results.Also another important factor in achieving 
good results was the length of the incubation period at 37°C. The optimum 
incubation period appeared to be around 17 hours. Gels left for significantly 
longer periods were colourless and devoid of bands. 
 
6.2.3   Results of TIMP-1 and TIMP-2 Reverse Zymography 
 
Levels of TIMP-1 and TIMP-2 in culture supernatants from HASMCs 
exposed to 1% hypoxia or normoxia for 48 hours were analysed using 
reverse zymography. 160ng of purified MMP-2 protein (Chemicon Europe 
Ltd., Chandlers Ford, UK) was incorporated into the polyacrylamide gel at 
the time of copolymerization and run under non-reducing conditions. TIMP-2 
protein (Abcam, Cambridge, UK) at a concentration of 70ng served as a 
positive control.  








Figure 65   Representative Reverse Zymogram Showing Bands of TIMP 
Inhibition 
Culture supernatants from HASMCs exposed to hypoxia (1%) or normoxia for 48hrs 
were equally loaded onto 12% gels and analyzed using reverse zymography,  
incorporating 160ng of purified MMP-2 protein plus 1% gelatin into the gels. 1: 
Positive control (70ng of purified TIMP-2 protein) 2: 1hr N 3: 1hr H 4: 3hrs N 5: 3hrs 
H 6:6hrs N 7: 6hrs H 8:30hrs N 9: 30hrs H 10: 48hrs N 11: 48hrs H 12: RSM (N: 







































Bands of TIMP inhibition visualised as dark bands against a lighter 
background were apparent on the reverse zymogram (Figure 65)  with lower 
bands corresponding to the TIMP-2 positive control and the upper bands 
seeming to fall within the molecular weight range of TIMP-1.  






                
 















Figure 66    Bar and Scatter Graphs Demonstrating Levels of TIMP-1 in 
HASMC Supernatant 
Analysis of TIMP-1 protein  in culture supernatants from HASMCs exposed to 1% 
hypoxia for 48 hrs. Results expressed as ADU per unit standardised total protein. 
Data expressed as means ±SEM of  6 replicate values. * p < 0.05; ** p < 0.01, ***  p 
< 0.001. Results are from three independent experiments with 6 replicates. n = 3. 
Statistical analysis was performed using Student's t-tests. 
A:   Normoxia (open bars),  1%  hypoxia  ( grey filled bars).   
































































                                                                                                                               
Figure 67    Bar and Scatter Graphs Showing Levels of TIMP-2 in 
Conditioned Media 
 
Reverse zymographic analysis of TIMP-2 protein in culture supernatants from 
HASMCs exposed to 1% hypoxia (filled bars) or normoxia (open bars) for 48 h. 
Results expressed as arbitrary densityunits (ADU) per unit standardised total 
protein. Data expressed as means ±SEM of triplicate values. * p < 0.05. Results are 
from three independent experiments with 3 replicates. n = 3. Statistical analysis was 
performed using Students t-tests. 
 A:   Normoxia (open bars),  1%  hypoxia  ( grey filled bars).    






Density analysis of the inhibition bands using the Scion Corporation Imaging 
programme established that in HASMC conditioned media, several time-
points demonstrated significant differences in levels of TIMP-1 and TIMP-2 
protein between the hypoxic and normoxic control samples.  
 
In Figure 66, significant elevations were seen in TIMP-1 inhibition in hypoxic 
samples in comparison to control samples at nearly all the time-points, at 1 
hour (* p < 0.05), 3  hour (**< 0.01) and 30 hours (**< 0.01) and 48 hours 
(***p < 0.001). The 6 hour time-point showed evidence of increased  
inhibition for the hypoxic  samples when compared with normoxia, although 
no statistical significance was noted.  
 
Interestingly TIMP-1 levels appeared higher than TIMP-2.  In Figure 67  
there were significant increases seen  in TIMP-2 inhibition in hypoxic 
samples at the 3 hour,  30 hour and 48 hour time-points (* p < 0.05) but at 
the 1 hour and 6 hour time-points, although inhibition levels were higher in 




6.2 4   MMP-9 Reverse Zymography 
 
For comparison purposes and because TIMP-1 is the specific inhibitor of 
MMP-9, further reverse zymography was carried out incorporating MMP-9 
protein instead of MMP-2 into the gels. The procedure was carried as before 
except that the concentration of purified MMP-9 (Chemicon Europe Ltd., 
Chandlers Ford, UK) included in the gel at the time of polmerization was 
reduced to 60ng as earlier optimisation of this assay had proved to give 






6.2.5    Results of TIMP-1 and TIMP-2 Levels in HASMC 















Figure 68    Representative Reverse Zymogram (Incorporating MMP-9) 
Showing  Analysis of TIMP Levels in HASMC Supernatant  
 
Culture supernatants from HASMCs exposed to hypoxia (1%) or normoxia for 48hrs 
were equally loaded onto 12% gels and analyzed using reverse zymography by 
incorporating 60ng purified MMP-9 protein into the gels. Purified TIMP-2 protein 
was used as a positive control. 1: Positive control (70ng of purified TIMP-2 protein) 
2: 1h rN 3: 1hr H 4: 3hrs N 5: 3hrs H 6:6hrs N 7: 6hrs H 8:30hrs N 9: 30hrs H 10: 
48hrs N 11: 48hrs H 12: RSM (N: Normoxia, H: Hypoxia, RSM: Rainbow size 




























































































Figure 69    Bar and Scatter Graphs Showing Levels of TIMP-1 in 
HASMC Conditioned Media 
MMP-9 Reverse zymographic analysis of TIMP-1 protein  in culture supernatants 
from HASMCs exposed to 1% hypoxia for 48 hours. Results expressed as arbitrary 
density units (ADU) per unit standardised total protein. Data expressed as means 
±SEM of triplicate values. *p < 0.05; ** p < 0.01. Results are from three independent 
experiments with 3 replicates. n = 3. Statistical analysis was performed using 
Student's t-tests.                                                                                                                                                                                                                                                
  A:   Normoxia (open bars),  1%  hypoxia  ( grey filled bars).   






Bands of TIMP inhibition were seen on the gel in Figure 68 which 
corresponded to being within the molecular weight range of TIMP-1. There 
were significant increases seen  in TIMP-1  inhibition in hypoxic samples at 
the 6 hour time-point (* p < 0.05) and 30 hour time-point (**< 0.01). At the 1 
hour  and 48 hour time-points, although inhibition levels were higher in 
hypoxic samples compared to normoxic controls they were not statistically 
significant.  
 
As a contrast to the reverse zymography performed using MMP-2 included in 
the gel, TIMP-2  inhibition was not detected on the gels incorporating MMP-
9. This could be explained as TIMP-2 is more selective and inhibits MMP-2 
whereas TIMP-1 has the ability to inhibit most MMPs. 
 
 
6.2.6   Reverse Zymography Control Gels 
 
To ensure that is was TIMP inhibition  responsible for the bands observed on 
the reverse zymograms, control gels were ran at the same time. Hawkes et 
al., (2001) suggested that a  parallel regular SDS-PAGE gel with identical 
samples is run under identical conditions at the same time. Bands that 
appear in the reverse zymogram but are not visible in the regular SDS gel 
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Figure 70   Parallel Control SDS Page Gel 1 
Culture supernatants from HASMCs exposed to hypoxia (1%) or normoxia for 48hrs 
were equally loaded onto a regular 12% SDS Page gel (without MMP-2 or 9 
incorporated into the gel) and stained using Coomassie Blue. A: Lysate from MDA 
MB 231 cells was used as a positive control B: (RSM: Rainbow size marker)  
 









Figure 71    Parallel Control SDS Page Gel 2 
Culture supernatants from HASMCs exposed to hypoxia (1%) or normoxia for 48hrs 
were equally loaded onto a regular 12% SDS Page gel (without MMP-2 or 9 
incorporated into the gel) and stained using Coomassie Blue. A: 70 ng purified 









As described by Hawkes et al., (2001)  all the TIMP bands were absent from 
the two control regular SDS Page gels (Figure 70 and 71) including the 
positive control Lane A on Gel 2, Figure 71  which contained 70ng of purified 
TIMP protein and had previously given a distinct band on the reverse 
zymograms in Figure 65 and Figure 68. 
To further verify the bands as TIMPs, control gels were incubated overnight 
in the presence of 1,10-phenanthroline (10mM) which interferes with 
development of inhibitor activity in reverse zymography and will inhibit any 
TIMP bands. Identical samples of HASMC conditioned media were run as 
normal reverse zymograms containing 1% gelatin. One gel contained 160ng 
purified MMP-2 and the second 60ng of purified MMP-9 and were treated 
exactly as the earlier reverse zymograms in except that 10mM 1,10-
phenanthroline was added to the incubation buffer.        
 
               
 
 




Figure 72     Control Reverse Zymogram Containing MMP-2  and 
Incubated  in 10mM 1,10-Phenanthroline 
 
Culture supernatants from HASMCs exposed to hypoxia (1%) or normoxia for 48hrs 
were equally loaded onto 12% gels and analyzed using reverse zymography by 
incorporating 160ng purified MMP-2 protein into the gels. Gels were incubated 
overnight in 10mM 1,10- phenanthroline. A: 140 ng purified TIMP-2 protein was 












                                                                                                             
 
 
Figure 73   Control Reverse Zymogram Containing MMP-9  and 
Incubated  in 10mM 1,10-Phenanthroline 
  
Culture supernatants from HASMCs exposed to hypoxia (1%) or normoxia for 48hrs 
were equally loaded onto 12% gels and analyzed using reverse zymography by 
incorporating purified 60ng MMP-9 protein into the gels. Gels were incubated 
overnight in 10mM 1,10- phenanthroline. A: 140ng purified TIMP-2 protein was 
used a positive control. B: (RSM: Rainbow size marker). 
 
 
The parallel gels in Figure  70 and  Figure 71 as expected, did not exhibit 
any bands apart from faint bands at the very top of the gel which were most 
likely to be MMP-2 and certainly not within the molecular weight range of any 
of the TIMP family.  
Additionally,  the gels in Figure 72 and Figure 73 which had been incubated 
overnight in 10mM 1,10- phenanthroline were negative for bands of TIMP 
inhibition.  Any TIMPS present in the HASMC conditioned media had been 
inhibited as expected, including the positive control lanes  where the purified 




All the control gels therefore appear to verify that the bands of inhibition 
seen on the reverse zymograms in Figure 65  and Figure 68  were  most 






Chapter 7 Potential role of Hypoxia-
inducible factor -1alpha (HIF-1α) in 
the pathogenesis of AAA 




7. Potential role of Hypoxia-inducible factor -1alpha 




The global oxygen sensor HIF-1α responds to low tissue oxygen by up-
regulating hypoxia responsive genes, controlling the expression of over 
seventy genes involved in intracellular adaptive responses to hypoxia 
(Semenza., 2004). HIF-1α targets genes by directly binding to hypoxia 
responsive elements within the promoters of these genes which also include 
VEGF (Forsythe et al., 1996) and Ets-1 (Oikawa et al., 2001) which are both 
of interest to this AAA study. HIF-1α is also known to modulate MMPs in 
other research areas such as joint disease and cancer studies (Pufe et al., 
2004, Yamaguchi et al., 2005, Krishnamachary et al., 2003). 
In AAA, expression of HIF-1α has been found to be significantly higher in 
aneurysm tissue than in normal aorta (Hu et al., 2004) which was later 
corroborated by our Group (Erdozain et al., 2011)  who found expression of 
Hif-1α, MMP-2 and Ets-1 strongly up-regulated within HASMC and 
inflammatory infiltrate of the tunica media of the aortic wall.  Arterial wall 
hypoxia has been investigated in other conditions such as atherosclerosis, 
intimal hyperplasia and myointimal hyperplasia and animal models of AAA 
have also demonstrated low oxygen tension (pO2) within the aortic media 
(Bjornheden et al., 1999). Preliminary human data have shown that hypoxia 
exists in vivo in patients with aneurysms (Vorp et al., 1998, 2001). 
Additionally, the earlier results (Chapter 4, section 4.4.2.2) exposing 
HASMCs to prolonged hypoxia resulted in increased secretion of MMP-2 
leading to the hypothesis that HIF-1α could be a potential initiating factor in 
the pathway leading to MMP up-regulation.  Sun et al.,(2007) designed a 
numerical model of oxygen transport in AAA which demonstrated O2 levels 
of 1% and lower within the thickest regions of the ILT and subsequently led 
this study to evaluate the effect of more severe hypoxia (1%) on MMP 
secretion, following on from our earlier study (Erdozain et al., 2011) where 
oxygen tension was sequentially reduced from 5% down to 2% over 72 hrs. 
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7.2  Chapter Aims 
 
1.To determine if HIF-1α is expressed in cultured SMC and if so analyse its 
expression after exposure to severe hypoxia (1%) by immunoblotting 
techniques                                                                                                        
2. To examine the differences in HIF-1 α expression in whole cell HASMC 
lysates between normoxia and hypoxic HASMC samples in preparation for 
further experimentation later in the study                                                        
3. To confirm the localisation of  HIF-1α  in control and aneurysmal tissue 




7.3.1 Materials List 
 
 ECLTM Western Blot Detection Reagents, HybondTM-C extra 
nitrocellulose (Amersham Biosciences UK Ltd. Buckinghamshire, UK).  
 Kodak BioMax XAR Film (VWR International Ltd. Dorset, UK).  
 Polyoxyethylene sorbitan monolaurate (Tween 20) (Sigma Aldrich 
Company Ltd. Dorest, UK).  
 Anti-human HIF-1 primary antibody (Novus Biologicals., Littleton, 
CO, USA). 
 
7.3.2 Western Blot Protocol 
 
All materials and recipes for sample buffer, running buffer, blotting buffer, 
washing buffer, blocking buffer, the stacking gel, and the resolving gel are 
shown in Appendix 1.   
HASMC total cell lysate samples were mixed with reducing loading buffer  
and heated to 100ºC for 5 mins and separated by 7.5% SDS-PAGE gel 
electrophoresis at 120V for approximately one hour or until the gel-front 
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neared the end of the resolving gel. Subsequently the proteins were 
transferred onto a nitrocellulose membrane under reducing conditions at 
150mA for approximately 2 hours. 
 Immunodetection of the nitrocellulose-bound proteins began with a one hour 
incubation in 5% blocking buffer at room temperature with continuous 
agitation. After this step the blocking buffer was removed and replaced with 
1:500 mouse monoclonal anti-human HIF-1 primary antibody (Novus 
Biologicals., Littleton, CO, USA) diluted in fresh blocking buffer. 
The nitrocellulose membrane was incubated with the 1º antibody overnight 
at 4°C after which the blocking buffer was discarded and any unbound 1º 
antibody was removed by 6 x 5mins wash steps in excess washing buffer. 
The membrane was next incubated in 1:200 polyclonal horseradish 
peroxidase-conjugated goat anti-mouse secondary antibody (DAKO UK Ltd., 
Cambridgeshire, UK) prepared in blocking buffer for approximately one hour.  
Unbound 2° antibody was removed by further 6 x 5mins wash steps in 
excess washing buffer. Following the wash steps the nitrocellulose 
membrane was covered in ECL detection reagents (prepared according to 
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The cassettes containing the acrylamide gel and nitrocellulose membrane 
are placed inside the blotting tank which is then filled with transfer buffer. It is 
vital that the nitrocellulose is placed nearest the positive electrode to enable 
the transfer of proteins from the gel onto the membrane and to ensure the 
proteins are not lost. The blot is run at 150 mA for 2 hours.   
 









Figure 75   HIF-alpha Protein levels in HASMC Total Cell Lysate 
 
HIF-1α protein levels in total HASMC lysate after exposure to 1%hypoxia (filled 
bars) or normoxia (open bars) for 48 h assessed by immunoblotting. Density 
analysis was carried out using Scion ImagingSoftware (version 4.0.2; 
www.scioncorp.com). Results expressed as arbitrary density units (ADU) per unit 
standardised total protein. Data expressed as means ± SEM of triplicate values.* p 
< 0.05; ** p <  0.01. Results are from three independent experiments repeated in 


























 Figure 76   Scatter Plot of HIF-1alpha Protein Levels in HASMC Total 
Cell Lysate  
HIF-1α protein levels in total HASMC lysate after exposure to 1% for 48 h assessed 
by immunoblotting. Density analysis was carried out using Scion Imaging Software 
(version 4.0.2; www.scioncorp.com). Results expressed as arbitrary density units 
(ADU) per unit standardised total protein. Data expressed as means ± SEM of 
triplicate values. Results are from three independent experiments repeated in 
triplicate. n = 3. Statistical analysis was performed using Student's t-test. Normoxia 




In Figure 75 HIF-1α immunoblot analysis established the presence of 
increased HIF-1α in total cell lysate from HASMCs exposed to over 48hrs of 
severe (1%) hypoxia. After 1 hour of hypoxia, there was an increase in levels 
of HIF-1 α protein between the hypoxic and normoxic samples,  although not 
statistically significant, but after 3 hours, 6 hours, 30 hours and 48 hours of 
hypoxia, a significant rise was demonstrated in the hypoxic samples(p < 
0.05, p < 0.01, p < 0.05 and p < 0.01 respectively) in comparison to 







7.4  Distribution of HIF-1 α in AAA 
 
Immunohistochemistry was performed using  5 x human AAA donors and 5 x 
normal aortic control tissue donors (n =10) to demonstrate HIF-1α was 
present within these tissues and also to illustrate its distribution. 
 
 
7.4.1 Materials List 
 
 
 Mouse monoclonal anti-human HIF-1α (Abcam, Cambridge, UK). 
 Alkaline phosphatase-conjugated avidin/biotin complex anti-mouse 
secondary antibody (ABC) kit (Vector Laboratories, Peterborough, 
UK). 
 Levamisole (Vector Laboratories, Peterborough,UK).  
 Horse serum (Sigma-Aldrich Ltd (Dorset, UK).  
 Fast Red TR/Naphthol AS-MX Tablets (Sigma-Aldrich Ltd (Dorset, 
UK). 
 Mayers haematoxylin (Sigma-Aldrich Ltd (Dorset, UK). 
 Monoclonal IgG1 (Dako UK Ltd, Cambridgeshire, UK). 
 
7.4.2  Immunohistochemistry Protocol 
 
With local ethics approval, AAA tissue was obtained from consented patients 
undergoing elective surgical repair. Sections were taken from the proximal 
distal and body of the aneurysm. Normal tissue free from signs of aortic 
disease was obtained from the aortic cuff of renal transplant donors. At the 
time of retrieval tissue samples were immediately fixed in 0.9% NaCl 
(10%v/v) histological formaldehyde and subsequently processed using a 
Shandon Hypercentre II firowax-embedding station (Shandon Inc., 
Pennsylvania, USA).   
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After processing, tissue sections (5µm) cut from the paraffin embedded wax 
blocks were de-paraffinised, then rehydrated in preparation for staining. 
Sections were evaluated using mouse monoclonal anti-human HIF-1α 
(Abcam) which was incubated overnight at 4°C. Subseqently the sections 
were incubated in a biotinylated anti-mouse secondary antibody solution 
(1:100) for 2 hours at room temperature followed by a minimum 30 minute 
incubation in Vectastain‘s ABC alkaline phosphatase solution. Endogenous 
alkaline phosphatase was inhibited using Levamisole. Visualisation of HIF-
1α was achieved by incubating the sections in Fast Red substrate solution 
until a red precipitate appeared and counterstaining with Mayers 
haematoxylin. Monoclonal IgG was used as a negative control or sections 
prepared minus the primary antibody.  
 












Figure 77   Photomicrograph Showing Localisation of HIF-1 Alpha in 
the Media of Normal Aorta (x63) 
Control specimens of normal human aorta were probed with mouse anti-human 
HIF-1 alpha using a  biotinylated horse anti-mouse secondary antibody (1:200) 
(Vector Laboratories) and counterstained with Mayers Haematoxylin for comparison 
with identically treated sections of human aneurysm tissue. The section appears 
negative for nuclear HIF-1α although some cytoplasmic may be expected under 
























Figure 78  Photomicrograph Showing the Immunolocalisation of HIF-1 
Alpha in the Body Region of AAA Tissues 
Sections of human aneurysmal tissue were probed with mouse anti-human HIF-1 
alpha and a biotinylated horse anti-mouse secondary antibody (1:200) (Vector 
Laboratories) followed by counterstaining with Mayers haematoxylin. HIF-1 alpha 
Immunopositive nuclei are present on both slides. Slide A: Demonstrates the 
nuclear immunolocalisation of HIF-1 alpha (red) in a human AAA tissue section 
(x126) Slide B: Lower power magnification showing the nuclear immunolocalisation 













Figure 79   Photomicrographs Showing the Immunolocalisation of HIF-
1 Alpha (Red) in AAA Tissue Sections (x126) 
Sections of human aneurysmal tissue were probed with mouse anti-human HIF-1 
alpha followed by a biotinylated horse anti-mouse secondary antibody (1:200) 
(Vector Laboratories) and counterstained with Mayers haematoxylin to demonstrate 
HIF-1α positivity within the inflammatory infiltrate and VSMCs of the aortic media. 
Proximal AAA regions: Slide A (x 63) and Slide B (x126), AAA Body regions: Slide 
C (x126) and Slide D (x252), AAA Distal regions: Slide E (x 126) and Slide F 




























Figure 80   Photomicrograph  Showing the Immunolocalisation of HIF-1 
Alpha  Surrounding the Vasa Vasorum 
Sections of human aneurysmal tissue were probed with mouse anti-human HIF-1 
alpha and a biotinylated horse anti-mouse secondary antibody (1:200) (Vector 
Laboratories). Vasa vasorum supply blood carrying oxygen to the vascular tissues 
but are scarce within the infrarenal region of the aorta. In this section of the media 
HIF positivity appears less pronounced within the area of the vasa vasorum which 
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8. Expression of Vascular endothelial growth factor 
(VEGF) and Ets-1 in AAA and analysis of VEGF and 
Ets-1 levels in HASMCs exposed to severe hypoxia 
 
8.1  Introduction 
 
8.1.2 Vascular endothelial growth factor (VEGF) and AAA 
 
Vascular endothelial growth factor (VEGF) is a family of homodimeric 
glycoproteins vital for vascular development and is induced in cells in 
response to hypoxia or ischemia stimulating angiogenesis in order to restore 
the blood supply to inadequately oxygenated tissues. The VEGF family 
covers a number of proteins from two families that result from alternate 
splicing of mRNA from the single 8-exon VEGF gene. All members of the 
VEGF family  stimulate cellular responses by binding to tyrosine kinase 
receptors (VEGFRs) on the cell surface, causing them to dimerize and 
become activated through transphosphorylation eliciting a variety of 
functions between all the family members (Holmes et al.,2007).  
Overexpression of VEGF can contribute to pathological conditions and is 
crucial for tumour angiogenesis in cancer (Shibuya, 2013). Nishibe et al., 
(2010) demonstrated the expression of VEGF in abdominal aortic aneurysm 
tissue samples and its absence in the normal abdominal aorta leading them 
to suggest that VEGF may play an important role in aneurysm formation via 
its direct and/or indirect actions.  
Interestingly they also found two thirds of their AAA samples displayed 
VEGF positivity localized within the SMCs. We know VEGF expression is 
induced by low oxygen in a number of cell types including SMCs and that 
Forsythe et al., (1996) had demonstrated the involvement of the master 
hypoxic transcription factor HIF-1α in the activation of VEGF transcription so 
therefore increased expression of VEGF in  AAA tissue through an unknown 
mechanism could possibly be via a signalling cascade involving HIF-1α (Hu 
et al., 2004).                                                                                                                                                      
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8.1.3   Ets-1 and AAA 
 
Although many of the events that occur within the signalling cascade that 
govern aneurysm development have been elucidated, a large amount is still 
unknown. In order to further explicate the tissue markers of hypoxia, AAA 
tissue samples were analyzed for the transcription factor Ets-1. Additionally, 
levels of this transcription factor in SMC total cell lysate from cells exposed 
to severe hypoxia were also investigated. 
   
Ets-1 is the founding member of the Ets oncogene family originally identified 
in the E26 avian erythroblastosis virus and is expressed in a variety of cells 
including vascular smooth muscle cells. Ets-1 is considered important for the 
transcriptional regulation of several MMPs including MMP-2 and MMP-9 
which contain Ets-1 binding sites in their promoters (Dittmer, 2003., Ito et al, 
2004., Nakamura et al., 2004) and which are both proven to play significant 
roles in the pathogenesis of AAA.  
Hypoxia has been shown to induce Ets-1 via the activity of HIF-1α (Oikawa 
et al., 2001) and Peters et al., (2004) also suggested that hypoxia and HIF-1 
α may be involved in the up-regulation of Ets-1 when they discovered that 
Ets-1 and HIF-1 α co-localize in the hypoxic synovium of inflamed rat joints 
in adjuvant induced arthritis.  
TlMP-1, in addition to MMPs, is also a gene target of Ets-1 (Logan et 
al.,1996) and levels of TIMPs in HASMCs exposed to hypoxia were found to 
be elevated in hypoxic samples compared to controls (Chapter 6, section 
6.2.3 ).  It seems reasonable to hypothesize that Ets-1 could be involved in 
the signalling pathway terminating in MMP up-regulation as observed in 





8.2   Exposure of HASMCs to Severe Hypoxia (1%) for 
30 hours 
 
Human aortic smooth muscle cells purchased from TCS Cellworks were 
passaged into 6-well plates, grown to sub-confluence under normal 
conditions in the presence of 10% FCS in DMEM with additions of 2mM L-
glutamine, penicillin (10,000 IU/ml) and streptomycin (10,000 IU/ml). The 
cells were then maintained in serum-free medium under severe hypoxia 
(5%CO2, 94%N2 and 1%O2) inside a sealed Minimac hypoxia chamber at 
37oC for up to 48 hours. Controls were maintained throughout the 48 hour 
period in an incubator at 37C in 95% air, 5%CO2. At termination of allotted 
time-points the media was removed from wells, cells washed with PBS and 
subsequently  lysed with ice-cold lysis buffer (0.5% Nonidet, 100mM NaCl, 




8.3   Ets-1 and VEGF Western blotting 
 
Samples standardised for protein were loaded onto 7.5% SDS-PAGE gels, 
then transferred onto nitrocellulose membranes and probed with mouse 
monoclonal anti-human VEGF (1:200) (Santa Cruz Inc.) or rabbit polyclonal 
anti-human Ets-1 (1:200) (Santa Cruz Inc.) and finally polyclonal horseradish 
peroxidase-conjugated goat anti-mouse or swine anti-rabbit secondary 
antibodies (1:10000)(Dako UK Ltd.,Ely, UK). Proteins were visualised using 
an Amersham ECL Advance TM Western blotting detection kit (GE 








8.4    Results of Ets-1 and VEGF Western Blotting 
 
 
8.4.1   Results: Levels of Ets-1 in HASMC total cell lysate 
after exposure to 1% hypoxia for 30 hours 
 
 









Figure 81    Representative Immunoblot Showing Levels of Ets-1 in 
HASMC Lysate 
HASMC whole cell lysate (7μg) was loaded onto 7.5% gels and analyzed by 
immunoblotting using rabbit polyclonal anti-human Ets-1 primary antibody (1:200) 
followed by a polyclonal horseradish peroxidase-conjugated swine anti-rabbit 
secondary antibody (1:10000) and visualised using chemiluminescence. 1: 
Negative (lysis buffer)  2: 1hr N 3: 1hr H 4: 3hrs N 5: 3hrs H 6:6hrs N 7: 6hrs H 
8:30hrs N 9: 30hrs H 10: RSM (N: Normoxia, H: Hypoxia, RSM: Rainbow size 
marker).  
The RSMs, also known as a molecular weight ladders do not appear on the 
blots in Figures 81, 83 and 85.  Prior to transfer they were visible on the 
SDS-PAGE gels but failed to transfer across to the nitrocellulose membrane 
during the Western blot protocol.  The protein samples were transferred over 
a 2 hour period to ensure complete transfer, but it is possible the ladder 
transferred too far and was lost or the SDS present in the transfer buffer 
stripped the dye from the ladder. 
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Figure 82   Bar and Scatter Graphs Showing Levels of Ets-1 in HASMC 
Total Cell Lysate After Exposure to Hypoxia 
 
Levels of Ets-1 protein in total HASMC lysate after exposure to 1% hypoxia for 30 
hours and assessed by immunoblotting. Results expressed as arbitrary density 
units (ADU) per unit standardised total protein. Data   expressed  as  means  ±  
SEM of  triplicate   values (* p < 0.05;   ** p < 0.01). Results are from three 
independent experiments with 3 replicates. (n = 3). Statistical analysis was 
performed using Student's t-tests. 
A:   Normoxia (open bars),  1%  hypoxia  ( grey filled bars).  







Results of Ets-1 Western blot showed significant induction in Ets-1 protein 
levels in the hypoxic samples at the 1 hour time-point  (p < 0.01) which was  
sustained at 3 hours  (p < 0.05), 6 hours (p<0.05) and at 30 hours (p>0.05). 
 
 
8.4.2  Results: Levels of VEGF in HASMC total cell lysate 
after exposure to 1% hypoxia for 30 hours 
 
 






Figure 83    Representative Immunoblot Showing Levels of VEGF in 
HASMC Lysate 
Whole cell lysate (7μg) was loaded onto 7.5% gels and analyzed by immunoblotting 
using mouse monoclonal anti-human VEGF primary antibody (1:200) followed by a 
polyclonal horseradish peroxidase-conjugated goat anti-mouse secondary antibody 
(1:10000) and  visualised using chemiluminescence. 
1: Negative (lysis buffer)  2: 1hr N 3: 1hr H 4: 3hrs N 5: 3hrs H 6:6hrs N 7: 6hrs H 






               



























Figure 84    Bar and Scatter Graphs Showing Levels of VEGF in HASMC 
Total Cell Lysate After Exposure to Hypoxia 
 
Levels of VEGF protein in total HASMC lysate after exposure to hypoxia for 30 
hours and assessed by immunoblotting. Results expressed as arbitrary density 
units (ADU) per unit standardised total protein. Data expressed as means  ± SEM 
of triplicate values (* p < 0.05). ). Results are from three independent experiments 
with 3 replicates. (n = 3). Statistical analysis was performed using Student's t-tests. 
A:   Normoxia (open bars),  1%  hypoxia  ( grey filled bars)  







Results of the VEGF Western blot found VEGF protein levels significantly 
up-regulated in the hypoxic samples at the 1 hour time-point (p < 0.05), at 3 
hours  (p < 0.05) and 6 hours (p < 0.05). At the 30 hour time-point there was 
a small increase in VEGF levels in the hypoxic sample in comparison to the 
control but this was not statistically significant. 
 
 
8.4.3   Beta Actin Loading Controls 
 
To ensure equal sample loading and to check that there has been even 
transfer from gel to nitrocellulose membrane across the whole gel beta actin 
(Abcam, Cambridge, UK) loading controls were carried out.  
 






Figure 85    Representative Beta Actin Loading Control Immunoblot 
 
Whole cell HASMC lysate (7μg) was loaded onto 7.5% gels and analyzed by 
immunoblotting using a mouse monoclonal anti-human beta actin (1:5000) (Abcam) 
followed by a polyclonal horseradish peroxidase-conjugated goat anti-mouse 
secondary antibody (1:10000) and visualised using chemiluminescence.  
1: Negative (lysis buffer)  2: 1hr N 3: 1hr H 4: 3hrs N 5: 3hrs H 6:6hrs N 7: 6hrs H 





8.5   Distribution of VEGF and Ets-1 in AAA  
 
Immunohistochemistry was performed on human AAA and normal aortic 
control tissue to demonstrate the presence of VEGF and Ets-1 within these 
tissues and also to illustrate distribution of these two proteins within 
aneurysmal tissue. With local ethics approval, AAA tissue was obtained from  
5 consented patients undergoing elective surgical repair and normal aortic 
tissue was obtained from the aortic cuff of 5 renal transplant donors (n = 10). 
 
8.5.1   Materials List 
 
All materials were purchased from Sigma-Aldrich Ltd (Dorset, UK) unless 
stated otherwise. 
 
 Rabbit polyclonal anti-human Ets-1 (Santa Cruz Inc, Heidelberg, 
Germany) 
 Mouse monoclonal anti-human VEGF (Santa Cruz Inc, Heidelberg, 
Germany) 
 Alkaline phosphatase-conjugated avidin/biotin complex anti-mouse or 
anti-rabbit secondary antibodies (ABC) kit (Vector Laboratories) 
 Monoclonal IgG1 (negative control) (Dako UK Ltd., Cambridgeshire, 
UK). 
 Levamisole (Vector Laboratories).  
 Naphthol AS-MX phosphate/fast red TR Fast TM substrate solution. 
 Horse serum 
 Goat serum 







8.5.2    Immunohistochemistry Protocol 
 
With local ethics approval, AAA tissue was obtained from consented patients 
undergoing elective surgical repair. Sections were taken from the proximal 
distal and body of the aneurysm from 5 x donors. Normal tissue free from 
signs of aortic disease was obtained from the aortic cuff of 5 x renal 
transplant donors (n = 10). At the time of retrieval tissue samples were 
immediately fixed in 0.9% NaCl (10%v/v) histological formaldehyde and 
subsequently processed using a Shandon Hypercentre II firowax-embedding 
station (Shandon Inc., Pennsylvania, USA).   
After processing, tissue sections (5µm) cut from the paraffin embedded wax 
blocks were de-paraffinised, then rehydrated in preparation for staining. 
Sections were evaluated using mouse monoclonal anti-human VEGF (1:200) 
or rabbit polyclonal anti-human Ets-1 (1:200) which were incubated 
overnight at 4°C. 
  
Subsequently the sections were incubated in a biotinylated anti-mouse or 
anti-rabbit secondary antibody solution (1:100) for 2 hours at room 
temperature followed by a minimum 30 minute incubation in Vectastain‘s 
ABC alkaline phosphatase solution. Endogenous alkaline phosphatase was 
inhibited using Levamisole.
Visualisation of the proteins was achieved by incubating the sections in Fast 
Red substrate solution until a red precipitate appeared and counterstaining 
with Mayers haematoxylin. Monoclonal mouse IgG1 directed against 
Aspergillus niger glucose oxidase (1:200) was used as a negative control or 

























Figure 86   Photomicrograph Showing the Distribution of Ets-1 Within 
the Normal Aortic Media (x126) 
Control specimens of normal human aorta without evidence of aneurysmal disease 
were probed with rabbit anti-human Ets-1 (1:200) followed by a biotinylated goat 
anti-rabbit secondary antibody (1:200) (Vector Laboratories) and counterstaining 
with Mayers haematoxylin for comparison with identically treated sections of human 
aneurysm tissue. Some cytoplasmic staining (red) is evident but there does not 
appear to be any Ets -1 immunopositivity within the nuclei where  as a transcription 
factor Ets-1 would generally be localized in order to bind to the Ets-1 binding sites 























Figure 87   Photomicrographs Showing the Localisation of Ets-1 Within 
the Body and Distal  Regions of AAA and Control Sections of Normal 
Aorta 
Aneurysmal tissues were probed with rabbit anti-human Ets-1 (1:200) followed by a 
biotinylated goat anti-rabbit secondary antibody (1:200) and counterstained with 
Mayers haematoxylin. Slides A, B and C show the same areas of the body region of 
AAA from the same slide at different magnifications (x63, x126 and x252 
respectively). Slide D shows the distal region of a AAA section (x126) and all 
demonstrate Ets-1 positivity (red) within the inflammatory infiltrate. Slides E and F 
show sections of normal aortic tissue probed with monoclonal mouse IgG1 directed 
against Aspergillus niger glucose oxidase (1:200) as a negative control at x63 and 










      
Figure 88   Photomicrograph Showing the Distribution of Ets-1 Within 
the Distal Region of AAA Tissue (x126) 
 
Sections of human aneurysmal tissue were probed with rabbit anti-human Ets-1 
(1:200) followed by a biotinylated goat anti-rabbit secondary antibody (1:200) 
(Vector Laboratories) and counterstained with Mayers haematoxylin. Diffuse Ets-1 
immunopositivity can be seen throughout the tunica media of this distal region of 


























Figure 89   Photomicrograph Showing the Localisation of Ets-1 Within 
the Distal Region of AAA Tissue (x 126) 
 
Sections of human aneurysmal tissue were probed with rabbit anti-human Ets-1 
(1:200) followed by a biotinylated goat anti-rabbit secondary antibody (1:200) 
(Vector Laboratories) and counterstained with Mayers haematoxylin. This slide 
demonstrates Ets-1 nuclear and cytoplasmic immunopositivity within the VSMCs of 
the medial region of AAA tissue. Typical tears are also present in this tissue section 
which is a common problem occurring when trying to cut sections from aneurysm 
tissue which is often brittle and friable in comparison to cutting normal aortic 





































Figure 90    Photomicrograph of Normal Aortic Tissue Probed for VEGF 
(x 126) 
 
Sections of normal human aortic tissue were probed with mouse monoclonal anti-
human VEGF(1:200) followed by a biotinylated goat anti-mouse secondary antibody 
(1:200) (Vector Laboratories) and counterstained with Mayers haematoxylin. This 



































Figure 91   Low Power Photomicrograph (x 31.5) Showing the 
Distribution of VEGF Within the Distal Region of AAA Tissue 
 
Sections of AAA tissue were probed with mouse monoclonal anti-human 
VEGF(1:200) followed by a biotinylated goat anti-mouse secondary antibody 
(1:200) (Vector Laboratories) and counterstained with Mayers haematoxylin. 
Widespread and diffuse VEGF immunopositivity is seen within the tunica adventia 






























Figure 92   Photomicrograph Showing the Localisation of VEGF Within 
the Body and  and Distal Region of AAA 
 
Sections of AAA tissue were probed with mouse monoclonal anti-human 
VEGF(1:200) followed by a biotinylated goat anti-mouse secondary antibody 
(1:200) (Vector Laboratories) and counterstained with Mayers haematoxylin. Slides 
A, B and C show the same areas of the body region of AAA on the same slide at 
different magnifications (x63, x126 and x252) respectively).  Slide D shows the 
distal region of a AAA section (x126) and all clearly demonstrate cytoplasmic  
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9. Analysis of MMP-2 levels in HASMCs Exposed to 




As described in Chapter 2, section 2.3.1, HIF-1 functions as a master 
regulator of cellular and systemic homeostatic response to hypoxia by 
activating transcription of many genes involved in  increasing oxygen 
delivery or facilitating the metabolic adaptation to hypoxia. Our earlier study 
(Erdozain et al., 2011) described strong immunopositivity for HIF-1α, MMP-2 
and Ets-1 within the tunica media of all AAA tissue sections evaluated in  
comparison to normal aortic tissue controls. 
In Chapter 4, section 4.4.2.2 results demonstrated significantly increased 
expression of MMP-2 in HASMCs exposed to severe hypoxia for 48 hours.  
In order to further elucidate if HIF-1α has any involvement in the signalling 
pathway ending with the up-regulation of MMP-2 as seen in this hypoxia 
study, it will be necessary to inhibit HIF using bisphenol A (BpA) and 
subsequently evaluate HASMC samples for any changes in MMP-2 
expression. The presence of an active Hsp90 is necessary for HIF-1 
activation in hypoxia and BpA is an environmental endocrine disruptor which 
Kubo et al., (2004) found promoted HIF-1α degradation by dissociation of 
the chaperone protein Hsp90 from HIF-1a. 
 Under normal oxygen levels HIF-1a is hydoxylated on its proline residue by 
prolyl hydroxylases which result in its ubiquitination by the von Hippel–
Lindau tumor suppressor protein (pVHL) and degradation by the proteasome 
(Ivan et al., 2001., Jaakola et al., 2001). 
 During hypoxia, proline hydroxylation is inhibited and HIF-1a is not 
ubiquitinated and HIF-1α translocates and accumulates in the nucleus of 
hypoxic cells resulting in activation of its target genes. Disruption of Hsp90 
function by BpA (which has a similar effect to the antibiotic geldanamycin) 
under hypoxic conditions  is followed by HIF-1 degradation and therefore no 




9.1.2   Aims of the chapter 
 
1:   To determine the optimal concentration of BpA necessary to inhibit HIF-
1α in HASMCs during 48 hours of 1% hypoxia. 
2:   To treat HASMCs with 250µM BpA during a 48 hour period of 1% 
hypoxia. 
3:   To assess the effect of HIF-1α inhibition  if any, on the expression of 
MMP-2 secretion into HASMC conditioned medium. 
 
 
9.2   HIF-1 α Inhibition  using BpA 
 
 
9.2.1 Cell Culture 
 
The primary HASMC culture was seeded into T25 flasks and routinely grown 
in DMEM supplemented with 10% foetal calf serum, 2mM L-glutamine, 100 
units/ml penicillin and 100μg/ml streptomycin or Smooth Muscle Cell 
Complete Medium  which was replaced every two to three days.  The cells 
were kept in 5% CO2, 95% air at 37C in a humidified Jencons Millenium 
incubator (Jencons Ltd. Bedfordshire, UK). Upon reaching confluence (100% 
monolayer covering flask base) the cells were split 1:5 into T75 flasks. 
HASMCS were washed in PBS then dissociated from the flasks using 2mls 
Accutase /T25 and incubated at 37ᴏC for approx 2-5 minutes.  DMEM was 
added to inactivate the Accutase and the cells were brought out of 
suspension by centrifugation at 1600rpm for 5 minutes. The supernatant was 
removed and the pellet resuspended in fresh DMEM. For hypoxia studies 
cells were passaged into 6-well plates or for cell staining experiments grown 





9.2.2    Preparation of Cells for BpA Treatment 
 
For this hypoxia study cells were passaged into 6-well plates or into 6/12-
well plates containing sterilised 13mm diameter glass coverslips ready for 
staining procedures. They were maintained as before in a standard 
incubator at 37°C until the start of the experiment. Cells were maintained in 
serum-free media  for 24 - 48 hours prior to the start of the hypoxia study. 
 
 
9.2.3  Experimental Trial of BpA 
 
Prior to the main hypoxia study, a small trial was set up to determine the 
optimum concentration of BpA necessary to completely inhibit the activity of 
HIF-1α. Whilst the cells were subconfluent and 24 hours prior to the start of 
the trial the media was removed and replaced with serum-free medium. At 
the start of the trial, under sterile conditions BpA (Enzo Life Sciences Ltd, 
Exeter, UK)  was initially dissolved in ethanol which was then added 
dropwise to serum-free media whilst stirring to minimise the possibility of 
precipitation to make a 5mM BpA stock solution. The stock solution was 
further diluted with serum-free media to make 50μΜ, 100μM, 200μΜ and 
250μM concentrations of BpA.  
HASMC were subsequently cultured for 48 hours inside a sealed Minimac 
chamber at 37°C and 1% hypoxia (Don Whitley Scientific DG250 
Workstation ) in the presence of BpA (0, 50, 100, 200 and 250μM). Controls 
were maintained in a standard incubator at 37°C under normoxic conditions 
(5% CO2, 95%). At termination of the trial, media was removed and 
HASMCs lysed with ice-cold lysis buffer (0.5% Nonidet, 100mM NaCl, 10mM 
Tris HCL pH 7.5) and stored at ˉ80C. 
Immunoblotting analysis of trial HSMC lysate samples was carried out as 
described earlier in Chapter 7, section  7.3.2,  using mouse monoclonal anti-
human HIF-1α (1:500)(Novus Biologicals) followed by a polyclonal 
horseradish peroxidase-conjugated goat anti-mouse secondary antibody 
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(1:200) (Dako UK Ltd). Proteins were visualised using an Amersham ECL 
AdvanceTM Western blotting detection kit (GE Healthcare Life Sciences). 
 
 
9.2.3.1 Results of BpA Trial 
 
Subsequently the 250µM BpA concentration was chosen for the main study. 
Vehicle controls were also carried out to ensure ethanol used to initially to 




9.3    Results: Expression of MMP-2 in BpA Inhibited 
HASMCs After 48 Hours of 1% Hypoxia 
 
 









Figure 93   Levels of MMP-2 in HASMC Supernatant      (Gel 1) 
Representative zymographic analysis of MMP-2 activity in culture supernatants 
from HASMCs treated with 250μM of the HIF-1α inhibitor BpA and exposed to 1% 
hypoxia or normoxia for 48 hours. 
 1: Positive control (Purified human MMP-2) 2: 1hr N 3: 1hr H 4: 1hr + BpA 5: 3hrs 
N 6: 3 hrs H 7: 3hrs + BpA 8: 48 hrs N 9: 48hrs H 10: 48hrs + BpA 11: Purified 
































Figure 94   Bar and Scatter Graphs Showing Levels of MMP-2 in 
HASMC Conditioned Media     (Gel 1) 
Analysis of HASMCs treated with 250μM of the HIF-1α inhibitor BpA and exposed 
to 1% hypoxia or normoxia for 48 hours. Results expressed  as  arbitrary  density  
units (ADU) per  unit  standardised total protein.  Data  expressed  as  means  ±   
SEM  of  triplicate  values. Results are from three independent experiments 
repeated in triplicate. (n = 3). Statistical analysis was performed using Student's t-
test and correction for  multiple comparisons using the Holm-Sidak method. 
Statistical significance was indicated by p values < 0.05. 
 
A:   Bar graph: Normoxia (open bars),  1%  hypoxia   ( grey filled bars),  bisphenol A 
(black filled bars).  
B:  Scatter plot: Normoxia (black circles), 1% hypoxia (blue squares), bisphenol A 
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Figure 95    Representative Gel Showing Levels of MMP-2 in HASMC 
Supernatant  After Inhibition of HIF-1α     (Gel 2) 
 
Representative zymographic analysis of MMP-2 activity in culture supernatants 
from HASMCs treated with 250µM of the HIF-1α inhibitor BpA and  exposed to 1% 
hypoxia or normoxia for 48 hours.  
 
1: Positive control (Purified human MMP-2) 2: 6hrs N 3: 6hrs H 4: 6hrs + BpA 5: 
30hrs N  6: 30 hrs H 7: 30 hrs + BpA 8: 48hrs N 9: 48hrs H 10: 48hrs + BpA 11: 































Figure 96     Bar and Scatter Graphs Showing Levels of MMP-2 in 
HASMC Supernatant     (Gel 2) 
Analysis of HASMCs treated with 250μM of the HIF-1α inhibitor  BpA and exposed 
to 1% hypoxia or normoxia for 48 hours.Results expressed  as  arbitrary  density  
units (ADU) per  unit  standardised total protein.  Data  expressed  as  means  ±   
SEM  of  triplicate  values. Results are from three independent experiments 
repeated in triplicate. n = 3. Statistical analysis was performed using Student's t-test 
and correction for  multiple comparisons using the Holm-Sidak method. Statistical 
significance was indicated by p values < 0.05. 
 
A:  Bar graph:  Normoxia (open bars),  1%  hypoxia   (grey filled bars),  bisphenol A 
(black filled bars).  
B:  Scatter plot:  Normoxia (black circles), 1% hypoxia (blue squares), bisphenol A 




























































Results of the MMP-2 zymography carried out after HASMCs were treated 
with 250μM of the HIF-1α inhibitor BpA and exposed to 1% hypoxia or 
normoxia for 48 hours yielded promising results. Hypoxic samples minus 
BpA  had some significant increases in MMP-2 activity at the 1 hour time-
point (p < 0.05), 3 hours (p < 0.05), 6 hours (p < 0.05) (Figure 94), 24 hours 
(p < 0.01) and 30 hours (p < 0.03) (Figure 96) versus nornoxic controls. 
Elevations were sustained at 48 hours (Figure 96) but not statistically 
significant. These results were as anticipated, demonstrating higher MMP-2 
levels in hypoxic samples as seen in my earlier results (Chapter 4, section 
4.4.2.2). Hypoxic samples treated with the HIF inhibitor showed decreased 
MMP-2 activity comparable to the normoxic control samples and were 
statistically not significant versus normoxic controls. (Figures 94 and 96)The 
only exceptions occurred at the1 hour time-point  (Figure 94) which showed 
higher MMP-2 activity than the 1 hour  control normoxic control  (explanation 
given later during the discussion) and at the 3 hour time-point  (Figure 94) 
which showed significantly lower MMP-2 activity (p < 0. 001) than the 



















The aim of this study was to investigate whether  hypoxia is an initiating 
factor in the MMP up-regulation seen AAA, to determine the effects of 
hypoxia on TIMPs the natural inhibitors of MMPs and to examine whether 
HIF-1α, VEGF and Ets-1 are mediating factors in the progression of 
aneurysmal disease. 
The existing clinical approach to patients diagnosed with AAAs is 
surveillance of aortic dimensions with a view to perform open or 
endovascular surgical repair when the aortic diameter has  enlarged 
sufficiently to be at high risk of rupture. There are limited options for medical 
treatment beyond risk factor modification as currently no pharmacological 
therapy to limit human AAA progression or rupture has been validated 
through randomised clinical trials highlighting the importance of ongoing 
AAA research (Robertson et al., 2014).  
The first introductory Chapter focuses on the vascular biology of the human 
aorta  by giving an overview of the main aortic structural components and 
important aspects of its physiology which are relevant to understanding the 
pathology of AAA. The aorta is the largest artery in the body and is 
composed of three layers known as the tunica intima, tunica media and 
tunica adventitia containing the major structural components collagen and 
elastin which are vital for the tensile strength and elasticity of the aorta. 
Other specialised proteins of the aortic ECM such as fibrillin, fibronectin, 
laminin and proteoglycans have also been described here as well as cells of 
the arterial intima including intimal endothelial cells, medial SMCs and 
adventitial fibroblasts. These vascular cells have the capacity to express 
components of the ECM, growth factors and proteases including MMPs 
which are calcium-dependent zinc-containing endopeptidases which are 
responsible for tissue remodelling and degradation of the aortic ECM under 
normal physiological conditions and are tightly controlled by their natural 
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inhibitors. The central pathological role MMPs play in the progression of AAA 
is discussed  in Chapter 2. Section 2.2.1. 
To enable the reader to gain insight into the pathophysiology of AAA 
Chapter 2 outlines factors known to be associated with AAA formation. It 
should be emphasised that this research concentrates on AAAs and does 
not include thoracic aortic aneurysms (TAAs)  because,  although they both 
occur within the aorta,  they are located in different anatomical locations and 
have differing aetiologies. For example, AAAs are associated with older age, 
male gender and risk factors such as smoking and high blood pressure 
(Lerderle et al., 1997)  whereas TAAs occur frequently at younger ages 
without  obvious gender predominance (Thompson et al., 2006). In AAA, 
whilst  there is no single genetic defect or polymorphism responsible, there is 
familial clustering, a common HLA subtype, and several altered gene 
expressions suggesting some genetic role in pathogenesis (Tilson and 
Seashore, 1984). Hereditary studies estimate that  20% of TAAs have a 
positive family history and are also linked to known genetic syndromes such 
as Marfan Syndrome or Ehlers - Danlos Syndrome involving  mutations 
affecting  the  fibrillin-1 and  procollagen genes (COL3A1) respectively (Dietz 
et al., 1991, Pope et al., 1975). Furthermore,  as TAAs are predominantly 
located in the ascending aorta and AAAs in the infrarenal region they are 
therefore subjected to differing haemodynamic forces in addition to the 
progressive  decrease in collagen to elastin ratio resulting  in the infrarenal 
area being thinner and stiffer  (Wolinsky and Glagov, 1969). Importantly, for 
this study where hypoxia is being investigated as a factor in AAA,  it should 
be noted that the thoracic aorta is well oxygenated by vasa vasorum as 
opposed to the infrarenal aorta which is normally devoid of medial vasa 
vasorum and derives its oxygen and nutrient supply by simple diffusion from 
the lumen (Zarins et al., 2001). 
 
Although the pathogenesis of AAA remains unexplained, we know its 
initiation and progression is multifactoral.  A large body of existing evidence 
has demonstrated increased MMP levels are the major factor destroying the 
integrity of the ECM and leading to the degradation of major  structural 
elements such as elastin and collagen within the aortic wall. Currently, 
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research has not fully elucidated the chain of events such as the exact 
signalling pathway that terminates in MMP-2 up-regulation. Factors already 
known to increase MMP levels such as inflammation and reactive oxygen 
species were discussed in Chapter 2. A prominent pathological feature of 
AAA is the inflammatory response during which oxidative stress is invariably 
increased, further contributing to the pathophysiology of inflammation and 
progression of AAA. Associated with this inflammatory response, Martinez-
Pinna et al., (2014) noted an increased presence of haemoglobin (Hb) -
derived iron in the adventitia of AAA patients. This observation correlated 
with haematoxylin and eosin stained AAA tissue sections of which a 
representative example is shown in  Figure 56, slide B showing extensive 
inflammatory infiltrate and adventitial haemosiderin deposition. 
Haemosiderin is an iron-storage complex seen  as a yellowish-brown 
granular intracellular pigment produced from the breakdown of Hb and 
is often found in macrophages which are also known to be present within 
AAA inflammatory infiltrate. Recently Rubio-Navarro et al. (2015) reported 
that the presence of Hb in the adventitial AAA wall promotes the migration 
and differentiation of activated circulating monocytes in AAA patients, 
explaining the existence of a protective CD163-macrophage phenotype that 
could take up the Hb present in the AAA-wall. 
Our group (Erdozain et al., 2011) proposed that hypoxia may be an initiating 
factor in the up-regulation of MMP-2  in AAA.  Immunohistological studies by 
Erdozain et al., (2011)  found that the global hypoxic transcription factor HIF-
1α co-localised with high expression of MMPs in the tunica media and pro-
inflammatory infiltrate of AAA tissue and that MMP-2  immunopositivity was 
observed in the VSMCs within the region of tunica media distant from the 
vasa vasorum. These observations showing localisation of MMP-2 to AAA 
medial SMCs, is supported by earlier research showing that MMP-2 
production is elevated in SMCs  derived from aortic aneurysms (Crowther et  
al., 2000). MMP up-regulation driven by hypoxia and HIF-1α has also been 
explored in other research areas such as cancer studies. Krishnamachary  
et al., (2003) showed that HIF-1 regulates the expression of genes including 
cathepsin D and MMP- 2 in HCT116 human colon carcinoma cells whilst 
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Choi et al., (2011) found HIF-1α was stabilized under hypoxic conditions and 
stimulated MMP-9 expression which affected the tumour invasiveness of 
breast cancer cells. A further study by Jing et al., (2012) also determined 
 that HIF-1α contributed to hypoxia-induced invasion and metastasis of 
oesophageal carcinoma by promoting MMP-2 expression.  
 
Arterial wall hypoxia has been investigated in other conditions such as 
atherosclerosis and intimal hyperplasia (Heughan et  al., 1973, Crawford et 
al., 1991., Martin et al., 1991, Bjornheden et al.,1999, Lee et al., 2000, 
Santilli et al., 2000). Research has shown that hypoxia exists in vivo in 
patients with aneurysms (Choke et al., 2006) and that intraluminal thrombus 
(present in approximately 75% of all cases of AAA) contributes to aortic wall 
hypoxia and weakening (Vorp et al., 1996, 1998, 2001). In view of all this 
evidence of hypoxia-driven MMP up-regulation it was decided to explore if 
this also occurred in AAAs. 
 
In our first study (Erdozain et al. 2011) HSMCs were maintained in FCS- 
containing medium at decreasing oxygen levels (5% down to 2%) over a 72 
hour period and the results showed significant increases in MMP-2 and 
MMP-9 activity. In the studies presented here, I sought to further investigate  
more severe hypoxia as a driving force behind elevated HASMC MMP 
secretion and assess the induction times of the response to severe hypoxia 
(1% O2).  In this instance the cells were maintained in serum-free media to 
rule out foetal calf serum as  a potential confounding factor. It was important 
to investigate MMP levels subjected to more severe hypoxia as Sun et  al.,   
(2007) had designed a numerical model of oxygen transport in AAA with 
intraluminal thrombus (ILT) which demonstrated O2 levels of 1% and lower 
within the thickest regions of the ILT which are known to be present in more 
than 75% of all cases of AAA (Harter,et al., 1982). In Chapter 4, section 
4.4.2.2,  results  of HASMCs exposure to severe hypoxia (1%) revealed  that 
hypoxic samples in comparison to normal controls showed significant 
increases in secreted pro and active MMP-2  at all time-points except at 48 
hours which showed a sustained elevation but was not statistically 
significant. These findings suggest that smooth muscle cells, the major cell 
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type found within the aortic tunica media respond to severe hypoxic stress 
(1% O2) by secreting MMP-2 strengthening the hypothesis that localised 
hypoxia could be an initiating factor in the pathogenesis of AAA.  
 
The identification of MMPs  was achieved by comparison with known 
molecular weight standards but MMP-2 immunoblotting analysis  of samples 
(Chapter 4, section 4.7.2.2 ) was carried out to further corroborate that MMP-
2 protein was present in the HASMC culture supernatant and verify the 
increases in enzymatic activity seen in the hypoxic HASMC samples in 
comparison to normoxic samples were due to MMP-2 activity (Chapter 4, 
section 4.4.2.2).     
 
MMP-9 was not detected in normoxic or hypoxic HASMC conditioned 
samples after a 48 hour exposure to 1% oxygen. This data appears to 
correlate with our earlier findings (Erdozain et al., 2011) where a significant 
increase in MMP-9  was only seen at 2% hypoxia after 72 hours of 
decreasing O2 levels, suggesting the driving force behind MMP-9 exportation 
is a sustained sequential decrease in O2 over time and which also seems 
more comparable to the chronic hypoxic conditions found within the 
aneurysm. Additionally MMP-2 is constitutively expressed while MMP-9 
tends to be inducible by growth factors and inflammatory stimuli so this may 
account for lack of this enzyme in the HASMC-conditioned media. In our 
original study (Erdozain et al., 2011), HASMC conditioned medium from 
hypoxic samples demonstrated elevated levels of MMP-9 but those 
HASMCs were maintained in medium containing foetal calf serum (FCS) 
during the period of hypoxia; FCS contains growth factors capable of 
potentially inducing release of MMP-9 as opposed to my present study 
where cells were maintained in serum-free media.  
The decision to investigate MMP-7 levels in HASMCs subjected to severe 
hypoxia was made following our previous findings (Erdozain et. al.,2011) of 
significant transcriptional up-regulation of MMP-7 (p< 0.001) in HASMCs 
potentiated by hypoxia, suggesting a role for this factor in the development 
of AAA.  MMP-7, also known as Matrilysin, has a broad proteolytic activity 
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against a variety of extracellular matrix substrates and has been implicated 
in tumour metastasis, inflammation and is expressed in SMCs under hypoxic 
conditions. 
It was important to assess whether the marked  MMP-7 mRNA up-regulation 
was also seen at the MMP-7 protein level in hypoxic HASMC samples. 
MMP-7 and its involvement in AAA pathogenesis is largely unknown, 
although immunohistochemical analysis of aneurysmal aortae has indicated 
differences in the distribution of this MMP from normal aorta (Borges et al., 
2009).  More recently, Lyon et al., (2015) also detected increased  MMP-7 
activity in human AAA sections  compared  to normal human aortae, in 
addition to demonstrating  that MMP-7 can modify the behaviour of VSMCs  
by cleaving N-cadherin,  thereby modulating AAA formation and progression. 
Burke et al., (2003) also identified a putative HRE containing HIF-1 binding 
sequences within the promoter of the MMP-7 gene although they 
subsequently found it to be incapable of conferring hypoxic inducibility but 
considered  other possibilities  that the hypoxic inducibility of MMP-7 
transcription is mediated by a different HIF binding site within the promoter. 
Yu and Frederick Woessner (2000) suggested heparin might enhance MMP-
7 activity during  zymography  by either inducing a conformational change 
that increases activity, facilitating refolding, reducing autolysis, or by helping 
to anchor the enzyme in the gel overnight. Therefore, levels of MMP-7 
protein were investigated  using heparin-enhanced zymography, ensuring 
that even low levels of  MMP-7 could be detected.  
 
Results of zymographic analysis  proved inconclusive for MMP-7 protein in 
both conditioned media and whole cell lysate,  even after sample volume 
was considerably increased and time incubated in development buffer 
extended (Chapter 5, section 5.2.2).   One explanation for these results may 
be because the HASMCs were exposed to severe hypoxia for only 48 hours 
the hypoxic exposure period was not extensive enough for it to translate at 
the MMP-7 protein level. 
Interestingly, research by Yamasaki et al.,(2013) determined that expression   
of MMPs-7, -9, -14, and -15 were significantly up-regulated in LNCaP human 
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prostate cancer cellsbut only after exposure to chronic  hypoxia (1%) of up to 
6 months but not under acute hypoxia. Furthermore research has also 
demonstrated increased levels of MMP-7 in the aneurysm wall in AAA, 
seemingly expressed by cells within the aortic wall such as SMCs rather 
than the luminal thrombus (Fontaine et al., 2002, Kazi et al., 2005) 
suggesting that MMP-7 may play a late role in aneurysm progression though 
promotion of continued cellular attrition within the aortic wall (Ikonomidis et 
al., 2007).  
 
Additionally, the absence of MMP-7 could be attributed to being maintained 
in serum-medium throughout the period of hypoxia. Certain genes contain 
serum response elements within their promoters which respond to serum 
response factors, if MMP-7 does contain a serum response element, it could 
modify MMP-7 expression negatively. In fact, during our earlier study 
(Erdozain et al., 2011)  the HASMCs were maintained in medium containing 
FCS, and interestingly, MMP-7 mRNA  was detected and found to  be 
elevated in those hypoxic samples. Research investigating the role of MMP-
13 in AAA by Mao et al., (1999) may also support this theory, as they noted 
that  human aortic SMCs did not express MMP-13 when maintained in a 
basal medium supplemented with only 2.5% fetal calf serum and thought it 
likely that additional factors were necessary for the induction of SMC MMP-
13 expression in vitro.  
 
After establishing that HASMC MMP-2 levels were significantly upregulated 
by severe hypoxia (Chapter 4, section 4.4.2.2), it was important to 
investigate if the global hypoxia transcription factor HIF-1 α also played a 
role in the signalling pathway as  it  is a key regulator responsible for the 
induction of genes that facilitate adaptation and survival of cells under 
hypoxic conditions (Wang et al., 1995, Semenza, 1998). HIF-1α    
immunoblotting     analysis    established     the     presence    of  increased  
HIF-1α   in  HASMC  total  cell  lysate   following   exposure  to  severe 
hypoxia (1%) over 48 hours (Chapter 7, section 7.3.3) and 
immunohistological staining showed the presence of HIF-1α in the 
inflammatory infiltrate and medial SMCs of AAA tissue  (Chapter 7, Figures 
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78, 79) demonstrating HIF-1α expression was significantly higher in AAA  in 
comparison to non-aneurysmal control tissue (Chapter 7, Figure 77) which 
supports the findings of Hu et al., (2004) and our earlier results (Erdozain et 
al., 2011). Importantly,  immunohistological staining of AAA tissue also 
established that HIF-1α immunopositivity was principally localised in the 
nucleus signifying that nuclear translocation had taken place (Chapter 7, 
Figures 78,79). When identifying transcription factors It is important to 
differentiate between true nuclear staining and that of cytoplasmic staining 
because it is only when HIF stabilisation within the nucleus has occurred that 
it can then associate with the HRE regions of promoters of hypoxia-
responsive target genes. Weak cytoplasmic HIF-1α staining seen  in normal 
control aortic sections is likely to be transient prior to being targeted for 
proteosomal degradation during normal oxygen levels (Semenza., 2000). 
 
The idea that HIF-1α is an initiating factor in the pathway leading to MMP up-
regulation is also consistent with research which demonstrated elevated 
levels of TNFα to naïve or small AAAs (<50mm) far higher than levels seen 
in larger AAAs (Harmano et al., 2003) along with the knowledge that HIF-1α  
is also proven to be up-regulated in response to inflammatory TNFα 
(Hellwig-Bürgel et al., 1999) appears to suggest these are early events in the 
pathogenesis of AAA. 
 
During hypoxia HIF-1α activates the expression of  certain genes by directly 
binding to a 50-base pair cis -acting hypoxia responsive element located  in 
their enhancer and promoter regions (Semenza et al., 1991) In order to 
examine additional tissue markers of hypoxia  AAA tissue samples were 
probed  for the transcription factor  Ets-1 and the angiogenic factor VEGF. 
Research by Forsythe et al., (1996) had previously demonstrated the 
activation of VEGF gene transcription by HIF-1α and a later study 
established Ets-1 can also be induced by VEGF (Hashiya et al., 2004). It has 
also been suggested that a positive feedback loop may exist for the Ets-
1/VEGF interaction and that by  inducing Ets-1expression, VEGF may trigger 
its own production leading to further Ets-1 synthesis (Dittmer, 2003). 
Hypoxia, in addition  to VEGF  has been shown to induce Ets-1 via the 
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activity of HIF-1α (Oikawa et.al. 2001), therefore it could be  surmised that 
Ets-1 and VEGF may participate in the AAA signalling pathway terminating 
in  MMP up-regulation as seen  in these present hypoxia studies.   
 
VEGF immunohistological staining of AAA tissues demonstrated widespread 
and diffuse VEGF immunopositivity within the tunica adventia and tunica 
media (Chapter 8, Figure 91 ) but  no obvious VEGF immunopositivity was 
noted in normal aortic tissue (Chapter 8, Figure 90). This corresponds with 
research carried out by Nishibe et  al., (2010) who found VEGF  was 
expressed in AAA tissue samples and absent in the normal abdominal aorta 
leading them to suggest that VEGF may play an important role in aneurysm 
formation via its direct and/or indirect actions. They also found two thirds of 
their AAA samples displayed VEGF positivity localised within the aortic 
SMCs which was also consistent with my findings in this present study  
where marked cytoplasmic VEGF staining was seen within VSMCs of 
aneurysmal tissue (Chapter 8, Figure 92).                                   
Ets-1   immunohistochemical   analysis (Chapter 8)  also   demonstrated   an   
obvious difference in Ets-1  immunopositivity in AAA tissues in comparison   
to normal aorta tissue samples  (Figures 86, 87, 88, and 89) and  was 
localised mainly to the nuclei of matrix cells within the tunica media  and   
inflammatory cells of the diffuse infiltrate, although some cytoplasmic 
staining was visible. AAA tissues were found to display a marked increase in 
immunopositivity of both Ets-1 and HIF-1α transcription factors, when 
compared with the results obtained for normal aortic tissue (Chapter 8, 
Figure 86).  Both factors appear localised to the VSMC and inflammatory 
infiltrate and predominately expressed within the medial layer of the 
aneurysm wall. This too is consistent with research carried out by Peters et 
al., (2004) in our group, who also found co-localisation of HIF-1α and Ets-1 
in areas of hypoxia in the synovium of inflamed rat joints in adjuvant-induced 
arthritis and suggested HIF-1α may be involved in the up-regulation of Ets-1. 
Furthermore immunohistological staining  of AAA tissues had shown MMP-2 
is also localised to the same regions which may be of relevance as research 
by Okuducu et.al. (2006) demonstrated MMP-2 and MMP-9 are target genes 
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of Ets-1. Burke et al. (2003) suggested hypoxia could act on the MMP-7 
promoter via HIF-1α mediated up-regulation of Ets-1 as its promoter 
contains two binding sites for Ets-1 for up-regulation of this MMP. 
It had been established earlier in the study that severe hypoxia induced 
HASMCs to secrete significantly higher levels of MMP-2 into conditioned 
media in comparison to normoxic controls (Chapter 4, section 4.4.2.2). In 
order to further investigate the possible role of VEG and Ets-1 in the hypoxic 
induction of MMP-2, levels of VEGF and Ets-1 in total HASMC cell lysate 
after exposure to severe hypoxia were analysed by the Western blotting 
technique (Chapter 8, Figures 81 - 84). VEGF is a known target of HIF-α 
during hypoxia (Forsythe et al., 1996) and significant increases of VEGF 
were noted in hypoxic samples. Additionally, HASMCs exposed to hypoxia 
also demonstrated significantly increased levels of Ets -1 (Chapter 8, Figure 
82) which is consistent with Watanabe et al., (2004) who established that 
 VEGF and hypoxia increased Ets-1 expression in cultured bovine retinal 
endothelial cells. More recently, Qiao et al., (2015) determined that severe 
hypoxia induced a rapid increase in Ets-1 in pancreatic β cells within one 
hour which also corresponds with the findings of this study. Furthermore they 
suggested that this pattern of activity defined Ets -1 as an early response 
gene which is interesting as immunoblotting results of this study indicate 
levels of HIF-1α, Ets-1 and VEGF rise earlier than MMP-2. Initiation of the 
hypoxic response would begin with cellular hypoxia being sensed by the 
prolyl-4-hydroxylases of HIF-1α leading to stabilisation of the HIF-1α subunit 
and translocation from the cytoplasm to the nucleus where it dimerises with 
HIF-1β (Huang et al., 1996,  Kallio et al., 1997) to bind with  the HREs in the 
regulatory regions of VEGF and Ets-1 resulting in up-regulation of these 
target genes. Subsequently this could be followed by up-regulation of MMP-
2 by Ets-1 accounting for the delayed rise seen in the MMP-2 immunoblot. 
Similarly, Ghosh et  al., (2012) hypothesized that in the human ovarian 
carcinoma cell line SKOV-3, VEGF induces Ets-1 through the activation of 
the PI3K/AKT and p38 MAPK pathways after which Ets-1 is enriched in the 
nucleus followed by the activation of specific MMP genes. 
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Chapter 6 focused on the potential role of the endogenous inhibitors of 
MMPs known as TIMPs in the formation of AAAs. Although the activity of 
MMPs has been shown to be essential in cell biological processes it is vital 
that they are tightly controlled by TIMPs under normal physiological 
conditions to provide a balancing mechanism to prevent excessive 
degradation of the ECM. Under pathological conditions associated with 
unbalanced MMP activities such as in AAA, changes in TIMP levels are 
considered to be important because they directly affect the level of MMP 
activity. Another important feature of TIMP-2 is its role in the activation of 
proMMP-2 where levels of TIMP-2 are crucial for MMP-2 activation. Often 
the production of TIMPs is elevated by the same stimuli that promote MMP 
expression (Thompson et al., 2002). Therefore, as this study has established 
that hypoxia is a factor in increasing the expression of MMPs it would seem 
prudent to analyse TIMP levels during experimental hypoxia. Furthermore, 
our earlier study  (Erdozain et. al., 2011)  found significant transcriptional up-
regulation of TIMP-1 mRNA using PCR analysis of HASMC lysate after 
exposing HASMCs to hypoxia for up to 48 hours.  TIMP-1 and TIMP-2 levels 
in HASMC conditioned media from cells exposed to severe hypoxia over a 
48 time period were analysed using the reverse zymography  technique. 
Results did in fact show that there were significant increases in TIMP-1 and 
TIMP-2 protein levels in the hypoxic HASMC supernatant samples in 
comparison to controls (Chapter 6, Figures 65-69) rather than decreases in 
TIMP expression which might be expected due to the increased MMP-2 
levels found in hypoxic samples earlier in the study. However, these results 
are consistent with substantial evidence that the production of TIMPs is 
actually increased within the aneurysm wall (Tamarina et al., 1997,  
Nishimura et al., 2003).  Misra et al., (2010) also found hypoxia significantly 
increased levels of TIMP-1 and TIMP-2 in murine fibroblasts and more 
recently TefÃ-Silva et  al. (2013) using an experimental AAA rat model which 
combined inflammation and turbulent blood flow found dramatic increases in 
levels  of HIF-1α, MMP-2 and -9, TIMP-1 and TIMP-2. Although little is 
known about TIMP behaviour in aneurysmal formation, increases in TIMP-1 
expression noted in this study may be explained by research carried out to 
examine if hypoxia promotes fibrogenesis in human renal fibroblasts by 
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Norman et al (2000).  They identified a HRE in the TIMP-1 promoter and 
established that the hypoxic induction of TIMP-1 expression was dependent 
on the binding of HIF-1α to a  HRE in the 5' promoter. My findings in this 
study had already established HIF-α levels are increased in hypoxic 
HASMCs therefore if TIMP-1 is hypoxia-inducible via a HIF-1α dependent 
pathway this may  account  for the increased TIMP-1 expression in hypoxic 
HASMCs samples. TIMP-1 levels in normoxic  HASMCs could be due to 
constitutive expression as Fabunmi et. al. (1998) had found TIMP-1 and 
TIMP-2 were constitutively expressed in  cultured human SMCs during their 
vascular research. TIMP-2 protein levels were also found to be significantly 
increased in HASMCs subjected to hypoxia even though Norman et  al. 
(2000) noted that HIF-1α binding motifs were absent from the TIMP-2 
promoter. However another possibility is that TIMP-2 could be hypoxia-
inducible via HIF-1α mediated up-regulation of Ets-1, as research carried out 
into the renal expression of proto-oncogene Ets-1 on matrix remodelling in 
experimental diabetic nephropathy demonstrated that Ets-1 may be involved 
in the transcriptional regulation of MMP-2 and TIMP-2 (Lui et al., 2011). 
Constitutive TIMP-2 expression would account for the lower levels found in 
normoxic HASMC control cells conditioned media. 
In this study, when carrying out  image analysis of band intensity and size 
using Scion Imaging Software, it may have been advantageous to have 
quantified MMPs, TIMPs or other proteins. They were analysed by defining 
the arbitrary densitometry units but could have been calibrated against  a 
standard curve prepared from a purified enzyme which would have made 
quantification more accurate when comparing  MMP/TIMP ratios. However 
the limited number of wells per zymogram gel did not allow a full standard 
curve, as normoxic and hypoxic samples were run side-by-side for each 
time-point for easier visual comparison.  Nonetheless, this did not prevent 
the study from establishing that exposure to severe hypoxia significantly 
increased the levels of the aforementioned proteins in comparison to 
normoxic controls. Another point to note is that these results represent three 
independent experiments in triplicate at different times. Three different 
primary sources of HASMCs (different donors) were used during these 
studies, however experimental results from one batch was discounted  and 
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not used even though up-regulation of MMP-2 was also noted on analysis, 
as during the hypoxic experimental period at some time-points the cells lifted 
off from the base of the 6-well plates possibly due to the cells being too 
confluent prior to the start of the study. However I believe sufficient biological 
variance has been satisfied and reproducible experimental results achieved 
using primary cells from different donors.  Additionally,  our earlier study 
(Erdozain et al., 2011), looking at the effect of progressive hypoxia (5% 
down to 2%) on the activity of HASMC  MMPs and again using different 
HASMCs isolated and cultured from normal human aorta, also demonstrated 
similar results. Human aneurysmal and normal control aortic tissue rather 
than primary cells were used during histological analysis, with aneurysm 
tissue from 5 consented patients undergoing elective surgical repair and 
normal aortic tissue from 5 renal transplant donors (n=10). 
 
The final chapter explains the effect of inhibiting HIF-1α on MMP-2 up-
regulation in HASMCs exposed to severe hypoxia.  Using a HIF-1α inhibitor 
seemed the logical next step to determine whether hypoxia and HIF-1α are 
an initiating factor in the MMP-2 up-regulation observed in this study and 
consequently in AAA formation. It was important to select the correct HIF 
inhibitor and Bisphenol A (BpA) which promotes HIF-1α degradation by 
dissociation of the chaperone protein Hsp90 was chosen. BpA works in a 
similar fashion to the antibiotic geldanamycin, inhibiting Hsp90 followed by 
degradation although their structures are quite different and BpA is more 
economical to use (Minet et al.,1999, Kubo et al., 2004). Preliminary 
experimentation was carried out to ascertain the optimum concentration of 
BpA necessary to inhibit HIF-1α in HASMCs during hypoxia. BpA required 
solubilisation in ethanol prior to being further diluted in serum-free media to 
the final concentration therefore care needed to be exercised to ensure the 
ethanol was sufficiently diluted in media before being applied to the 
HASMCs to prevent any detrimental effects to them. Cell viability assays 
were also carried to ensure the BpA was not harmful to the cells in addition 
to vehicle controls to make certain experimental results were unaffected by 
ethanol. Controls during this final hypoxia study included HASMCs kept 
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under normoxic conditions, HASMCs kept under 1% hypoxia and HASMCs 
plus BpA kept under 1% hypoxia. 
 
Following the HIF-1α inhibition experiment,  levels of MMP-2 activity in 
HASMC conditioned media were analysed by zymography and results 
yielded very promising results (Chapter 9, section 9.3). Although at the 1 
hour time-point, both the hypoxic and hypoxic plus BpA samples were 
significantly higher than normoxic controls.  It is understandable that the BpA 
containing sample matched the hypoxic sample as the inhibitor would 
require time to be taken up by the cells and to take effect. All subsequent  
time-points up to 48 hours demonstrated significant increases in MMP-2 
levels in hypoxic samples compared to normoxic controls as seen in the 
earlier study (Chapter 4) .Hypoxic samples containing the inhibitor BpA 
which promoted HIF-1α degradation under hypoxia on the contrary showed 
much lower MMP-2 levels and were not significantly different from control 
normoxic samples. The only exception was the 3 hour time-point in which 
the BpA inhibited sample was significantly lower than the normoxic control. 
 
 I believe that it is reasonable to state, from these results, that hypoxia 
signalling via HIF-1α up-regulates MMP-2 as HIF-1α inhibition prevents its 
stabilisation and thus down- regulates MMP-2 during hypoxia. Furthermore it 
suggests that  the hypoxia-induced MMP-2 activation in early aneurysm 
formation is mediated by a signalling cascade initiated by HIF-1α and 
potentially may play a primary role in AAA. 
 
Importantly, recent work by Tsai et al., (2016) has further corroborated  my 
research. Firstly, using AngII induced AAA in a hyperlipidemic mouse model 
they stabilised HIF-1α using deferoxamine (DFO) a prolyl hydroxylase 
inhibitor and found increased HIF-1α expression was associated with 
increased MMP-2 and MMP-9 levels in the DFO treated mice which is 
consistent with the hypoxic induced stabilisation of HIF-1α and subsequent 
up-regulation of MMP-2 seen in the hypoxic cultured HASMCs. Secondly, 
administration of HIF-1α inhibitors decreased AngII- mediated HIF-1α and 
VEGF in addition to down-regulating  MMP-2 and MMP-9 expression in the 
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mouse aortic homogenates which also correlates to the decreased MMP-2 
levels seen in hypoxic HASMCs after treatment with the BpA inhibitor during 
this research (Chapter 9, Figures 93-96). 
 
 
10. 2 Future Work 
 
During the present study,  analysis of TIMP levels in  hypoxic and normoxic 
HASMC conditioned media after inhibition of HIF-1α with BpA was carried 
out. However, bands were not detected on the reverse zymograms even 
though the concentrations of MMP and gelatin were the same as those used 
in earlier reverse zymograms and in addition to further concentration 
modifications. Therefore it would be important to repeat the experiment to 
see if inhibiting HIF-1α affects TIMP levels.  I believe the lack of bands 
occurred as the original purified MMP-2 protein incorporated into the gel was 
not available to purchase and therefore a new protein had to be trialled 
which obviously was not successful. Further types of MMP-2 protein would 
need to be acquired and optimised in order to obtain good bands as reverse 
zymography is critically dependent on the source of gelatinase activity used 
to define the zones of TIMP inhibition. 
 
Additionally VEGF and Ets-1 levels could be evaluated in HASMC total cell 
lysate after HIF-1α inhibition under hypoxic and normoxic conditions. This 
could also be followed by sequential inhibition of VEGF and Ets-1 in 
HASMCs under hypoxia  and subsequent analysis of HASMC MMP-2 levels 
which could also  give further insight into the sequence of events in the 
hypoxic signalling pathway if MMP-2 levels are changed by either of the 
inhibited proteins. Clearly HIF should not be inhibited prior to VEGF or Ets-1 
inhibition as we now  already know that HIF inhibition affects MMP-2 levels 
but need to establish if this is in conjunction with either VEGF or Ets-1.   
 
Like VEGF and Ets-1, NF- κB is also known to be markedly activated in 
AAA. NF- κB is a  transcription factor that has a major role in regulating pro-
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inflammatory genes which are implicated AAA and  also regulates the 
transcription of MMP-1, MMP-2, MMP-3 and MMP-9 (Bond et al., 1999, 
Takeshita et al., 1999, Kim et al., 2000). Culver et al., (2010) demonstrated 
the activation of NF-κB in response to hypoxia. Hypoxia and inflammation 
are intimately connected at the cellular and molecular level (Biddlestone et 
al.,2015) and Bandarra and Rocha, (2015) also demonstrated crosstalk 
between HIF-1α and NF-κB. Therefore it could also be useful to block NF-κB 
in HASMCs under hypoxic and normoxic conditions and then re-evaluate 
HASMC MMP levels to determine the effects of NF- κB inhibition. 
During the present study gelatin zymograms only demonstrated bands of 
MMP activity which was verified using EDTA inhibition assays which 
abolished all MMP activity thus resulting in the absence of bands from 
treated gels. However, Wilder et. al. (2011) reported a zymography protocol 
to detect and distinguish proteolytic activity for different cathepsin family 
members, modifiying individual cathepsin substrate preferences, varying pH 
and electrophoretic mobility. Therefore adaptions to the present zymography 
protocol could be used to assess any possible cathepsin activity in HASMCs 
exposed to experimental hypoxia. If analysis did show elevated hypoxia-
driven expression of these proteases then it would be prudent to see if the 
up-regulation was mediated by HIF-1α by inhibiting HIF as in the present 
study. 
 
Another useful procedure  is sequential double immunofluorescence using a 
selection of different fluorophores after which separate fluorescent images 
can be digitally captured and overlaid using software such as Photoshop  
which would definitively allow visual clarification of localisation and co-










Although there is further research required to elucidate the precise 
mechanism for AAA induction. and the knowledge regarding the role of 
hypoxia and HIF-1α in the pathogenesis  of aneurysm formation is still 
limited, results from this study will  add to the pool of knowledge within the 
field of AAA research. Targeting HIF-1α or disruption of the HIF-1 pathway 
could represent a novel pharmacological approach for small AAAs and the 
many aspects of HIF-1 regulation provides a number of possibilities for 
therapeutic intervention. Clearly the mechanisms involved in AAA formation 
are multiple and complex. Nevertheless I believe that this work provides 
insight into a possible mechanism for the progression, if not the initiation, of 
aneurysmal disease. The work undertaken here shows that hypoxia is a 
prime candidate for driving matrix metalloproteinase regulation, expression 
and activation and may have serious consequences in the inflamed 


















Haematoxylin and Eosin Stain Protocol 
 
Tissues sections mounted on slides were treated by submersion in the 
following solvents for the times indicated: 
 Ice cold acetone : 1-5mins (Tissue Fixation) 
 Tap water : 5mins (Rehydrate tissue) 
 Harris Haematoxylin (prepared 1 part Haematoxylin : 3 parts water) : 
5mins 
 Tap water : 5mins 
 Acid alcohol (1% HCl in IMS) : 1min with gentle agitation 
 Tap water : 5mins 
 Eosin : 0.5min 
 Tap water : 5mins 
 IMS : 1min 
 IMS : 1min 
 Xylene : 1min 
 Xylene : 1min 
 A coverslip was mounted onto the treated tissue sample with excess 
DePeX mounting medium. 
 
SDS-PAGE, Western and Dot Blot Recipes 
 
SDS-PAGE Resolving Gel (8%) 
 10.66mls    dH20 
 4.0mls        40% Acrylamide (Anachem. Bedfordshire, UK) 
 5.02mls      1.5M Tris/Base pH8.8 (Promega UK Ltd. Southampton, 
UK) 
 100μl        20% SDS (Sigma Aldrich Company Ltd. Dorset, UK) 
 200μl        10% Ammonium Persulphate (Sigma Aldrich Company 
Ltd. Dorset, UK) 
 15μl  N, N, N´, N´-Tetra-methyl-ethylenediamine (TEMED) (Sigma 
Aldrich  Company Ltd. Dorest, UK) 
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SDS-PAGE Stacking Gel (4%) 
 4.98mls  dH20 
 660μl  40% Acrylamide 
 840μl  1.0M Tris/Base pH6.8 
 33.4μl  20% SDS 
 66μl  10% Ammonium Persulphate 
 8μl  TEMED 
                                                                   
 
SDS-PAGE Running Buffer 
 14.4g  Glycine (VWR International Ltd. Dorset, UK) 
 3.06g  Tris/Base 
 1.0g  SDS 
 1000mls dH20 
 
SDS-PAGE Sample Buffer 
 6.75mls  dH20 
 0.75mls  1M Tris/Base pH6.8 
 2.0g  Sucrose (VWR International Ltd. Dorset, UK) 
 1mg  Bromophenol Blue (Promega UK Ltd. Southampton, UK) 
 0.5mls 2-mercaptoethanol (Sigma Aldrich Company Ltd. 
Dorset, UK) 
 
Western and Dot Blot Transfer Buffer 
 see SDS-PAGE Running Buffer but made with 20% Methanol (VWR 
International Ltd. Dorset, UK) 
 
Western and Dot Blot Washing Buffer 
 0.5% Tween 20 (Sigma Aldrich Company Ltd. Dorset, UK) in PBS 
 
 Western and Dot Blot Blocking Buffer 








2x Sample Buffer Solution (reducing buffer) 
 
 5ml stacking gel buffer solution 
 8ml 10% SDS solution 
 1ml dH2O 
 4ml glycerol 
 2ml 2 – mercaptoethenol and mix well (use fume hood) 
 Small amount (1-2mg of bromophenol-blue indicator dye) 
 Divide sample buffer into 1ml portions (eppendorfs) and store at -70C 
or  -20C for short periods 
 NB – warm to dissolve crystallized SDS 
 
2x Sample Buffer (non-reducing) 
 
 5ml stacking gel buffer solution 
 8ml 10% SDS solution 
 3ml dH2O 
 4ml glycerol 
 Small amount (1-2mg of bromophenol-blue indicator dye) 
 Divide sample buffer into 1ml portions (eppendorfs) and store at -70C 
or  -20C for short periods  
 
Stacking Gel Buffer Solution 
 
 Dissolve 15.2g Tris base in 200ml water 
 Adjust to pH 6.8 by slow addition of concentrated HCL 
 Add dH2O to give 250ml final volume 
 
0.5M Tris-HCL Stock solution 
 
 Dissolve 60.5 g Tris Base in 900ml dH2O 
 Adjust  to pH 7.6 by slow addition of concentrated HCL 




10% SDS  
 
 10g SDS (Lauryl Sulfate) into 90ml of dH2O (main shelf) Make up to 
100ml 




Resolving Gel Buffer Solution 
 
 90.6g Tris Base in 350ml dH2O 
 Adjust to pH 8.8 by slow addition of concentrated HCL 
 Add dH2O to a final volume of  500ml 
 
         or 
 pH 9.2 as this enhances resolution and shortens run time 
 
 
Water Saturated Butanol Solution 
  
 100ml n-Butanol and 5ml dH2O  
 Shake and use top layer 
 
Zymogram Development Solution 
 
 100ml 0.5M Tris-HCL solution 
 100ml 50mM Calcium Chloride Solution (7.35g CaCl2 in 1 litre = 
50mM) (main shelf) 









   Coomassie Blue Staining Solution 
 
 Dissolve 2g Coomassie Brilliant Blue R-250 in       
 500ml Methanol 
 100ml glacial acetic acid (17.4M) 
 400ml acetic 




 1.6L or (400ml) Methanol 
 400ml or (100ml) glacial acetic acid 
 2L or (500ml) dH2O 
 Mix and store at below 25C 
  
Renaturing Buffer (allows MMPs to renature and digest gel) 





 100mg in 1ml dH2O – must be prepared fresh (acts with TEMED to 
set gel)  
 
 
4 x Tank Buffer (4 x Electrophoresis Tank Buffer Solution) 
 
Dissolve 
  48g Tris Base  (shelf by IMS) 
 230.4g glycine (shelf by IMS) 






 12g Tris Base 
 57.6 glycine 




1 x Tank Buffer Solution 
 
 Mix 1 part (4 x Tank Solution) to 3 parts dH2O to get 1 x Tank Buffer 




 1ml acrylamide/bis 37.5:1  (neat) 
 2.5ml stacking gel buffer 
 6.3ml dH2O 
 0.2ml or 200μl 10% SDS 
 0.2ml or 200μl ammonium persulphate 




 10mls acrylamide/bis 37.5:1 soln (neat) made by Amresco)(Fridge 1)  
 10mls resolving gel buffer 
 15.5mls dH2O 
 4mls made-up gelatine solution (main shelf) 
 (0.8ml)800μl 10%SDS (Lauryl sulphate) (main shelf) 
 (0.6ml)600μl ammonium persulphate ( main shelf) 





 Make up resolving  and stacking gels as per recipes 
 Make up gelatin in 20mls (heat to dissolve gelatin) 
 Prepare 2 x sets glass gel plates(protein cupboard), place on blue 
tissue and spray with acetone Place gasket on gel plate – raised edge 
271 
 
of gasket goes against raised edge of glass plate (do when wet from 
acetone –easier) 
 with water or acetone. 
 Use a glass pipette to fill gel plate with resolving gel (add TEMED just 
before) 
 Using a glass pipette drizzle water saturated butanol on top of the 
resolving gel to reduce bubbles and to give the gel a level top 
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